Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 1of 138Clinical Study Protocol
Study Intervention AZD9977 and dapagliflozin
Study Code D6402C00001
Version 7.0
Date 02Feb2022
A Phase 2b, Randomised, Double -Blind, Active -Controlled, 
Multi -Centre Study to Evaluate the Efficacy, Safety and 
Tolerability of Oral AZD9977 and Dapagliflozin T reatment in 
Patients with Heart Failure and Chronic Kidney Disease
Sponsor  Name: AstraZeneca AB
Legal Registered Address: AstraZeneca AB, 151 85 Södertälje, Sweden
Regulatory Agency Identifier  Number(s): IND 149932; EudraCT 2020 -003126-23
This Clinical Study  Protocol  has been subject to a peer review according to AstraZeneca 
standard procedures. The Clinical Study Protocol  is publicly  registered, and the results are 
disclosed and/or published according to the AstraZeneca Global Policy on Bioethics and in 
compliance wi th prevailing laws and regulat ions.
Protocol Number: D6402C00001
Amendment Number: 6
Study  Intervent ion: AZD9977 and dapagliflozin
Study  Phase: Phase 2b
Short Title: Efficacy , safety ,and tol erabili ty of AZD9977 and dapagliflo zin in patients with 
heart failure and chronic kidney  disease
Acronym :MIRACLE (MIneRAlocortico id reCeptor moduLator and sodium-glucosE 
cotransporter -2-inhibitor in HF and CKD trial)
Study Physician Name and Contact Information will be pr ovided separately
International co- ordinating investigators:  (Universit y of Glasgow , Uni ted 
Kingdo m);  (Harvard Medical School, United States);  
(Nati onal Heart Centre, Singapore)
PPD
PPD
PPD
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 2of 138PROTOCOL AMENDMENT S UMMARY OF CHANGES
DOCUMENT HISTORY
Document Date
Version 1.0 25August2020
Amendment 1, Version 2.0 06October 2020
Amendment 2, Version 3.0 26January 2021
Amendment 3, Version 4.0 19March 2021
Amendment 4, Version 5.0 15 July 2021
Amendment 5, Version 6.0 20December 2021
Amendment 6, Version 7.0 02February 2022
A summary  of changes for the previous amendments is provided in  Appendix K.
Amendment 6 (02February 2022 )
This amendment is considered to be substant ialdue to being a correcti on and cl arificat ion of 
CSP Amendment 5/CSP 6.0 which is a substant ial amendment based on the criteria set forth in 
Article10(a) of Direct ive2001/20/EC of the European Parliament and the Council of the 
European Unio n.
Overall Rationale for  the Amendment
The previous Clinical Study  Protocol  (CSP) versi on, versi on6.0, dated 20December 2021 has 
been updated . The updates are summarised below .
Section Number and Name Description of Change Brief Rationale
Section 1.3 Schedule of Activities, 
Table 1Blood samples for 
cardiovascular biomarkers to be 
collected at Follow -Up Visit 11.Correction of typo to align with 
Section 8.6.1 .
Section 1.3 Schedule of Activities, 
Table 1 (footnote)
Section 7.1 Discontinuation of Study 
InterventionText added on open label 
dapa gliflozin use during Safety 
Follow -Up period .Clarification of study 
procedures .
Section 2. 3.1 Risk Assessment, 
Table 2; Section 11 ReferencesInclusion of an additional 
literature reference .To provide the correct literature 
reference .
Sectio n 5.4 Screen Failures New definition of Screen 
Failures .Correction of definition to align 
with revised study design .
In addit ion, the fo llowing administrative changes were made:
Tables of Contents updated.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 3of 138Minor edi torial changes.
TABLE OF CONTENTS
TITLE P AGE ........................................................................................................................ 1
PROTOCOL  AMENDMENT S UMMAR Y OF CHANGES .................................................. 2
TABLE OF CONTENTS ...................................................................................................... 3
1 PROTOCOL  SUMMAR Y.................................................................................. 7
1.1 Synopsis ............................................................................................................. 7
1.2 Schema ............................................................................................................. 12
1.3 Schedule of Act ivities....................................................................................... 13
2 INTRODUCTION ............................................................................................ 25
2.1 Study  Rati onale ................................................................................................ 25
2.2 Background ...................................................................................................... 25
2.2.1 Heart Failure with Chronic Kidney  Disease ...................................................... 26
2.2.1.1 Prevalence of Heart Failure ............................................................................... 26
2.2.1.2 Heart Failure Management ................................................................................ 26
2.2.1.3 Mineralocortico id Receptor Antagoni st for Treatment of Heart Failure and 
Chronic Kidney  Disease .................................................................................... 27
2.2.1.4 Sodium-glucose Co-transporter 2 Inhibitors in Heart Failure and Chronic 
Kidney Disease ................................................................................................. 28
2.3 Benefit/Risk Assessment ................................................................................... 29
2.3.1 Risk Assessment ............................................................................................... 29
2.3.2 Benefit Assessment ........................................................................................... 33
2.3.3 Overall Benefit: Risk Conclusio n...................................................................... 33
3 OBJECTIVES AND ENDPO INTS ................................................................... 34
4 STUDY  DESIGN ............................................................................................. 37
4.1 Overall Design .................................................................................................. 37
4.1.1 Optional Pre-screening ...................................................................................... 38
4.2 Scientific Rationale for Study  Design ............................................................... 38
4.3 Justification for Dose ........................................................................................ 39
4.4 End of Study  Definit ion.................................................................................... 39
5 STUDY  POPULA TION .................................................................................... 40
5.1 Inclusio n Criteria.............................................................................................. 40
5.2 Exclusio n Cri teria............................................................................................. 43
5.3 Lifest yle Considerat ions................................................................................... 45
5.3.1 Meals and Dietary  Restri ctions......................................................................... 45
5.4 Screen Failures ................................................................................................. 46
6 STUDY  INTER VENTION ............................................................................... 47
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 4of 1386.1 Study  Intervent ion(s) Administered ................................................................... 47
6.1.1 Invest igational Products .................................................................................... 47
6.1.2 Medical Devices ............................................................................................... 48
6.2 Preparati on/Handling/Storage/Accountabilit y................................................... 49
6.3 Measures to Minimise Bias: Rando misat ion and Blinding ................................. 49
6.4 Study  Intervent ion Compliance ......................................................................... 50
6.5 Concomitant Therapy ........................................................................................ 51
6.5.1 Prohibited Medications ..................................................................................... 51
6.5.2 Background Medicat ions.................................................................................. 52
6.5.3 Medicat ions Inducing Hypoglycaemia .............................................................. 52
6.6 Dose Modificat ion............................................................................................ 53
6.7 Intervention After the End of the Study ............................................................. 53
7 DISCONTINUA TION OF STUDY  INTER VENTION AND PARTICIPANT 
DISCONTINUA TION/WITH DRA WAL........................................................... 54
7.1 Discontinuati on of  Study  Intervent ion............................................................... 54
7.1.1 Temporary  Discontinuation and Rechallenge .................................................... 55
7.2 Parti cipant W ithdrawal fro m the Study .............................................................. 55
7.3 Lost to Follow -up............................................................................................. 56
8 STUDY  ASSESSMENTS AND PROCEDURES .............................................. 57
8.1 Efficacy Assessments ........................................................................................ 57
8.1.1 Primary/Secondary V ariable:  Urinary  Albumin to Creatinine Rat io (UACR) ....57
8.1.2 Exploratory  Variables –Not Applicable ............................................................ 58
8.2 Safety Assessments ........................................................................................... 58
8.2.1 Physical Examinat ions...................................................................................... 58
8.2.2 Vital Signs ........................................................................................................ 58
8.2.3 Electrocardiograms ........................................................................................... 59
8.2.4 Clinical Safety  Laboratory  Assessments ............................................................ 59
8.3 Adverse Events and Serious Adverse Events ..................................................... 62
8.3.1 Time Period and Frequency for Collect ing AE and SAE Informat ion................ 62
8.3.2 Follow-up of  AEs and SAEs ............................................................................. 62
8.3.3 Causalit y Collection.......................................................................................... 63
8.3.4 Adverse Events Based on Signs and Symptoms ................................................ 64
8.3.5 Adverse Events Based on Examinat ions and T ests............................................ 64
8.3.6 Hy’s Law .......................................................................................................... 64
8.3.7 Reporting of Serious Adverse Events ................................................................ 64
8.3.8 Pregnancy ......................................................................................................... 65
8.3.8.1 Maternal Exposure ............................................................................................ 65
8.3.8.2 Paternal  Exposure ............................................................................................. 66
8.3.9 Medicat ion Error ............................................................................................... 67
8.3.10 Medical Device Deficiencies ............................................................................. 68
8.4 Overdose .......................................................................................................... 68
8.5 Hum an Bi ological  Samples ............................................................................... 68
8.5.1 Pharmacokinet ics.............................................................................................. 69
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 5of 1388.5.1.1 Determinat ion of Drug Concentration ............................................................... 69
8.5.2 Pharmacodynamics ........................................................................................... 70
8.5.2.1 Collect ion of Samples ....................................................................................... 70
8.6 Hum an Bi ological  Sample Bi omarkers ............................................................. 71
8.6.1 Collect ion of Mandatory  Samples for Bi omarker Analysis ................................ 71
8.6.2 Collect ion of Opt ional Biomarker Sam ples....................................................... 71
8.7 Optional Genomics Ini tiative Sample ................................................................ 71
8.8 Medical Resource Utilisat ion and Health Economics ........................................ 71
9 STATISTICAL  CONSIDER ATIONS ................................................................ 72
9.1 Statistical Hypotheses ....................................................................................... 72
9.2 Sample Si ze Determinat ion............................................................................... 72
9.3 Popul ations for Analyses ................................................................................... 73
9.4 Statistical Analyses ........................................................................................... 73
9.4.1 General Considerations ..................................................................................... 73
9.4.2 Efficacy ............................................................................................................ 74
9.4.2.1 Primary En dpoint .............................................................................................. 74
9.4.2.2 Secondary  Endpo int.......................................................................................... 75
9.4.3 Pharmacokinet ics.............................................................................................. 75
9.4.4 Pharmacodynamics and Bio markers .................................................................. 76
9.4.5 Safety............................................................................................................... 76
9.4.5.1 Adverse Events ................................................................................................. 76
9.4.5.2 Vital Signs ........................................................................................................ 77
9.4.5.3 Labora tory........................................................................................................ 77
9.4.5.4 Electrocardiograms ........................................................................................... 78
9.4.5.5 Physical Examinat ion........................................................................................ 79
9.4.5.6 Safety Topics of  Interest .................................................................................... 79
9.5 Interim Analyses ............................................................................................... 79
9.6 Data Monitoring Committee ............................................................................. 79
10 S UPPOR TING DOCUMENT ATION AND OPERA TIONAL 
CONSIDERA TIONS ........................................................................................ 81
11 REFERENCES ............................................................................................... 133
LIST OF FIGURES
Figure 1 Study  Design ........................................................................................... 12
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapag liflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 6of 138LIST OF TABLES
Table 1 Schedule of Act ivities.............................................................................. 13
Table 2 Risk Assessment ...................................................................................... 29
Table 3 Object ives and Endpo ints......................................................................... 34
Table 4 Study  Treatm ents..................................................................................... 38
Table 5 Invest igational Products ........................................................................... 48
Table 6 Laboratory  Safety Variables ..................................................................... 61
Table 7 Popul ations for Analysis .......................................................................... 73
Table 8 CYP3A4 -Interacting Medicat ion that are Prohibited During the Study ...109
LIST OF APPENDICES
LIST OF APPENDICES
Appendix A Regulatory , Ethical , and Study  Oversight Consi derat ions......................... 82
Appendix B Adverse Events: Definit ions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting ........................................................................ 87
Appendix C Handling of Human Bio logical  Samples .................................................. 92
Appendix D Optional Genomics Ini tiative Sample ....................................................... 94
Appendix E Actions Required in Cases o f Increases in Liver Biochemistry  and 
Evaluat ion of Hy’s Law ........................................................................... 97
Appendix F Management of Hyperkalaemia and Deteriorating Renal Funct ion......... 103
Appendix G COVID -19 Specifics .............................................................................. 106
Appendix H Strong and Moderate Cy tochrom e P450 3A4 (CYP3A4) Inhibitors and 
Inducers ................................................................................................. 109
Appendix I Clinical Study  Medical  Device / Device Constituent Report Form ......... 110
Appendix J Abbreviat ions........................................................................................ 111
Appendix K Protocol  Amendment Hi story................................................................. 116
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 7of 1381 PROTOCOL SUMMARY
1.1 Synopsis
Protocol Title: A Phase 2b, Rando mised, Double -Blind, Active-Controlled, Mul ti-Centre 
Study  to Eval uate the Efficacy , Safety  and Tol erabili ty of Oral  AZD9977 and Dapagliflozin 
Treatment in Patients with Heart Failure and Chronic Kidney  Disease
Short Title: Efficacy , safety ,and tol erabili ty of AZD9977 and dapagliflo zin in patients with 
heart failure and chronic kidney  disease
Rationale: Although mineral ocorticoid receptor antagonists ( MRAs )are an important 
standard therapy  for heart failure ( HF), they are currently contraindicated in pat ients with 
estimated glo merular filtrat ion rate ( eGFR )<30mL/min/1.73 m2and are highly underused in 
patients wi th eGFR < 60 mL/min/1.73 m2due to risk of hyperkalaemia. 
AZD9977 is a selective mineralocorticoid receptor (MR) m odulator, with a different iated 
mode of act ion compared with the currently prescribed MR As (eg,
spironol actone/epl erenone).
The m echanism sof action of AZD9977 and dapagliflo zin are different and outcome of the 
combinat ion treatm ent is expec ted to be synergist ic since the main bio logical  effects of 
AZD9977 would be to block MR driven oxidat ive stress, inflammat ion and fibrosis and of 
dapagliflozin to inhibit sodium-glucose co -transporter -2 (SGLT2)-driven metabo lic 
dysfunct ion, vo lume overload ,and endothelial cell dysfunct ion. 
The overall clinical evidence suggests that the combinat ion of AZD9977 and dapagliflozin 
woul d have clinical benefit and an acceptable safety  profile in pat ients with HF and that 
further development is warranted. Hence, a global, randomised, Phase 2b study  is planned to 
evaluate the efficacy and safet y of AZD9977 and dapagliflozin in pat ients with HF.
The purpose of the study  is to establish a dose -response for effect on urinary albumin to 
creatinine ratio ( UACR )and ass ess the safet y of AZD9977 given in co mbinat ion with 
dapagliflozin 10 mg once daily , considering serum /plasma potassi um+(K+)and safet y topics 
of interest (hy perkalaemia, hypotension and deteriorating renal funct ion) in addit ion to general 
safet y.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 8of 138Objectiv es and Endpoints
Objectives Endpoints
Primary
To evaluate the effect of AZD9977 in 
combinat ion with dapagliflo zin 
compared wi th dapaglifl ozin alone on 
UACRPercent change fro m baseline in UACR 
at the end of 12 weeks of study  
treatment
Secondary
To assess the dose -response 
relationship of dapagliflo zin (10 mg) 
alone and 3 doses of AZD9977 (15, 50, 
or 150 mg) combined with 
dapagliflozin (10 mg) on UACRPercent change fro m baseline in UACR 
at the end of 12 weeks of study 
treatm ent
Safety 
To assess the general safety and 
tolerabilit y of AZD9977 in combinat ion 
with dapagliflozin com pared wi th 
dapagliflozin aloneAE/SAE reporting
Vital signs (BP, pulse rate)
Clinical laboratory  tests (clinical 
chemistry , haematol ogy, and urinalysis)
Digital 12-lead safet y ECG assessments
Safety topics of  interest (hy perkalaemia, 
hypotension and deteriorating renal 
funct ion)
To assess the effect of AZD9977 in 
combinat ion with dapagliflo zin 
compared wi th dapaglifl ozin alone on 
serum  K+and eGFRAbsolute value and change fro m 
baseline in serum K+and eGFR over 
time
AE=adverse event; BP=blood pressure; ECG=electrocardiogram; eGFR=estimated glomerular filtration rate; 
K+=potassium; SAE=serious adverse event; UACR=urinary albumin to creatinine ratio.
For expl oratory object ives and endpo ints, see Section  3of the protocol.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 9of 138Overall Design: This is a Phase 2b, mult i-centre, rando mised, double -blind, active -controlled 
parallel group, study  to assess the efficacy, safet y and tol erabilit y of AZD9977 and 
dapagliflozin administered for 12 weeks in patients with HF (LVEF below 60%) and chronic 
kidney disease ( CKD )(eGFR ≥20and ≤60mL/min/1.73 m2),with at least 20% of patients 
with eGFR ≥20 to <30mL/min /1.73 m2and a maximum o f 35% of patients with 
eGFR ≥45mL/min /1.73 m2.
The study  will be conducted atapproximately 150to 250 sites in approximately 20countri es 
including North America , Asia-Pacific, and European countries.
Patients who m eet the eligibilit y criteria will be rando mised to one of the fo llowing 
4treatm ent group s:
AZD9977 15 mg + dapagliflo zin 10 mg 
AZD9977 50 mg + dapagliflo zin 10 mg 
AZD9977 150 mg + dapagliflo zin 10 mg 
Dapagliflozin 10 mg
Parti cipants will be stratified according to T2DM (yes/no) and eGFR ( ≥20 to 
<30mL/min/1.73 m2; or ≥30 to < 45mL/min/1.73 m2; or ≥45 mL/min/1.73 m2)based o n the 
latest eGFR assessment prior to the start of study  treatm ent (eGFR assessment at Visit2).
A Safet y Unblinded Data Review Co mmittee will be set up for this study  for ongoing safet y 
monitoring. In addit ion to general safet y/tolerabilit y, the committee will focus on potential 
risks related to hy potensi on, deteri orating renal function and hyperkalaemia.
An Interim Unblinded Data Review Co mmittee will be set up to review data from the 
pre-planned interim analysis and make recommendations regarding future clinical 
development.
Disclosur e Statement : This is a parallel group treatment study  with 4arms that is 
participant -and invest igator -blinded.
Number of Participants:
Approximately  500participants will be randomly  assigned to study  interventi on 
(125participants per group) such that approximatel y 476evaluable part icipants ( 119 per 
group) complete the study .
Intervention Groups and Duration:
For each participant, the total duration of part icipatio n will be approximately 22to 24 weeks, 
including a 1-week screening period, fo llowed by  up to 7-week run-in period fo llowed by  a 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 a nd dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 10of 13812-week treatment period (including 6 visits), the end of treatment ( EOT )visit, and a 4 -week 
safet y follow-up after last dose (including 1 visit). An optional pre-screening visit may be 
scheduled .Week and day  for pre -screening visit will be at the discretion of the invest igator .
After screening, eligible part icipants currently on treatment with a SGL T2i other than 
dapagliflozin should stop taking the SGL T2i and start on dapagliflo zin 10 mg. Participants on 
dapagliflozi n treatm ent will cont inue on treatment but the medicat ion will be provided. 
Parti cipants will then undergo a 4to 5-week run -in period to ensure washout of forbidden 
medicat ions and stable doses of allowed background medicat ions.
For parti cipants eligible after screening , and not on treatment with a SGL T2i, treatm ent wi th 
dapagliflozin 10 mg will be init iated. Parti cipants will  then undergo a 6to 7-week run -in 
period to ensure washout of forbidden medicat ions and stable doses of allowed background 
medicat ions.
During the treatment period, participants will be rando mly assigned in a 1:1:1:1 ratio to 
receive once daily  administrati on of one of the 4study  treatm ents as described below . To 
ensure blinding , the study  treatm ent w ill be administered in the form of 3oral capsules and 
1oral tablet in the following combinat ions:
Study Treatment Capsule 1 Capsule 2 Capsule 3 Tablet
AZD9977 15 mg + 
Dapagliflozin 10 mgAZD9977 15mg Placebo Placebo Dapagliflozin 10 mg
AZD9977 50 mg + 
Dapagliflozin 10 mgPlacebo AZD9977 50 mg Placebo Dapagliflozin 10mg
AZD9977 150 mg + 
Dapagliflozin 10mgPlacebo AZD9977 50mg AZD9977 100mg Dapagliflozin 10 mg
Dapagliflozin 10 mg 
alone Placebo Placebo Placebo Dapagliflozin 10mg
No dose m odificat ions are allowed during the study .
Data Monitoring Committee: Yes
Statistical Methods
The primary  hypothesis for thi s study  is that AZD9977 in co mbinat ion with dapagliflo zin will 
induce a reduction of albuminuria greater than wit h dapagliflozin alo ne, as assessed by the 
percent chang e from baseline in UACR at 12 weeks.
A total of 119evaluable part icipants per arm will provide 80% power to detect a 30% 
difference in a AZD9977 dose group combined with dapagliflozin 10 mg co mpared to 
dapagliflozin 10 mg alone in percent change fro m baseline in UACR at 12 weeks, assuming a 
standard deviat ion(SD) of1.0 on the natural log -scaleand alpha =0.05. To account for 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 11of 138approximately  5% drop -outfrom the study , approximately  500participants will be rando mly 
assigned to study  interventi on (125participants per group) such that approximately 
476evaluable participants ( 119per group) complete the study . 
Patients randomi sed according to CSP  versions 1. 0to 5.0 (before dropping placebo and 
AZD9977 150 mg monotherapy  arms) will be considered as par t of Cohort 1, while pat ients 
rando mised subsequent ly will be included in the Cohort 2. The primary analysis for remaining 
4treatm ent groups will combine data from both cohorts, while the accrued data from 
discontinued treatm ent groups will be analy sed de scriptively .
The primary  efficacy endpo int for thi s study  is the percent change fro m baseline in UACR at 
12weeks. The mean log percent changes in UACR at 12 weeks for each of the 3 doses of 
AZD9977 combined wit h dapagliflozin 10 mg, and dapagliflozin alo ne will be est imated in a 
mixed model for repeated measures (V isits7, 8, 9, and 10). The values will be 
back-transformed onto the original scale to give the geometric mean relat ive change from 
baseline at 12 weeks. The analysis model will include UACR base line value, treatment ,and 
visit as fixed effect , and the stratifying factors (T2DM [y es/no] and eGFR 
[≥20to<30mL/min/1.73 m2; or ≥30 to <45mL/min/1.73 m2;or ≥45mL/min/1.73 m2])as 
well as the Cohort variable (1 or 2) as covariates . Moreover, treatm ent-by-visit interact ion will 
also be included in the model. The final analy tical approach will be described in detail in the 
Statistical Analysis Plan (SAP).
For the primary  analysis, the m ain treatm ent com parisons to be evaluated are (in a fixed 
sequence of testing) :
1Overall c omparison of the percentage changes from baseline in UACR at week 12 across
all 4 treatm ent groups
2Each of the 3 doses of AZD9977 in co mbinat ion wit h dapagliflozin 10 mg versus 
dapagliflozin 10 mg in the fo llowing order :
1.AZD9977 150 mg + dapagliflo zin 10 mg versus dapagliflo zin 10 mg
2.AZD9977 50 mg + dapagliflo zin 10 mg versus dapagliflozin 10 mg
3.AZD9977 15 mg + dapagliflo zin 10 mg versus dapagliflozin 10 mg
For the analysis addressing the secondary  object ive, the dose -response relat ionship of percent 
change from baseline in UACR at 12 weeks will be assessed using data from dapaglifl ozin 
(10mg) alone and 3 doses of AZD9977 (15, 50, or 150mg) combined wit h dapagliflozin 
(10mg).
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 12of 1381.2 Schema
Figure 1 Study Design
AZD9977 15 mg + dapagliflozin 10 mg
Pre-screening 
informed 
consent and 
local laboratory 
urine sample for 
albumin and 
creatininePatients
with 
HF and CKDDapagliflozin 
10mgLaboratory tests 
for eligibilityDapa -
gliflozin 
10mgAZD9977 50 mg + dapagliflozin 10 mg 
R
AZD9977 150 mg + dapagliflozin 10 mg
Dapagliflozin 10 mg
Pre-screening Screening Start Run -in bPre-
RandomisationBaseline Treatment period
(12weeks)EOT/
ETSafety 
follow -up
(4weeks)
Visit Optional 1a 1b 2 3 4 5 6 7 8 9 10 11
Weeksa(-8 to -7) c
-6 to -5(-7 to -6) c
-5 to -4-1 1 2 3 4 7 10 13 17
Daya-56 to -49) c
-42 to -35(-49 to -42) c
-35 to -28-10 to -3 1 3 8 15 22 43 64 85 113
CKD=chronic kidney disease; EOT=end of treatment; ET=early termination; HF=heart failure; R=randomisation
Note: Visits at Week 7 and Week 13 (Visits 8 and 10) correspond to visits after completion of 6 weeks and 12 weeks of study treatment, respectively.aWeek and day for pre -screening will be at the discretion of the investigator.bDuration of run -in period for patients on treatment with a SGLT2i: 4to 5weeks
Duration of run -in period for patients not on treatment with a SGLT2i: 6to 7weekscApplies to SGLT2i naïve patients
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 13of 1381.3 Schedule of Activities
Table1 Schedule of Activities
ProcedurePre-
scre
enin
gScreeni
ngStart 
Run-inPre-
rando -
misationBaseline/ 
Rando 
misationTreatment PeriodEOT/ET 
aSafety 
Follow -u
pNotesDetails in CSP 
Section or 
Appendix
Visitb Opti
onal1a 1b 2 3 4 5 6 7 8 9 10 11
* Applies to 
SGLT2i naïve 
patientsFor details 
on run- in 
period see 
Section 4.1Weekc(-8 
to -7)*
-6 to -5(-7 
to -6)*
-5 to -4-1
1 1 2 3 4 7 10 13 17
Dayc(-56 
to -49)*
-42 
to -35(-49 
to -42)*
-35 
to -28-10 to -3 1 3 
±
18 
±215 
±322 
±343 
±364 ±3 85 
±3113
±4
Informed 
consentX XAppendix A 3
Local 
laboratory urine 
samples for 
albumin and 
creatinineXSample 
according to 
local clinical 
practice.Section 8.2.4
Inclusion and 
exclusion 
criteriaX X XSections
5.1, 5.2
Enrolment in 
RTSMX Section 6.3
Demography, 
height, smoking 
history, alcohol 
consumptionXSections
5.1, 5.2
Physical 
examination, 
weightXX (pre -
dose)X XFor site visits 
only.Section 8.2.1
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 14of 138ProcedurePre-
scre
enin
gScreeni
ngStart 
Run-inPre-
rando -
misationBaseline/ 
Rando 
misationTreatment PeriodEOT/ET 
aSafety 
Follow -u
pNotesDetails in CSP 
Section or 
Appendix
VisitbOpti
onal1a 1b 2 3 4 5 6 7 8 9 10 11
* Applies to 
SGLT2i naïve 
patientsFor details 
on run- in 
period see 
Section 4.1Weekc(-8 
to -7)*
-6 to -5(-7 
to -6)*
-5 to -4-1
1 1 2 3 4 7 10 13 17
Dayc(-56 
to -49)*
-42 
to -35(-49 
to -42)*
-35 
to -28-10 to -3 1 3 
±
18 
±215 
±322 
±343 
±364 ±3 85 
±3113
±4
Medical/
surgical history X XSections
5.1, 5.2
Concomitant 
medication X X X X X X X X X X X Section 6.5
Adverse eventsSAEs 
onlySAEs 
onlyX X X X X X X X XSection 8.3
Vital signs 
(blood pressure, 
pulse rate)XX (pre -
dose)X X X X X X X XBackground 
treatment for 
hypertension 
should be 
individually 
optimised and 
stable for 
3weeks before 
randomisation 
(Visit 3); BP 
assessed for 
eligibility at 
Visit 3.Sections 
5.1, 6.5.2 , 
8.2.2
Digital 12 -lead 
safety  ECGX dX (pre -
dose)X X X XECGs to be 
added as 
clinically 
indicated.Section 8.2.3
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 15of 138ProcedurePre-
scre
enin
gScreeni
ngStart 
Run-inPre-
rando -
misationBaseline/ 
Rando 
misationTreatment PeriodEOT/ET 
aSafety 
Follow -u
pNotesDetails in CSP 
Section or 
Appendix
VisitbOpti
onal1a 1b 2 3 4 5 6 7 8 9 10 11
* Applies to 
SGLT2i naïve 
patientsFor details 
on run- in 
period see 
Section 4.1Weekc(-8 
to -7)*
-6 to -5(-7 
to -6)*
-5 to -4-1
1 1 2 3 4 7 10 13 17
Dayc(-56 
to -49)*
-42 
to -35(-49 
to -42)*
-35 
to -28-10 to -3 1 3 
±
18 
±215 
±322 
±343 
±364 ±3 85 
±3113
±4
Local 
echocardio -
graphyX dNeeded to 
confirm 
eligibility if 
not assessed in 
past 12 monthsSection 8.2.3
Local 
laboratory 
blood samples 
for clinical 
chemistry and 
haematologyX dSection 8.2.4
Local 
laboratory urine 
sample for 
albumin, 
creatinine, and 
urinalysisX d Spot urine 
sampleSections 
8.1.1 , 8.2.4
Local 
laboratory 
blood sample 
for NT -proBNPX dSection 8.5.2
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 16of 138ProcedurePre-
scre
enin
gScreeni
ngStart 
Run-inPre-
rando -
misationBaseline/ 
Rando 
misationTreatment PeriodEOT/ET 
aSafety 
Follow -u
pNotesDetails in CSP 
Section or 
Appendix
VisitbOpti
onal1a 1b 2 3 4 5 6 7 8 9 10 11
* Applies to 
SGLT2i naïve 
patientsFor details 
on run- in 
period see 
Section 4.1Weekc(-8 
to -7)*
-6 to -5(-7 
to -6)*
-5 to -4-1
1 1 2 3 4 7 10 13 17
Dayc(-56 
to -49)*
-42 
to -35(-49 
to -42)*
-35 
to -28-10 to -3 1 3 
±
18 
±215 
±322 
±343 
±364 ±3 85 
±3113
±4
Local 
laboratory 
blood sample 
for FSH 
measurementX dTo confirm 
postmenopausa
l status of 
women (only 
women of non -
child- bearing 
potential will 
be included in 
the study).Sections
5.1and 8.2.4
Local 
laboratory 
RT-PCR test 
for 
SARS -CoV -2X eOptional.
If available at 
site.Section 8.2.4
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 17of 138ProcedurePre-
scre
enin
gScreeni
ngStart 
Run-inPre-
rando -
misationBaseline/ 
Rando 
misationTreatment PeriodEOT/ET 
aSafety 
Follow -u
pNotesDetails in CSP 
Section or 
Appendix
VisitbOpti
onal1a 1b 2 3 4 5 6 7 8 9 10 11
* Applies to 
SGLT2i naïve 
patientsFor details 
on run- in 
period see 
Section 4.1Weekc(-8 
to -7)*
-6 to -5(-7 
to -6)*
-5 to -4-1
1 1 2 3 4 7 10 13 17
Dayc(-56 
to -49)*
-42 
to -35(-49 
to -42)*
-35 
to -28-10 to -3 1 3 
±
18 
±215 
±322 
±343 
±364 ±3 85 
±3113
±4
Local 
laboratory 
serum/plasma 
samples for K+
and Na+X eX X X X X X X XResults needed 
for eligibility 
and to assess 
discontinuation 
criteria at each 
visitSection 8.2.4
Local 
laboratory 
serum/plasma 
samples for 
creatinine 
including eGFR 
calculationX X X X X X X X Section 8.2.4
Central 
laboratory 
blood samples 
for clinical 
chemistry and 
haematology; 
and plasma 
sample for K+
measurementX (pre -
dose)X X X X X X X X Section 8.2.4
Clinical St udy Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 18of 138ProcedurePre-
scre
enin
gScreeni
ngStart 
Run-inPre-
rando -
misationBaseline/ 
Rando 
misationTreatment PeriodEOT/ET 
aSafety 
Follow -u
pNotesDetails in CSP 
Section or 
Appendix
VisitbOpti
onal1a 1b 2 3 4 5 6 7 8 9 10 11
* Applies to 
SGLT2i naïve 
patientsFor details 
on run- in 
period see 
Section 4.1Weekc(-8 
to -7)*
-6 to -5(-7 
to -6)*
-5 to -4-1
1 1 2 3 4 7 10 13 17
Dayc(-56 
to -49)*
-42 
to -35(-49 
to -42)*
-35 
to -28-10 to -3 1 3 
±
18 
±215 
±322 
±343 
±364 ±3 85 
±3113
±4
Central 
laboratory 
serum sample 
for creatinine 
for eGFR 
calculationX eSection 8.2.4
Central 
laboratory 
serum sample 
for cystatin C 
for eGFR 
calculationX eX (pre -
dose)X X X X X X X X Section 8.2.4
Central 
laboratory 
blood samples 
for HbA1c, 
cholesterol, and 
lipidsX (pre -
dose)X XAfter at least 
8-hour fasting 
for lipids.Section 8.2.4
Central 
laboratory 
urinalysisX (pre -
dose)X X XSection 8.2.4
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 19of 138ProcedurePre-
scre
enin
gScreeni
ngStart 
Run-inPre-
rando -
misationBaseline/ 
Rando 
misationTreatment PeriodEOT/ET 
aSafety 
Follow -u
pNotesDetails in CSP 
Section or 
Appendix
VisitbOpti
onal1a 1b 2 3 4 5 6 7 8 9 10 11
* Applies to 
SGLT2i naïve 
patientsFor details 
on run- in 
period see 
Section 4.1Weekc(-8 
to -7)*
-6 to -5(-7 
to -6)*
-5 to -4-1
1 1 2 3 4 7 10 13 17
Dayc(-56 
to -49)*
-42 
to -35(-49 
to -42)*
-35 
to -28-10 to -3 1 3 
±
18 
±215 
±322 
±343 
±364 ±3 85 
±3113
±4
Central 
laboratory urine 
samples for 
albumin, 
creatinine (for 
UACR 
calculation) , 
Na+, K+, uric 
acid, urea, 
osmolality, 
glucose, and 
cortisolfX e, fX X X X X XFirst morning 
void urine 
sample 
collected at 
home in 
provided vials 
over 
3consecutive 
days until the 
visit day.Sections 
8.1.1 , 8.5.2 , 
8.6.1
Pharmaco -
kinetics
Predose sample 
for AZD9977 
and 
dapagliflozin 
plasma 
concentrationsX X XCollected 
before dose 
intake at site, 
or 1day after 
last dose for 
the EOT/ET 
visit.Section 8.5.1
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 20of 138ProcedurePre-
scre
enin
gScreeni
ngStart 
Run-inPre-
rando -
misationBaseline/ 
Rando 
misationTreatment PeriodEOT/ET 
aSafety 
Follow -u
pNotesDetails in CSP 
Section or 
Appendix
VisitbOpti
onal1a 1b 2 3 4 5 6 7 8 9 10 11
* Applies to 
SGLT2i naïve 
patientsFor details 
on run- in 
period see 
Section 4.1Weekc(-8 
to -7)*
-6 to -5(-7 
to -6)*
-5 to -4-1
1 1 2 3 4 7 10 13 17
Dayc(-56 
to -49)*
-42 
to -35(-49 
to -42)*
-35 
to -28-10 to -3 1 3 
±
18 
±215 
±322 
±343 
±364 ±3 85 
±3113
±4
Optional 
postdose 
plasma samples 
for AZD9977 
and 
dapagliflozin 
concentrationsXCollected at 
1(±0.25), 
2(±0.25), 
4(±0.5), and 
6(±1) hours 
postdose.Section 8.5.1
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 21of 138ProcedurePre-
scre
enin
gScreeni
ngStart 
Run-inPre-
rando -
misationBaseline/ 
Rando 
misationTreatment PeriodEOT/ET 
aSafety 
Follow -u
pNotesDetails in CSP 
Section or 
Appendix
VisitbOpti
onal1a 1b 2 3 4 5 6 7 8 9 10 11
* Applies to 
SGLT2i naïve 
patientsFor details 
on run- in 
period see 
Section 4.1Weekc(-8 
to -7)*
-6 to -5(-7 
to -6)*
-5 to -4-1
1 1 2 3 4 7 10 13 17
Dayc(-56 
to -49)*
-42 
to -35(-49 
to -42)*
-35 
to -28-10 to -3 1 3 
±
18 
±215 
±322 
±343 
±364 ±3 85 
±3113
±4
Pharmaco -
dynamics 
(Central 
laboratory)
Blood samples 
for 
NT-proBNP, 
aldosterone, 
renin, ACTH, 
cortisol, 
copeptin, and 
FPGX (pre -
dose)X X X XCollected at 
the same time 
of the day.
After at least 
8-hour fasting 
for FPG.Section 8.5.2
Exploratory 
measurements 
and 
biomarkers
Serum/plasma 
samples for 
cardiovascular 
biomarkers X (pre -
dose)X X XCentral 
laboratory.Section 8.6.1
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 22of 138ProcedurePre-
scre
enin
gScreeni
ngStart 
Run-inPre-
rando -
misationBaseline/ 
Rando 
misationTreatment PeriodEOT/ET 
aSafety 
Follow -u
pNotesDetails in CSP 
Section or 
Appendix
VisitbOpti
onal1a 1b 2 3 4 5 6 7 8 9 10 11
* Applies to 
SGLT2i naïve 
patientsFor details 
on run- in 
period see 
Section 4.1Weekc(-8 
to -7)*
-6 to -5(-7 
to -6)*
-5 to -4-1
1 1 2 3 4 7 10 13 17
Dayc(-56 
to -49)*
-42 
to -35(-49 
to -42)*
-35 
to -28-10 to -3 1 3 
±
18 
±215 
±322 
±343 
±364 ±3 85 
±3113
±4
Optional 
serum, plasma, 
and urine 
samples for 
exploratory 
assessment of 
biomarkers X (pre -
dose)X X Section 8.6.2
Optional 
genetic sample 
for Genomics 
Initiative 
exploratory 
analysisX (pre -
dose)Section 8.7, 
Appendix D
Study 
treatments
Randomisation 
in RTSMXSection 6.3
Dapagliflozin 
10mg Daily (morning) 
self-administrationDaily (morning) 
self-administrationaSections 4.1, 
6.1.1 , and 6.7
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 23of 138ProcedurePre-
scre
enin
gScreeni
ngStart 
Run-inPre-
rando -
misationBaseline/ 
Rando 
misationTreatment PeriodEOT/ET 
aSafety 
Follow -u
pNotesDetails in CSP 
Section or 
Appendix
VisitbOpti
onal1a 1b 2 3 4 5 6 7 8 9 10 11
* Applies to 
SGLT2i naïve 
patientsFor details 
on run- in 
period see 
Section 4.1Weekc(-8 
to -7)*
-6 to -5(-7 
to -6)*
-5 to -4-1
1 1 2 3 4 7 10 13 17
Dayc(-56 
to -49)*
-42 
to -35(-49 
to -42)*
-35 
to -28-10 to -3 1 3 
±
18 
±215 
±322 
±343 
±364 ±3 85 
±3113
±4
Study  treatmentDaily  (morning) self -administration of the assigned 
study  treatmentTaken at the 
site on visit 
days, after 
completing all 
predose 
procedures.Sections
4.1, 6.2, 6.4
Drug 
dispensationX X X X X XSections 6.2, 
6.3, and 6.4
Drug
accountabilityX X X X X X X X XSections
6.2, 6.4
ACTH=adrenocorticotropic hormone; BP=blood pressure; BUN=bl ood urea nitroge n; CKD=chronic kidney disease; CSP=Clinical Study Protocol; 
ECG=electrocardiogram; eGFR =estimated glomerular filtration rate; EOT=end of treatment; ET=early termination; FPG=fasting plasma glucose; FSH=follicle 
stimulating hormone; HbA1c=glycated haemoglobin; HF=heart failure; K+=potassium; Na+=sodium; NT -proBNP=N -terminal natriuretic peptide; 
RT-PCR=reverse transcriptase polymerase chain reaction; RTSM=Randomisation and Trial Supply Management, SAE=serious adverse event; 
SARS -CoV -2=severe acute re spiratory syndrome coronavirus 2 ; UACR=urinary albumin to creatinine ratio .
Note: Visits at Week 7 and Week 13 (Visits 8 and 10) correspond to visits after completion of 6 weeks and 12 weeks of study treatment, respectively.
aPatients will continue on open label dapagliflozin 10 mg after the E OT visit during the safety follow up period up to Visit 11.Patients who discontinue 
study treatment early may continue on open label dapagliflozin 10 mg after the ET visit during the safety follow up period up to Visit 11, as judged by the 
investigator. Patients who withdraw consent may perform an ET visit but the safety follow -up will not be performed.
bIf site visits are not possible due to local SARS -CoV -2 restrictions, home nursing visits may be considered after disc ussion with and approval by the 
Sponsor.
cWeek and day for pre -screening will be at the discretion of the investigator.
dResults from the screening tests are needed to confirm eligibility before the run -in period can start.
eResults are needed to confirm elig ibility before randomisation. Serum/plasma Na+will be assessed at Visit 2 only. The eGFR -based participant stratification 
will rely on central eGFR assessment at Visit 2.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 24of 138fPhone call will occur prior to the visit to remind the participants to collect the f irst mo rning void samples.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 25of 1382 INTRODUCTION
2.1 Study Rationale
Although MRAs are an important standard therapy for HF , they  are current ly contraindicated 
in patients with eGFR < 30 m L/min/1.73 m2and are highly underused in pat ients with eGFR 
<60 mL/min/1.73 m2due to ri sk of hyperkalaemia.
AZD9977 is a selective MR modulator , with a different iated mode of action co mpared with 
the currently prescribed MR As(eg,spirono lactone/eplerenone).
The m echanism o f action for AZD9977 and dapagliflo zin are different and outcome of 
treatm ent is expected to be synergist ic since the main bio logical effects of AZD9977 would be 
to block MR driven oxidative stress, inflammat ion and fibrosis and dapagliflozin to in hibit 
SGLT2-driven metabo lic dysfunct ion, vo lume overl oad,and endothelia l cell dysfunct ion. 
The overall clinical evidence suggests that the combinat ion of AZD9977 and dapagliflozin 
woul d have clinical benefit and an acceptable safety  profile in pat ients with HF and that 
further development is warranted. Hence, a global, randomised, Phase 2b study  is planned to 
evaluate the efficacy and safet y of AZD9977 and dapagliflozin in pat ients with HF.
The purpose of the study  is to establish a dose- response for eff ect on UACR and assess the 
safet y of AZD9977 given in combinat ion with dapagliflozin 10 mg once daily , considering 
serum /plasma K+and safet y topics of  interest (hy perkal aemia, hypotensio n and deteriorating 
renal funct ion) in addit ion to general safet y.
2.2 Background
The presence of significant concomitant renal dysfunct ion in pat ients with HF severely limit s 
the use and the benefits of proven HF medicat ions, such as ACEIs, ARBs, MRAs, and ARNIs. 
In the absence of evidence -based therapies capable of both renal and cardi ovascular 
protecti on, new treatments are warranted. 
Mineralocorticoid receptor antagonists have proven benefit s on HF, but use has been limited 
due to ri sks associ ated wi th hyperkalaemia, in particular in pat ients with reduced renal 
funct ion, although exist ing evidence suggests that MRAs also provide benefit in HF patients 
with CKD. Sodi um-glucose co -transporter -2 inhibitors have proven benefits on HF , as well as 
potenti al beneficial effects on kidney function. In the recent DAP A-HF tri al (D 1699C00001) 
the treatment benefit of dapagliflozin was observed in HF rEFpatients both wi thT2DM and 
without di abetes. In thatstudy, approximately 70% of the patients were treated with MRAs 
and effect of dapagliflozin was independent of baseline MRA therapy, suggesting addi tive 
effects on top of MRA  treatm ent(McMurray  et al  2019 ). In the recent DAP A-CKD tri al 
(D169AC00001), among patients with CKD, regar dless of the presence or absence of T2DM, 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 26of 138the risk of a composite of a sustained decline in the eGFR of at least 50%, end -stage kidney 
disease, or death from renal or cardiovascular causes was significantly lower with 
dapagliflozin than wit h placebo (Heerspink et al 2020 ). Combinat ion of AZD9977 wit h 
dapagliflozin, could have synergist ic effects and importantly improve outcomes in HF 
patients, especially those wi th lower GFR who do not receive MRA  treatm ent. By  provi ding 
different ial effects on disease mechanisms related to MR driven inflammat ion and fibrosis as 
well as SGLT2-driven mechanisms the action of both drugs is ant icipated to provide 
significant patient benefit. 
2.2.1 Heart Failure with Chronic Kidney Disease
2.2.1.1 Prevalence of Heart Failure 
Chronic HF continues to be a major cause of mortalit y, hospi talisat ions,and suboptimal 
qualit y of life. Even with the best possible treatment, the 5 -year survival rate for HF pati ents i s 
worse than for most cancers ( Braunwald 2015 ). Moreover, the prevalence of chronic HF 
continues to increase glo bally . An est imate d 38 millio n people are affected worldwide 
(Braunwald 2015 ), with over 1 millio n hospitalisatio ns annually in both the United States and 
Europe ( Ambrosy et al 2014 ). The annual glo bal economic burden in 2012 was estimated to 
be $108 billio n 
(Cook et al 2014) and will increase dramat ically as the population ages.
2.2.1.2 Heart Failure Management
Foundat ions of HF management rely on vo lume status with appropriate diuret ic dosing, 
control  of BP, treatm ent of contribut ing risk factors such as sleep apnoea, coronary artery 
disease and valvular disease, alongside with dietary  educati on. The ACCF/AHA  guidelines 
(Yancy et al 2017 ) support the use of beta -blockers, ACEI, ARBs and MRAs. Angiotensin 
receptor -neprilysin inhibitors can replace ACEI or ARB in pat ients with HF who rem ain 
symptom atic despite optimal treatment with an ACEI or ARB, a beta -blocker and an MRA . 
Isosorbide dinitrate /hydralazine and the If-channel  inhibi tor (ivabradine) and di goxin can be 
prescribed in some patients , as appropriate . The European Society o f Cardi ology guidelines 
now include a Class -1 recommendation for treatment with dapagliflozin or em paglifl ozin for 
patients wi th HFrEF to reduce the risk o f HF hospitalizat ion and death ( ESC Gui delines 
2021 ). 
Heart failure patients with CKD have even higher risk and fewer treatment options result ing in 
a pati ent group with high unmet medical need. Studies have indicated that between 20% and 
67% of patients with HF also have CKD ( Sarraf et al  2009 ). Pati ents wi th both HF and renal 
insufficiency have approximately 25% to 30% higher risk of mortalit y compared with pat ients 
with HF wi thout CKD ( Ather et al 2012). However, in patients with poor kidney funct ion 
(eGFR< 30mL/min/1.73 m2) there are no specific therapies approved for renal impairment 
and reco mmended treatments for HF are underused b ecause of intolerance and safet y concerns 
and may  even be contraindicated in some individuals. 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 27of 138This ty pe of  concern primarily  involves inhibitors of the RAAS, including MRAs, and RAAS 
blockers. An addit ional and related concern is the risk of hyperkalaemi a, which is greatest for 
MRAs, with potential risk of or actual hyperkalaemia events being a major cause of underuse 
of this type of therapy . While concerns about worsening renal funct ion and hyperkalaemia 
resul t in underut ilisat ionof MRAs, there i s evide nce from  rando mised clinical trials that 
patients wi th HF and renal impairment have important clinical benefit from MRA  therapy  (Pitt 
et al 1999 , Zannad et al 2011 ). Recent data from the FIDELIO -DKD and FIGARO -DKD tri als 
assessing the non -steroi dal MRA  finerenone in patients with CKD and T2DM esta blished that 
MRAs also are reno -protective in the long term and reduce the CV risks in this pat ient 
popul ation (Bakris et al 2020 , Pitt et al  2021 ).
2.2.1.3 Mineralocorticoid Receptor Antagonist for Treatment of Heart Failure and 
Chronic Kidney Disease
The steroidal MRAs spirono lactone and eplerenone reduce mort ality and hospi talisati ons f or 
HF in pat ients with HFrEF ( Pitt et al  1999 , Zannad et al 2011 ) and have a class 1A 
recommendat ion for the treatm ent of thi s pat ient populat ion in int ernati onal guidelines. In 
patients wi th CKD, MRA  treatm ent has been shown to reduce albuminuria and may i mprove 
long-term kidney  function (Kato et al 2015, Bakri s et al  2015 ). The m ineralocorti coid receptor 
antagonist finerenone was recently shown to prevent the development of cardiovascular 
disease and progression to end -stage kidney disease in patients with CKD and T2DM (Bakri s 
et al 2020 , Pitt et al  2021 ).
One of the primary  safety  concerns rel ated to MRA  treatm ent is the development of 
hyperkalaemia, especially in pat ients taking concomitant medications associated with K+
retenti on (such as ACEIs or ARBs), and in patients with diabetes mellitus and/or kidney 
dysfunct ion (Cooper et al  2017 ). In pl acebo -controlled clinical trials with MRAs in H F 
patients, the incidence of hyperkalaemia is approximately 9%, with 54% of these being truly 
attributable to MRA  therapy  (Vukad
inovi
ć et al 20
17) . Howe ver, real world data suggest that 
the incidence of hyperkalaemia in pat ients with HF coul d be greater than this ( Abbas et al
2015 ). Concern about hyperkalaemia, especially in patients with reduced kidney funct ion 
resul ts in underuse and suboptimal dosing of MRAs in these HF pat ients (Savarese et al
2018 ). 
While dose escalat ion with exist ing MRA  therapies i s limited by  the risk of hyperkalaemia, 
this may  not be the case with novel MR modulators (such as AZD9977), as the dose -response 
relationship for acute effects on urinary electrolyte excretion ma y differ from that for organ 
protection ( Bamberg et al 2018). Novel  MR antagoni sts or m odulators shoul d increase the 
therapeuti c window by  increasing se lectivity against other steroid nuclear receptors thereby  
avoiding gynaeco mastia (eg, wi th spironol actone) as well as improving the separat ion of 
cardi ac and ki dney  protective effects from electroly te regul ation thereby  avoi ding 
hyperkalaemia (seen wit h spironolactone and eplerenone) ( Capelli et al 2020 ). Pre -clinical 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 28of 138data have demo nstrated that AZD9977 at clinically relevant exposures is effect ive in redu cing 
MR-mediated cardiac and renal patho logy, as well as reducing the risk of treatment -related 
hyperkalaemia, when compared to currently available MR antagonists. AZD9977 has been 
evaluated in 7 Phase 1 studi es invo lving healt hy vol unteers at doses up to 1200 mg as a single 
dose and m ultiple dosing of 300 mg twi ce daily , with no clinically  relevant effect on serum K+
levels (see the Invest igator ’s Brochure of AZD9977). In addit ion, a Phase 1b study  com paring 
AZD9977 to spironolactone in pat ients with HF wi th preserved LVEF>40%) and CKD with 
eGFR between 40 and 70 mL/min/1.73 m2was recent ly completed (NCT 03682497). 
Recent ly, the novel non -steroi dal MRA  finerenone was found to be safe and to reduce adverse 
kidney and cardiovascular outcom es in pat ients with CKD and diabetes ( Bakris et al 2020 ).
2.2.1.4 Sodium -glucose Co -transporter 2 Inhibitors in Heart Failure and Chronic 
Kidney Disease
Recent data from cardio vascular outcome studies of the SGL T2i dapagliflozin and real world 
studi es (including patients treated with dapagliflozin) show that treatment with dapagliflozin 
can reduce the risk of cardio vascular death and hospitalisat ion due to HF in patients with and 
without T2DM ( Zinman et al 2015, Ferrannini et al 2016, Fi tchett et al  2016 , Neal  et al  2017 , 
Rådholm et al 2018 , McMurray  et al  2019 , Petri e et al 2020)
. 
It has been postulated that kidney  protecti on al ong wi th diuretic and natriuretic effects induced 
by SGL T2i may contribute to the reductions in HF hospitalisat ion in the EMP A-REG 
OUTCOME, CANV AS, and DECLARE -TIMI58 trials ( Zelniker et al 2019 ). Moreover, the 
reducti on in HF hospitalisat ion in these trials was greater in pat ients with worse baseline 
kidney function; a 40% reduction in HF hospitalisation was observed in pat ients with eGFR 
< 60 mL/min/1.73 m2compared wi th 31% in pat ients with eGFR > 60 to 
< 90 mL/min/1.73 m2and 12% reduction in pat ients wi th eGFR > 90mL/min/1.73 m2
(Zelniker et al 2019 ). Dapagliflozin also reduced UACR by 21% in T2DM patients in the 
DELIGHT study ( Pollock et al 2019 ). In the recent DAP A-HF tri al(D1699C00001) , 
dapagliflozin demo nstrated a reassuring safet y profile in a populat ion with a broad range of 
kidney funct ion (including pat ients with eGFR < 45 and a few with eGFR 
< 30 mL/min/1.73 m2). In this study , approximately  70% of  the pati ents were treated with 
MRAs and effect of dapagliflozin was independent of baseline MRA, suggest ing addit ive 
effects on top of MRA  treatm ent. In the DAP A-CKD trial (D169AC00001), an event -driven 
study  in pat ients with CKD (eGFR ≥ 25 and ≤ 75 mL/min/1.73 m2) with albuminuria (UACR 
≥200 and ≤ 5000 mg/g) with T2DM or without diabetes , dapaglifl ozin was superi or to 
placebo in reducing the incidence of the primary  com posite endpoint of ≥50% su stained 
decline in eGFR, reaching ESRD, cardiovascular or renal  death when added to current 
background therapy . Treatment effects on ESRD were driven by reduct ions in sustained eGFR 
≤ 15 mL/min/1.73 m2and chronic dialysis. There were 1 1events (3 in dapagliflozin, 8 in 
placebo group) of renal transplants in the study . Treatment effects on the exploratory 
composite endpoint of renal death, renal transplant, and chronic dialysis were consistent with 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and d apagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 29of 138effects on ESRD .In addit ion, dapagliflozin was superi or to pl acebo for time to first event of 
the com posite of ≥50% sustained decline in eGFR, reaching ESRD, and renal death; time to 
first event of the com posite of cardi ovascular death and hospitalisat ion for HF; and time to 
death fro m any cause. Treatment benefit was observed in CKD patients both with T2DM and 
without di abetes (Jongs et al 2021 ).
A detailed descript ion of the chemistry , pharmaco logy, efficacy , and safet y of AZD9977 and 
dapagliflozin is provided in the Investigator ’s Brochure of each product.
2.3 Benefit/Risk Assessment
More detailed informat ion about the known and expected benefits and potential risks of 
AZD9977 and dapagliflozin may be found in their respective Invest igator ’s Brochures.
2.3.1 Risk Assessment
Table 2 Risk Assessment
Potential Risk of 
Clinical SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Dapagliflozin
Diabetic ketoacidosis 
in patients with 
diabetes mellitusDiabetic ketoacidosis was only observed in patients 
with diabetes mellitus:
• Type 2 diabetes mellitus :
In the DECLARE study with a median exposure 
time of 48 months, events of DKA were reported 
in27 out of 8574 patients in the dapagliflozin 
10mg group and 12 out of 8569 patients in the 
placebo group.
The events were evenly distributed over the study 
period. Of the 27 patients with DKA events in the 
dapagliflozin group, 22 had concomitant insulin 
treatment at the time of the event.
Precipitating factors for DKA were as expected in 
a T2DM population.
In the DAPA -HF study , events of DKA were 
reported in 3 patien ts with T2DM in the 
dapagliflozin group and none in the placebo 
group.
In the DAPA -CKD study, DKA was not reported 
in any  patient in the dapagliflozin group and in 
2patients with T2DM in the placebo group.
• Type 1 diabetes mellitus :
In the 2 placebo -contro lled clinical trials of 
dapagliflozin in T1DM , patients were advised to 
monitor blood ketones in case of suspected 
symptoms of DKA and seek medical 
advice/attention if their self -measured blood 
ketone reading was ≥0.6 mmol/L. In the pooled 
24-week data, e vents of DKA were reported in 
11(1.9%) patients in the dapagliflozin 10 mg 
group and 3 (0.6%) patients in the placebo group. 
DKA events occurred evenly distributed over the Patients with uncontrolled diabetes 
mellitus (HbA1c > 10%) and patients 
with T1DM are excluded from the 
study  (see exclusion criteria # 6and 
#7).
If ketoacidosis is suspected, 
discontinuation or temporary 
interruption of dapagliflozin/placebo 
should be considered and the patient 
should be promptly evaluated (see 
Section 7.1).
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 30of 138Table 2 Risk Assessment
Potential Risk of 
Clinical SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
study  period. Inadequate insulin doses (missed 
insulin dose or insulin pump failur e) were the 
most common precipitating factors. Three of the 
11patients with DKA in the dapagliflozin 10 mg 
group had blood glucose in the euglycemic range 
(<14mmol/L or 250 mg/dL). Patients with DKA 
events responded to conventional treatment for 
DKA.
• Inaddition, there have been post marketing 
reports of ketoacidosis, including diabetic 
ketoacidosis, in patients with T1DM and T2DM 
taking dapagliflozin or other SGLT2i.
AZD9977 
Hyperkalaemia The primary safety concern related to the on -target 
effects of MR antagonism is the potential for 
development of hyperkalaemia.
The pre -clinical data generated for AZD9977 suggests 
that the risk of hyperkalaemia will be significantly 
lower than for approved MR antagonist drugs (namely 
spironolactone and eplerenone) due to its different 
mechanism of action.
No clinically significant changes were seen in serum K+
levels in completed healthy volunteer studies.
In the phase 1b study in patients with HFmrEF or 
HFpEF and eGFR ≥40 and ≤70 mL/min/1.73 m2, there 
were generally small increases in serum potassium from 
baseline in the AZD9977 and spironolactone groups 
that were generally similar and not considered clinically 
relevant, and there were no discontinuations due to 
hyperkalaemia (confirmed s erum K+≥5.6 mmol/L).
Considerations for combination with dapagliflozin:
In the DAPA -HF trial, patients treated with 
dapagliflozin in conjunction with an MRA at baseline 
showed a reduced incidence of mild and 
moderate/severe hyperkalaemia compared to patients 
treated with placebo ( McMurray et al 2019 ).Patients enrolled in the study should 
have serum /plasma K+level ≥3.5 and 
<5.0mmol/L (see inclusion 
criterion #7).
During the study, changes in 
serum /plasma K+will be closely 
monitored (see SoA). Specific 
discontinuation criteria and 
instructions for management of 
hyperkalaemia are provided (see 
Section 7.1and Appendix F 1).
Deteriorating Renal 
Function/Initial 
eGFR decrease In HF patients, MRA treatment is associated with an 
early  modest decrease in GFR (Rossignol et al 2014 ).
In healthy volunteer clinical studies with AZD9977, no 
clinically significant changes in GFR or creatinine were 
observed.
In the phase 1b study in patients with HFmrEF or 
HFpEF and eGFR ≥ 40 and ≤70 mL/min/1.73 m2, there 
were small decreases in eGFR from baseline in the 
AZD9977 and spironolactone groups that were not 
considered clinically relevant and showed improvement 
at follow -up/after last dose.
Considerations for combination with dapagl iflozin :  
SGLT2 inhibitor classes (including dapagliflozin) are During the study, changes in eGFR 
will be closely monitored (see SoA). 
Specific discontinuation criteria and 
instructions for the management of 
deteriorating renal function are 
provided (see Section 7.1and 
Appen dixF 2).
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 31of 138Table 2 Risk Assessment
Potential Risk of 
Clinical SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
known to be associated with an initial modest decrease 
in eGFR though long -term effects are thought to be 
nephroprotective. 
Hypotension Treatment with MRAs is associated with a BP lowering 
effect and some MRAs, including spironolactone, are 
used in resistant hypertension.
In dog toxicology studies, tachycardia and decreased 
BP were observed with high AZD9977 doses. 
In healthy volunteer clinical studies, no clinically 
significant effect on BP was observed.
In the phase 1b study in patients with HFmrEF or 
HFpEF and eGFR ≥40 and ≤70 mL/min/1.73 m2, there 
were generally decreases from baseline in systolic and 
diastolic blood pressure in both treatment groups, 
though the reduction in systolic blood pressure was 
numerically larger with AZD9977 than with 
spironolactone. These changes were not considere d 
clinically relevant from a safety perspective.
Considerations for combination with dapagliflozin :  
SGLT2 inhibitor classes (including dapagliflozin) are 
known to be associated with modest decreases in BP. Monitoring of BP according to the 
SoA.
Cardiova scular 
effectsIn dog toxicology studies, increases in HR, decreases in 
BP, and cardiac perivascular proliferation were 
observed with high AZD9977 doses.
A follow -up study  in dog and modelling showed that 
cardiac pathology was related to the HR increase an d 
that no pathology occurred with a mean HR below 
135bpm, and HR monitoring was used as a biomarker 
for cardiac pathology in the initial healthy volunteer 
studies.
In healthy volunteer clinical studies and in the Phase 1b 
study  in patients with HFmrEF or HFpEF and eGFR 
≥40 and ≤70 mL/min/1.73 m2, no clinically significant 
effects on HR or BP were observed. The cardiac injury 
biomarkers troponin and NT-proBNP were measured in 
the majority of the healthy volunteer studies, including 
multiple ascending dose studies, with no clinically 
significant effects observed. Monitoring heart rate, BP, and ECGs 
according to the SoA.
Hepatotoxicity In both rats and dogs isolated plasma chemistry changes 
in GLDH, AST, ALT and ALP were noted in some 
animals in the non -GLP studies. None had correlating 
histopathological findings and the findings were not 
reproduced in longer term studies up to 6 and 9 months 
in rat and dog, respectively. In healthy volunteer 
clinical studies and in the Phase 1b study in patients 
with HFmrEF or HFpEF and eGFR ≥40 and 
≤70mL/min/1.73 m2, no clinically relevant trends were 
observed in liver chemistry values.During the study, changes in AST, 
ALT, ALP and bilirubin and potential 
Hy’s law cases will be monitored (see 
SoA and Appendix E).
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 32of 138Table 2 Risk Assessment
Potential Risk of 
Clinical SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Metabolic control Increases in HbA1c by 0.4% and 0.6% were noted in 
2previously published clinical studies with 
spironolactone ( Nielsen et al 2012 , Matsumoto et al 
2006 ).
In the 1 -month and 6 -month rat GLP studies with 
AZD9977, there w as a dose -dependent increase in 
blood glucose, but glucose levels remained in the 
normal range at all doses tested In GLP studies up to 
9month sin dogs, once daily administration of 
AZD9977 was not associated with increased blood 
glucose.
In healthy volun teer clinical studies, no clinically 
relevant trends were observed in plasma glucose values.
In addition, there were no clinically relevant effects of 
AZD9977 on glucose control during an OGTT in the 
MAD study.During the study, changes in HbA1c 
will be monitored (see SoA).
Other
COVID -19 pandemic 
risksThere is currently an outbreak of respiratory disease 
(COVID -19) caused by a novel SARS -CoV-2, for 
which the WHO declared a pandemic situation on 
12March 2020. 
The mechanism of action of AZD9977 and 
dapagliflozin are unlikely impact the course of infection 
with SARS -CoV-2. Therefore, the risk of the 
participants exposure to SARS -CoV-2 or to suffer from 
COVID -19 is expected to be similar to the background 
population with the same co -morbidities as thos e in the 
study , in particular CKD and HF. The risk of exposure 
to infected people cannot be completely excluded as the 
participants may need to expose themselves to public 
areas (eg, commute to the site) and have additional 
human contact (eg, with site sta ff and other participants 
of the clinical study).Patients with signs or confirmation of 
infection are excluded from the study 
(see exclusion criterion # 25). Further 
risk mitigation measures are detailed 
in Appendix G.
ALP=alkaline phosphatase; ALT=alanine transaminase; AST=aspartate transaminase; BP=blood pressure; 
bpm=be ats per minute; CKD=chronic kidney disease; COVID -19=coronavirus disease 2019; DKA=di abetic 
ketoacidosis; ECG=electrocardiogram; eGFR=estima ted glomerular filtration rate; GFR=glomerular filtration 
rate; GLDH=gamma -lactone dehydrogenase; GLP=Good Laboratory Practice; HbA1c=glycated haemoglobin; 
HF=heart failure; HFmrEF=heart failure mid- range ejection fraction; HFpEF=heart failure preserved ejection 
fraction; HR=heart rate; MAD=multiple ascending dose; MR=mineral ocorticoid receptor; MRA= 
mineralocorticoid receptor antagonist; NT-proBNP=N -terminal pro -brain natriuretic peptide; OGTT=oral 
glucose tolerance test; SARS -CoV -2=severe acute respiratory syndrome coronavirus 2; SGLT2i=sodium -glucose 
co-transporter -2 inhibitor; SoA=schedule of activities; T1DM=type 1 diabetes mellitus; T2DM=type 2 diabetes 
mellitus ; WHO=World Health Organization.
The3-month combinat ion toxi cology studi es in rats with AZD9977 and dapagliflozin did not 
reveal aggravated or additional effects not seen with the compounds when studied separately .
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 33of 1382.3.2 Benefit Assess ment
Based on available clinical data with MRAs and dapagliflozin, it is expected that patients 
enrolled in the study  will benefi t from treatm ent wi th dapagliflozin and/or AZD9977:
Clinical data fro m patients wi th HF and CKD suggest clinical benefit of MRAs in 
prevent ing the development of cardiovascular di sease and progression to end- stage 
kidney disease in pat ients with CKD (see Section 2.2.1.3 ).
Recent data from cardio vascular outcome studies of dapag liflozin and real world studies 
(including pat ients treated with dapagliflozin) show that treatment with dapagliflo zin can 
reduce the risk of cardio vascular death and hospitalisat ion due to HF in pat ients with and 
without T2DM (al so when given in addit ion to an MRA), and it has been postulated that 
the kidney  protecti on and natri uretic effects induced by  SGLT2 inhibitors may  account 
for the reductions in HF hospitalisat ion (see Section 2.2.1.4 ).
Recent data from an event -driven study with dapagliflo zin in pat ients with CKD show
that treatment with dapagliflozin is superior to placebo in reducing the incidence of the 
primary  com posite endpoint of ≥50% sustained decline in eGFR, reaching ESRD, 
cardi ovascular or renal  death when added to current background therapy  (see 
Secti on2.2.1.4 ).
2.3.3 Overall B enefit: Risk Conclusion
The overall clinical evidence suggests that the combinat ion of AZD9977 and dapagliflozin 
woul d have clinical benefit and an acceptable safety  profile in pat ients with HF and that 
further development is warranted.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 34of 1383 OBJECTIVES AND ENDP OINTS
Table 3 Objectives and Endpoints
Objectives Endpoints
Primary
To evaluate the effect of AZD9977 in 
combinat ion with dapagliflo zin 
compared wi th dapaglifl ozin alone on 
UACRPercent change fro m baseline in UACR 
at the end of 12weeks of study  
treatm ent
Secondary
To assess the dose -response relat ionship 
of dapagliflozin (10 mg) alo ne and 
3doses of AZD9977 (15, 50, or 
150mg) co mbined with dapagliflozin 
(10mg) on UACRPercent change fro m baseline in UACR 
at the end of 12 weeks of study  
treatm ent
Safety 
To assess the general safety and 
tolerabilit y of AZD9977 in co mbinat ion 
with dapagliflozin compared with 
dapagliflozin alone AE/SAE reporting
Vital signs (BP, pulse rate)
Clinical laboratory  tests (clinical 
chemistry , haematology , and urinalysis)
Digital 12-lead safet y ECG assessments
Safety topics of  interest (hy perkalaemia, 
hypotension and deteriorating renal 
funct ion)
To assess the effect of AZD9977 in 
combinat ion with dapagliflo zin 
compared wi thdapaglifl ozin aloneon 
serum  K+ and eGFRAbsolute value and change fro m 
baseline in serum K+and eGFR over 
time
Exploratory 
To assess the effect of AZD9977 in 
combinat ion with dapagliflo zin 
compared wi th dapaglifl ozin alone on 
serum  NT-proBNP levelsChange from baseline in serum  
NT-proBNP over time
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 35of 138To assess plasma exposure of AZD9977 
and dapagliflo zinPlasma concentrations o f AZD9977 and 
dapagliflozin
To expl ore the rel ationships between 
AZD9977 and dapagliflozin 
dose/exposure and 
safet y/pharmacodynamic variablesDose/exposure of AZD9977 and 
dapagliflozin relat ive to safet y and 
pharmacodynamic variables (eg, 
serum /plasma K+, eGFR, aldosterone)
To assess the effect of AZD9977 in 
combinat ion with dapagliflo zin 
compared wi th dapaglifl ozin alone on 
blood uri c acid, BU N, fasting plasma 
glucose, haematocri t, renin, ACTH, 
cortisol and copeptin levelsChange from baseline in blood uric 
acid, BUN, FPG, haematocri t, renin, 
ACTH, corti sol and copeptin levels over 
time
To assess the effect of AZD9977 in 
combinat ion with dapag liflozin 
compared wi th dapaglifl ozin alone on 
MCV, MCHC, RBC distribut ion width, 
erythrocyte countChange from baseline in blood MCV, 
MCHC, RBC distribution width, 
erythrocyte count over time
To assess the effect of AZD9977 in 
combinat ion with dapagliflo zin 
compared wi th dapaglifl ozin alone on 
urine Na+, K+, uric acid, urea, 
osmolality, glucose, creatinine, and 
cortisolChange from baseline in urine Na+, K+, 
uric acid, urea, osm olality, glucose, 
creatinine, and cortiso l levels over time
To assess the effe ct of AZD9977 in 
combinat ion with dapagliflo zin 
compared wi th dapaglifl ozin alone on 
cardi ovascular bio markers in bloodEvaluat ion of changes in blood 
biomarkers (including but not limited to 
hsTnT, PIIIP3, GDF -15, ST2, ADMA, 
SDMA, L -Arg, ICAM, NGAL) over 
time
Optional : To collect and store serum, 
plasma, and urine samples for future 
exploratory  biomarker research related 
to PK, pharmacodynamics, safet y, and 
tolerabilit y of AZD9977 or 
dapagliflozin; or related to cardiorenal 
diseasesBiomarker assessment in serum, 
plasma, and urine samples
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 36of 138Optional : To collect and store blood 
samples for genetic research (according 
to each country’s local and ethical 
procedures)Exploratory  research into genes/genetic 
variat ion that m ay influence response to 
treatm ent
ACTH=adrenocorticotropic hormone; ADMA=asymmetric dimethylarginine; AE=adverse event; BP=blood 
pressure; BUN=blood urea nitrogen; ECG=electrocardiogram; eGFR=estima ted glomerular filtration rate;
FPG=fasting plasma glucose; GDF -15=growth differentiation fact or-15; hsTnT=high sensitivity troponin T; 
ICAM=intercellular adhesion molecule; K+=potassium; L -Arg=l -arginine; MCHC=mean corpuscular 
haemoglobin concentration; MCV=mean corpuscular volume; Na+=sodium; NGAL=neutrophil 
gelatinase -associated lipocalin; NT-proBNP=N -terminal pro -brain natriuretic peptide; PIIIP3=procollagen 
typeIII N -terminal propeptide; PK=pharmacokinetics; RBC=red blood cell; SAE=serious adverse event; 
SDMA=symmetric dimethylarginine; ST2=suppression of tumourigenicity 2; UACR=urinary albumi n to 
creatinine ratio .
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 37of 1384 STUDY DESIGN
4.1 Overall Design
This is a Phase 2b, m ulti-centre, randomised, double -blind, active-controlled parallel  group, 
study  to assess the efficacy , safet y and tol erabilit y of AZD9977 and dapagliflozin 
administered for 12 weeks in pat ients with HF and CKD (eGFR ≥20and 
≤60mL/min /1.73 m2, with at least 20% of patients with eGFR ≥20 to <30mL/min /1.73 m2
and a maximum of 35% of patients wi th eGFR ≥45mL/min /1.73 m2).
The study  will be conducted atapproximately 150to 250sites in approximately 20countri es 
including North America , Asia/Pacific, and European countries.
For each participant, the total duration of part icipatio n will be approximately 22to 24 weeks, 
including a 1-week screening period, fo llowed by  up to 7-week run-in period fo llowed by  a 
12-week treatment period (including 6 visits), the EOT visit, and a 4 -week safet y follow-up 
after last dose (including 1 visit). An optional pre -screening visit may be scheduled. W eek and 
day for pre -screening visit will be at the di scret ion of the invest igator .
After screening, eligible part icipants currently on treatment with a SGL T2i other than 
dapagliflozin should stop taking the SGL T2i and start on dapagliflo zin 10 mg. Participants on 
dapagliflozin treatment will cont inue on treatment but the medicat ion will be provided. 
Parti cipants will then undergo a 4to 5-week run -in period to ensure washout of forbidden 
medicat ions and stable doses of allowed background medicat ions.
For parti cipants eligible after screening not on treatm ent wi th a SGL T2i, treatment wi th 
dapagliflozin 10 mg will be init iated. Parti cipants will  then undergo a 6to 7-week run -in 
period to ensure washout of forbidden medicat ions and stable doses of allowed background 
medicat ions.
During the treatment period, participants will be rando mly assigned in a 1:1:1:1 ratio to 
receive once daily  administrati on of  one of the 4study  treatm ents as described below . To 
ensure blinding, the study  treatm ent will be administered in the form of 3 oral capsules and 
1oral tablet in the fo llowing combinat ions.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 38of 138Table4 Study T reatments
Study Treatment Capsule 1 Capsule 2 Capsule 3 Tablet
AZD9977 15 mg + 
Dapagliflozin 10 mgAZD9977 15mg Placebo Placebo Dapagliflozin 10 mg
AZD9977 50 mg + 
Dapagliflozin 10 mgPlacebo AZD9977 50 mg Placebo Dapagliflozin 10mg
AZD9977 150 mg + 
Dapagliflozin 10mgPlacebo AZD9977 50mg AZD9977 100mg Dapagliflozin 10 mg
Dapagliflozin 10 mg 
alone Placebo Placebo Placebo Dapagliflozin 10mg
Parti cipants willbe stratified according to T2DM (yes/no) and eGFR ( ≥20 to 
< 30 mL/min /1.73 m2; or ≥30 to < 45 mL/min /1.73 m2; or ≥45 mL/min /1.73 m2)based on the 
latest eGFR assessment prior to the start of study  treatm ent (eGFR at Visit2).
4.1.1 Optional Pre-screening
Patients who perform the optional pre -screening visit to evaluate UACR should sign a 
separate ,abbreviated ICF . Sam ples shoul d be obtained for analysis in a local laboratory . The 
resul ts are to be recorded in the medical records only .
4.2 Scientific Rationale for Study Design
The study  is desi gned to evaluate the effect of AZD9977 in co mbinat ion with dapagliflo zin 
compared wi th dapaglifl ozin alone on UACR. The secondary  object ive is to assess the 
dose-response relationship ofdapagliflozin (10 mg) alone and 3 doses of AZD9977 (15, 50, or 
150mg) co mbined with dapagliflozin (10 mg) on UACR.
The primary  endpoint (percent change from baseline in UACR at 12 weeks) is an established 
key surrogate m arker of the MRA  mechanism of act ion. This marker has also shown to be 
predi ctive for adverse cardiovascular outcomes in patients with HF (Selvaraj et al 2018 ) . 
Reported studies have sh own a cl ear dose -response with UACR for MRAs ( eg, finerenone), 
unlike other bio markers relevant for HF such as the cardiac bio marker NT -proBNP . Clear 
effects on UACR have also been established for dapagliflo zin (Pollock et al 2019 ), while 
dapagliflozin did not significant ly reduce NT -proBNP over 12 weeks compared with placebo 
(Nassif et al 2019 ).
The study  will evaluate general safet y and tol erabili ty with special focus on serum /plasma K+, 
eGFR, and hypotension of treatment with AZD9977 and dapagliflozin in co mbinat ion and 
alone. Expl oratory  object ives include PK, NT -proBNP , biomarkers reflect ing cardiac fibrosis, 
endothelial function,and other aspects of cardiovascular function as well as markers of the 
potenti al mechanisms of action of SGL T2 inhibi tors and AZD9977. 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 39of 1384.3 Justification for Dose
The doses of AZD9977 for combinat ion therapy  were sel ected to enable characterisat ion of 
the dose -response for UACR and to evaluate safety in this pat ient populat ion. 
The wide (10 -fold) range of doses for AZD9977 (15 to 150 mg) given in combinat ion with 
dapagliflozin 10mg and dapagliflo zin treatm entalone will provide a sufficient ly large range 
of AZD9977 exposures to evaluate the dose/exposure response relationship between UACR 
and AZD9977 +dapagliflozin in relat ion to dapagliflo zin alo ne. About one third of the do se is 
excreted as unchanged AZD9977 in urine suggest ing that renal clearance is contribut ing to the 
overall eliminat ion of AZD9977. The main metabolic enzyme for AZD9977 is CYP3A4 that 
may have changed capacit y in pat ients with low renal funct ion.  
. The ongoing PK renal impairment study  (D6401C00008) 
will confirm the PK profile of AZD9977 in pat ients with low renal funct ion including those 
with an eGFR < 30mL/min /1.73 m2. This data will be available ahead of including patients 
with eGFR< 30mL/min/1.73 m2into this study  (D6402C00001). The dose select ion for 
AZD9977 is based on PK, pharmacodynamic and safet y data from previ ous studi es in heal thy 
subjects and in pat ients with HF. Using in vitro and clinical literature data for epleren one, a 
transl ational PK/pharmacodynamic model for UACR reduction was developed. This model 
could well  predict the UACR reduction fo r both spironolactone and finere none assuming the 
same in vitro: in vivo ratio for IC50 and was therefore used to predict the UACR reduction for 
AZD9977. The 3 selected doses of AZD9977 are ant icipated to yield an effect on UACR 
covering the who le dose -response curve fro m approximately  20 to 60% UACR reduct ion.
Dapagliflozin is current ly under invest igation in HF patients with L VEF >40% (HFmrEF and 
HFpEF) in the DELIVER ◦study  ([STUDY_ID_REMOVED]). The dapagliflozin dose of 10 mg once daily 
is approved for treat ment of pat ients with T2DM, for patients with heart failure and reduced 
ejection fraction with or wi thout T2DM, and for patients with chronic kidney disease with or 
without T2DM.
There i s a low ri sk for m etabo lic drug -drug interactions between AZD9977 and dapaglifl ozin. 
AZD9977 is mainly eliminated by CYP3A4 -mediated m etabo lism and dapagliflozin is not an 
inhibitor of that metabo lic enzyme ( Kasichayanula et al 2012 ). Dapagliflozin is mainly 
eliminated by  UGT1A9 -mediated metabo lism and AZD9977 is not an inhibitor of that 
metabo lic enzyme.
4.4 End of Study Definition
A participant i s consi dered to have com pleted the study  if he/she has co mpleted all phases of 
thestudy  including the safet y follow-up visit.
The end o f the study  is defined as the date of the last visit of the last participant in the study .
CCI
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 40of 1385 STUDY POPULATION
Prospective approval o f protocol  deviati ons to recrui tment and enro lment criteria, also known 
as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
Parti cipants are eligible to be included in the study only if all o f the following criteria apply at 
screening (V isit1a):
Age
1Parti cipant m ust be 21years o f age or ol der, at the time of signing the informed consent.
Type of Participant and Disease Characteristics
2Docum ented di agnosis of stable symptomat ic HF (NYHA class II -III) at screening 
(Visit1a), and a medical history  of typical  symptoms and signs of HF in those who are 
currentl y receiving loop diuretic treatment.
Typical  symptoms associated with HF: breathlessness, orthopnoea, paroxy smal 
nocturnal  dyspnoea, reduced exercise tolerance, fatigue, tiredness, increased time to 
recover after exercise.
Signs associ ated wi th HF: 
oMore s pecific: elevated jugular venous pressure, hepatojugular reflex, third heart 
sound (gallop rhy thm), laterally  displaced apical impulse.
oLess specific: weight gain (> 2 kg/week), weight loss (in advanced HF), tissue 
wasting (cachexia), cardiac murmur, perip heral oedema (ankle, sacral, scrotal), 
pulmo nary crepi tations, reduced ai r entry  and dullness to percussion at lung 
bases (pleural effusio n), tachycardia, irregular pulse, tachypnoea, Cheyne Stokes 
respi ration, hepatomegaly, ascites, co ld extremit ies, olig uria, narrow pul se 
pressure.
3Left ventricular eject ion fraction <60% documented by the most recent echocardiogram 
2D or 3D or cardiac magnetic resonance imaging within the last 12 months prior to 
screening.
If pat ient has experienced an acute myocardial e vent/injury  associ ated wi th release of 
cardi ac troponin wit hin the previous 12 months, then a more recent echocardiogram to 
determine eligibilit y for parti cipat ion in the study must be at least 12 weeks after the most 
recent cardi ac event.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 41of 1384Patients shoul d be treated for HF, hypertensio n, T2DM, or renal disease according to 
guidelines .
Note: Background treatment should be in line wit h locally  recognised treatm ent 
guidelines in each indication, as described in Sect ion6.5.2.Both patients with or without 
SGLT2i  treatm ent can be included in the study  (Secti on6.1.1 ).
5NT-proBNP ≥ 300 pg/mL for pati ents wi th sinus rhy thm at screening ;and 
NTproBNP ≥ 600 pg/mL for pati ents wi th atrial fibrillat ion/flutter at screening , using 
local laboratory  sample .
6eGFR ≥30 and ≤ 60 mL/min /1.73 m2(by CKD- EPI f ormulabased on local laboratory  
sample ).
Note: Recruit ment will start with patients who have eGFR ≥30 m L/min/1.73 m2. During 
the study , the Safet y Unblinded Data Review Committee may  decide to also include 
patients wi th eGFR ≥ 20 to <30 mL/min /1.73 m2.
7UACR at screening: spot urine sample analysed at local laboratory  ≥30 m g/g 
(3mg/mmo l) and < 3000 mg/g (300 mg/mmo l) for parti cipants on SGLT2i ; spot urine 
sample analysed at local laboratory  ≥50 m g/g (5 mg/mmol) and < 3000 mg/g 
(300 mg/mmo l) for parti cipants not on SGLT2i.
Note: The l ower limit for participants not on SGLT2i may  be increased to ≥60 mg/g 
(6mg/mmo l) in case high proportion of randomisation failures due to UACR (eg ,if 
>50% of participants fail due to UACR < 30 m g/g [3mg/mmo l]) at the di screti on of  the 
Sponsor. 
Weight
8Body  mass index less than 40 kg/m2.
Sex
9 Male or f emale of non- childbearing potential.
Reproduction
10Female pat ients must be of non-child bearing potential .
Women of non-childbearing potential are defined as w omen who are ei ther perm anent ly 
sterilised (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are 
postm enopausal. Women will beconsidered postmenopausal ifthey have been 
amenorrhoei c for 12 months pri or to the pl anned date of randomisat ion without an 
alternat ive medical cause. The fo llowing age -specific requirements apply:
(a)Women <50years o ld would be considered postmenopausal if they have been 
amenorrhoei c for 12 months or more fo llowing ces sation of  exogenous hormonal 
treatm ent and FSH levels in the postmenopausal range.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 42of 138(b)Women ≥ 50 years ol d woul d be considered postmenopausal if they  have been 
amenorrhoei c for 12 months or more fo llowing cessation o f all exogenous hormonal 
treatm ent.
11Male pa tients m ust be surgi cally  sterile or using, in conjunct ion with their female partner, 
a highly effect ive method of contraception for the duration of the study  (from the time 
they sign consent) and for 3 months after the last dose of study  drug to prevent p regnancy 
in a partner. Male study  parti cipants m ust not donate or bank sperm during this same t ime 
period.
Informed Consent
12Capable of giving signed informed consent as described in Appendix Awhich incl udes 
compliance wi th the requi rements and restri ctions listed in the ICF and in this protocol.
13Provisio n of signed and dated, written ICF prior to any mandatory  study  specific 
procedures, sampling, and analyses.
NOTE: F or the opti onal pre -screening visit there is a separate informed consent. Refer to 
Secti on 4.1.1 .
14Provisio n of signed and dated written Optional Genet ic Research Informat ion informed 
consent prior to collection o f samples for optional genet ic research that supports Genomic 
Initiative.
Participants are eligible to be randomis ed in the study  only if all o f the following criteria apply 
at randomi sation(Visit3):
15eGFR ≥30 mL/min/1.73 m2(by CKD- EPI f ormula at central  laboratory )based on results 
from pre-rando misat ion Visit 2.
Note: Recruit ment will start with patients who have eGFR ≥ 30 mL/min/1.73 m2. During 
the study , the Safet y Unblinded Data Review Committee may  decide to also include 
patients wi th eGFR ≥20 to < 30 mL/min/1.73 m2
16UACR ≥30 m g/g (3 mg/mmo l) and < 3000 m g/g (300 mg/mm ol)based on central  
laboratory samples collected at pre-randomisation Visit 2.Refer to Section 8.1.1 .
17Serum /plasma K+level ≥3.5 and < 5.0mmo l/L within 10days prior to randomisat ion 
(Visit3) fro m local laboratory .
18Serum /plasma sodi um (Na+) level wi thin norm al reference values wit hin 10days pri or to 
rando misat ion (Visit 3) from local laboratory .
19Systolic BP ≥ 90 and < 150mmHg (or < 180mmHg if the patient is already receiving 3 or 
more ant ihypertensive drugs) at randomisat ion (Visit 3), with no change to 
antihypertensive treatments in previous 3 weeks. Ant ihypertensive drugs include, but are 
not limited to, a diuret ic, ACEI, ARB, beta -blocker and calcium channel blo cker.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 43of 1385.2 Exclusion Criteria
Parti cipants are excl uded from  the study  if any of the fo llowing cri teria apply:
Medical Conditions
1Primary glo merulopathy , vasculi tic renal disease (including ANCA -associ ated vasculit is), 
prior dialysis or unstable rapidly progressing renal disease, autosom al dominant or 
autosom al recessive polycyst ic kidney disease, lupus nephrit is or ANCA -associ ated 
vasculit is.
2Patients wi th current ly deco mpensated HF requiring hospitalisat ion for optimisation of 
HF treat ment and are not on stable HF therapy  at the time of enrolment.
3HF due to cardio myopathies that woul d primarily require specific other treatment such as 
cardi omyopathy  due to amyl oidosis or infiltrat ive diseases, primary hypertrophic 
cardi omyopathy , cardi omyopathy  related to current toxi c or infect ive condit ions (ie, 
ongoing chemotherapy , infect ive myocardi tis, septic cardio myopathy ).
4High output HF (eg, due to hy perthy roidism  or Paget’s di sease).
5HF due to pericardial disease, congenital heart disease or c linically significant 
uncorrected primary  cardi ac valvular disease or planned cardiac valve repair/replacement.
6Patients wi th uncontrolled diabetes mellitus (HbA1c > 10%).
7Patients wi th T1DM.
8Intermittent or persistent 2ndor 3rddegree atrioventricular block, sinus node dysfunct ion 
with clinically significant brady cardi a or sinus pauses, not treated with a pacemaker.
9Known congenital lo ng QT syndro me or history  of QT prol ongat ion associ ated wi th other 
medicat ions.
10History  of any life-threatening cardiac dysrhy thmia (con tinuous or paroxysmal) or 
uncontrolled ventricular rate in pat ients with atrial fibrillat ion or atrial flutter.
11Acute coronary  syndro me and/or elect ive/non -elective percutaneous cardiac intervent ions 
within 3 monthsprior to randomisat ion (Visit3) or is planned to undergo any  of these 
procedures during the study .
12Any major cardiovascular (eg ,open chest coronary artery  bypass grafting or valvular 
repai r/repl acement) or m ajor non -cardi ovascular surgery  as judged by  the invest igator 
within 3 months prior to randomisat ion (Vi sit3) or is planned to undergo any  of these 
procedures during the study .
13Heart transplantation or left ventricular assist device at any t ime or if these are planned.
14Kidney or any  organ transplanta tion or if these are planned.
15Addison’s disease (a medical condit ions associated with development of hyperkalaemia).
16History  or ongoi ng allergy/hypersensit ivity, as j udged by  the invest igator, to SGLT2i (eg, 
dapagliflozin, empagliflo zin).
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C0 0001
CONFIDENTIAL AND PROPRIETARY 44of 13817Any clinically  significant di sease or di sorder (eg, cardiovascular, gastrointest inal, liver, 
renal, neuro logical, muscul oskeletal , endocrine, metabolic, psychiatric, major physical 
impairment) which, as judged by the invest igator, might put the patient at risk because of 
participat ion in the study, or probable alternat ive primary reason for patient’s symptoms 
in judgement of investigator, including but not limited to:
(a)Isolated pulm onary arteri al hypertensio n (defined as mean PAP ≥ 25 mmHg at rest) 
or right ventri cular failu re; in the absence of left -sided HF.
(b)Anaemia defined as haemoglo bin level < 100 g/ L or < 10 g/ dL at time of screening 
(Visit 1a).
(c)Severe chronic obstructive pulmo nary disease or other lung disease including but not 
limited to pulmonary fibrosis requiring chronic oxygen therapy , regul ar nebuliser use 
or oral  steroi d therapy .
18Stroke, transient ischaemic attack, carotid surgery ,or caroti d angi oplast y within previ ous 
3months pri or to randomisation (Visi t 3).
19Active malignancy requiring treatment (except for basal cell or squamous cell carcino mas 
of the skin). 
20Hepati c disease, including hepat itis and/or hepatic impairment (Child -Pugh cl ass A -C), 
AST or ALT >2 × ULN; or TBL > 2 ×ULN at time of screening (Visit 1a).An isolated 
increase in bilirubin in pat ients with known Gilbert’s syndro me is not a reason for 
exclusio n. 
21Prior or ongoi ng drug or alcohol abuse.
22Patients treated with stron g or moderate CYP3A4 inhibitor or inducer (Appendix H).
23Patients wi th newly detected pathological laboratory  values or an ongoing disease 
condi tion requi ring investi gation and/or ini tiation or adjustment of current treatment (in 
the opi nion of th e invest igator).
24Any condit ion outsi de the renal and cardiovascular disease area, such as but not limited to 
malignancy, with a life expectancy of less than 2 years based on invest igator´s clinical 
judgement.
25Any of the fo llowing signs or confirmat ion of C OVID -19 infect ion:
(a)Optional in case RT -PCR i s available at the site with an appropriate turnaround time: 
Patient has a posi tive test result for SARS- CoV -2 at Vi sit 2 before rando misat ionat 
Visit 3.
(b)Clinical signs and symptoms consistent with COVID- 19 (eg, fever, dry  cough, 
dyspnoea, sore throat, fat igue) or confirmed infect ion by appropriate laboratory  test 
within the last 4 weeks prior to screening (Visit 1a) or at randomisat ion (Vi sit3).
(c)Patient has been previously hospitalised with COVID -19 infect ion and did notfully 
recover the irprevious healt h status .
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 45of 138Prior/Concomitant Therapy
26 P rior medical  treatm ent wi th an MRA where the medicat ion was taken wit hin 90 days 
prior to screening (Visit 1a).
27 T reatment with MRA and other prohibited conco mitant medicationsduring run -in.
Note: Prohibited medications are listed in Section 6.5.1 .
28 C urrent or prior treatment within 6 months prior to screening (Vi sit 1a) with cytotoxic 
therapy , immunosuppressive therapy , or other immunotherapy .
29Parti cipation in another clinical study  with an investi gational product administered in the 
last 3 months pri or to randomisat ion (Visit 3).
Other Exclusions
30Involvement in t he planning and/or conduct of the study (applies to both AstraZeneca 
staff and/or staff at the study  site).
31Judgement by  the investi gator that the participant should not participate in the study  if the 
participant is unlikely  to com ply with study  procedure s, restrict ions,and requi rements.
32Previous rando misation in the present study.
33Plasma donat ion within 1 month of the visit at the clinic or any  blood donati on/bl ood l oss 
> 500 mL during the 3 months prior to any  visit at the clinic.
Genetic Sampling (Optional)
Exclusio n from this genet ic research may be for any o f the excl usion criteria specified for the 
main study  or any  of the fo llowing:
34Previous allogeneic bone marrow transplant.
35Non-leukocyte depleted whole blood transfusio n wit hin 120 days of gen etic sample 
collect ion.
5.3 Lifestyle Considerations
5.3.1 Meals and Dietary Restrictions
Patients shoul d fast pri or to the collect ion of blood samples for FPG and lipids, on the days 
specified in the SoA. Fast ing is defined as no caloric intake for at least 8 hours prior to the 
collect ion of the sample.
There are no other specific meals and dietary  restricti ons.
Study  medicati ons shoul d be taken at approximately  the same hour each m orning, and the 
time recorded by  the participant in the diary  card (see Secti on6.4).
On days when participants will attend the study  site for a study  visit and assessments, they  
will be asked to nottake their study  medicati ons pri orto attending the study  visit. The 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 46of 138participant will take the study  medicat ion at the site after complet ing all predose procedures 
and provided they are permitted to con tinue in the study  following assessments.
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
fail to be eligible to start Run -in. A minimal set of screen failure informat ion is required to 
ensure transparent reporting of screen failure participants to meet the CONSOR T publishing 
requirements and to respond to queries fro m regul atory  authori ties. Minimal informat ion 
includes demography , screen failure details, eligibilit y criteria, and any  SAE.
Individuals who do not meet the eGFR and /orK+inclusion/exclusio n criteria forparticipat ion 
in the study  at screening ( Visit1a)and/or pre-randomi sation Visit2, may  have their eGFR 
and/or serum/plasma K+retested laterupon invest igator's discret ion.
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay be
rescreened. Only 1 rescreening is allowed in the study . Rescreened participants should be 
assigned the same participant number as for the initial screening.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 47of 1386 STUDY INTERVENTION
Study  intervent ion is defined as any invest igational intervent ion(s), m arketed product(s), 
placebo, intended to be administered to, or medical device(s) intended to be used by a study  
participant according to the CSP.
6.1 Study Intervention(s) Administered
6.1.1 Investigational Products
After screening, eligible part icipants currently on treatment with a SGL T2i other than 
dapagliflozin should stop taking the SGL T2i and start on dapagliflo zin 10 mgonce daily . 
Parti cipants on dapagliflozin treatment will cont inue o n treatment but the medicat ion will be 
provi ded. Parti cipants will then undergo a 4to 5-week run -in period to ensure washout of 
forbidden medicat ions and stable doses of allowed background medicat ions.
For parti cipants eligible after screening not on trea tment wi th a SGL T2i, treatment wi th 
dapagliflozin 10 mg once daily  will be init iated. Parti cipants will then undergo a 6to 7-week 
run-in period to ensure washout of forbidden medications and stable doses of allowed 
background medicat ions.
Parti cipants wil l be rando mly assigned with a 1:1:1:1 ratio to receive once daily 
administration of one of the fo llowing study  treatments:
AZD9977 15 mg + dapagliflo zin 10 mg
AZD9977 50 mg + dapagliflo zin 10 mg
AZD9977 150 mg + dapagliflo zin 10 mg
Dapagliflozin 10 mg
To ensure blinding to treatment allocation and the AZD9977 dose, daily  dosing will  consist of 
1 open l abel dapagliflozin 10 mg tablet and 3 AZD9977 capsules containing respectively 
AZD9977 150 mg or placebo, AZD9977 50 m g or pl acebo, and AZD9977 15 mg or plac ebo 
See Table 5and Sect ion4.1.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapaglif lozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 48of 138Table 5 Investigational Pr oducts
AZD9977 Dapagliflozin
Intervention 
NameAZD9977 15 mg 
or placeboAZD9977 50 mg 
or placeboAZD9977 
100mg or 
placeboDapagliflozin
10mg 
Type Drug Drug Drug Drug
Dose 
FormulationPellets in 
capsule (size 3)Pellets in 
capsule (size 0)Pellets in 
capsule (size 0)Film-coated tablet
Unit Dose 
Strength(s)15mg 50mg 100mg 10mg
Dosage Level(s) 15mg:
1AZD9977 15 mg capsule +
1 placebo size 0 capsule +
1 placebo size 0 capsule
10mgtablet50mg:
1 AZD9977 50 mg capsule +
1 placebo size 3 capsule +
1 placebo size 0 capsule
150mg:
1AZD9977 50 mg capsule +
1 AZD9977 100 mg capsule +
1 placebo size 3 capsule
Route of 
Administrationoral oral oral oral
IMP and NIMP IMP IMP IMP IMP, NIMPa
Sourcing AZD9977, dapagliflozin, and matching placebo treatments will be supplied 
centrally through AstraZeneca.
Packaging and 
LabellingFor each strength, AZD9977 and matching placebo will 
be provided in bottles containing 32 capsules.Dapagliflozin will be 
supplied in HDPE 
bottles containing 
35tablets.
All bottles will be labelled in accordance with GMP Annex 13 and per country 
regulatory requirement.
GMP=Good Manufacturing Practice; HDPE=high -density polyethylene; IMP=investigational medici nal product; 
NIMP=non -investigational medicinal product .aDapagl iflozin is NIMP during the run -in and safety follow -up, but IMP during the treatment phase.
6.1.2 Medical Devices
1No AstraZeneca manufactured medical devices (or devices manufactured for AstraZeneca
by a third party ) are provi ded for use i n this study .
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 49of 1382Other medical devices (not manufactured by  or for AstraZeneca) provi ded for use in this 
study  areas fo llows. 
dECG device: GE MAC 2000 ECG Analysis System (510k and CE marked)
3All medical device deficiencies (including malfunction, use error and inadequate 
labelling) will be docum ented and reported by  the investi gator throughout the clinical 
investigat ion (see Sect ion  8.3.10 ) and appropriately managed by the sponsor .
6.2 Preparation/Handling/Storage/Accountability
1The invest igator or designee must confirm appropriate temperature condit ions have been 
maintained during transit for all study  intervent ion received and any discrepancies are 
reported and resolved before use of the study  intervent ion.
2Only participants enro lled in the study  may receive study  intervent ion and only authorised 
site staff may supply or administer study  intervent ion. All study  intervent ion must be 
stored in a secure, environmentally controlled, and monitored (manual or automated) area 
in accordance wit h the labelled storage condit ions with access limited to the invest igator 
and authorised site staff.
3The inve stigator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  interventi on accountabilit y, reconciliat ion, and record maintenance 
(ie, recei pt, reconciliat ion, and final disposit ion records).
4Further gui dance and information for the final disposit ion of unused study  interventi ons 
are provided in the Study  Drug Handling Instructions.
6.3 Measures to Minimise Bias: Randomisation and Blinding
All participants will be centrally assigned to randomised study  interventi on using an 
IRT/RTSM. Before the study  is init iated, the telephone number and call -in directions f or the 
IRT and/or the log in informat ion and direct ions for the R TSM will be provided to each site.
Study  intervent ion will be dispensed at the study  visits summa rised in SoA. 
Unused r eturned study  intervent ion must not be re -dispensed to the participants.
The IR T/RTSM will provide to the invest igator(s) or pharmacists the kit ident ificat ion 
number sto be allocated to the participant at the dispensing visit.
Routines for this will be described in the IR T/RTSM user m anual  that will  be provi ded to each 
centre.
The rando misat ion code should not be broken except in medical emergencies when the 
appropriate management of the participant requires knowledge of the tre atment randomisation. 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 50of 138The invest igator documents and reports the action to AstraZeneca, without revealing the 
treatm ent given to participant to the AstraZeneca staff.
AstraZeneca retains the right to break the code for SAEs that are unexpected and are 
suspected to be causally  related to an invest igational product and that potentially  require 
expedited reporting to regulatory  authori ties. Randomisat ion codes will not be broken for the 
planned analyses of data until all decisio ns on the evaluabilit y of the da ta from each individual 
participant have been made and documented.
The IR T/RTSM will be programmed with blind -breaking instructions. In case of an 
emergency , in which the knowl edge of the specific blinded study  treatm ent will affect the 
immediate managemen t of the parti cipant ’s condi tion (eg, antidote available), the invest igator 
has the sole responsibilit y for determining if unblinding of a participants ’ interventi on 
assignment is warranted. Participant safet y must always be the first considerat ion in maki ng 
such a determination. If a participant ’s intervent ion assignment is unblinded, the sponsor must 
be notified wit hin 24 hours after breaking the blind. The invest igator documents and reports 
the acti on to AstraZeneca, without revealing the treatment given to parti cipant to the 
AstraZeneca staff.
The PK samples will be analysed at Labcorp Drug Development bioanalyt ical laboratory  only 
for pati ents on acti ve treatm ent. The bioanalyt ical laboratory  will, therefore, have access to the 
treatm ent codes but will not share the codes with the sponsor or others invo lved in the study  
until the blinding is broken for the study after closure.
6.4 Study Intervention Compliance
Parti cipants will take treatment at the site on visit days and at home between visit s.
When partici pants are dosed at the site, they  will receive study  treatm ents di rectly fro m the 
investigator or designee, under medical supervisio n, after checking treatment was not taken at 
home before coming to the study site. The date, and time of dose administered i n the clinic 
will be recorded in the source documents and recorded in the eCRF . 
When participants self -administer study  treatm ents at hom e, com pliance wi th study  treatm ent 
will be assessed at each visit. Diary  Cards will  be given to the pati ents at the ra ndomisat ion 
visit (Visit3) and the patients will be asked to fill in the dose intake informat ion (date and 
time) at hom e. The diary cards will be checked by study  site personnel at the study  visits and 
data transferred to the eCRF . 
Com pliance will  be ass essed by  direct questi oning and count ing returned tablets/capsules
during the site visits and documented in the source documents and eCRF . Deviat ion(s) fro m 
the prescribed dosage regimen should be recorded in the eCRF .
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 51of 138A record of the number of dapaglifloz in tablets and AZD9977/placebo capsules dispensed to 
and taken by each part icipant must be maintained and reconciled with study  intervent ion and 
compliance records. Intervention start and stop dates, including dates for intervent ion delays 
will also be rec orded in the eCRF . If treatm ent was taken at home before coming to the study  
site, no new dose should be administered, and the date and time of the dose administered at 
home should be recorded in the eCRF .
6.5 Concomitant Therapy
Any medicat ion or vaccine (inc luding over -the-counter or prescript ion medicines, vitamins, 
and/or herbal supplements) that the participant is receiving at the time of screening (V isit1a) 
or receives during the study  must be recorded along with:
Reason for use
Dates of administration including start and end dates
Dosage information including dose and frequency
Parti cipants may  be enrolled and or continue in the study  regardl ess of thei r choi ce to be 
vaccinated or not. COVID -19 vaccine received prior to or during the study  entry  must b e 
recorded including the ty pe of vaccine.
The Study  Physician shoul d be contacted if there are any  questi ons regarding prior or 
concomitant therap ies.
6.5.1 Prohibited Medications
The m edicati ons and supplements listed below are prohibited from at leaststart of run-in and 
for the durati on of  the study . Pati ents taking any  of these medicat ions at the start of the run- in 
period cannot be included into the study . 
Potassi um-sparing diuretics (eg, amiloride, triamterene)
MRAs or aldosterone antagonists (eg, eplereno ne, spirono lactone)
ACEI and ARB taken in combinat ion
Direct renin inhibitor (eg, Aliskiren)
Cyclosporin or tacrolimus
Strong or moderate CYP3A4 inhibitors or inducers (see Appendix H)
K+supplements or dietary  salt alternat ives containing K+such as Lo -Salt(prohibited 
during run -in unless if s erum K+<3.5mmo l/L,and can be started during the study as a 
corrective action if hypokal aemia is confirmed )
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 52of 138NSAIDs (The use of acet ylsalicylic acid as ant iplatelet agent is allowed prior and during 
the study  as well  as the intermittent use of topical NSAIDs if prescribed for a medical 
condi tion)
Potassi um binders (prohibi ted at scr eening/rando misation butcan be started as a 
corrective action during the study )
Medical treatment with an MRA  is exclusio nary if the medicat ion was taken within90days 
prior to screening (V isit1a). Cytotoxi c therapy , immunosuppressive therapy ,and other 
immunotherapy  for primary or secondary  renal  disease are prohibi ted wi thin 6 months prior to 
screening (V isit1a)and for the duration of the study .
6.5.2 Background Medications
Background treatment for HF , hypertensio n, or renal disease should be stable f or at l east 
3weeks prior to randomisat ion (see inclusio n criterion#4) and rem ain stable during the study .
Patients wi th HF and L VEF ≤40% shoul d receive background standard of care for HFrEF and 
be treated according to locally recognised guidelines with both drugs and devices, as 
appropriate.
Guideline -recommended medicat ions should be used at recommended doses unless 
contraindicated or not tolerat ed: an ACEI, or ARB or sacubitril/valsartan and a beta -blocker . It 
is advised that other guideline recommendat ions for m anagement of cardiovascular disease 
and CKD are also fo llowed (except for strong or moderate CYP3A4 inhibitors or inducers).
Patients wh o are on 10 mg dapagliflozin at screening should remain on the therapy  as 
indicated throughout the treatment period of the study . Pati ents who are on another SGL T2i 
(eg, canagliflozin or empagliflozin) will be switched to 10 mg dapagliflozin starting at the 
start run -in(Visit1b)after confi rmed eligibilit y and will remain on the therapy  throughout the 
treatm ent peri od of  the study . Pati ents who are not on a SGL T2i will be started on 10 mg 
dapagliflozin at the start run -in (Visit1b)after confi rmed eligib ility and will remain on the 
therapy  throughout the safet y follow-up peri od.
Glycaemic control should be performed according to local guidelines.
It is preferable that any  background medical therapy  (eg, HF , antihypertensive therapy  as well  
as therapy  withstatins) will not be changed during study  drug treatm ent,ie, between the 
screening visit and the last dose of study  drug. However, if this is necessary , the parti cipant 
does not need to be withdrawn fro m study  drug.
6.5.3 Medications Inducing Hypoglycaemia
Participants using m edicati ons that can cause hypoglycaemia in T2DM pat ients, including 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 53of 138insulin or SU, may  be requi red to reduce insulin by  10 to 20% (total  daily dose) and SU by  
25to 50%. In addi tion, m ore frequent bl ood gl ucose m onitoring may  be considered in 
participants receiving insulin and/or SU and with baseline HbA1c ≤7%at rando misat ion.
6.6 Dose Modification
No dose m odificat ions are allowed during the study .
6.7 Intervention After the End of the Study
Following the E OT visit, participants will stop study  drug and continue on open label 
dapagliflozin 10 mg during the safet y follow-up peri od.After the safet y follow-up visit ,
participants shoul d return to thei r usual  treatm ents at the di screti on of  the invest igator .
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 54of 1387 DISCONTINUATION OF S TUDY INTERVENTION AN D 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL
7.1 Discontinuation of Study Intervention
It may be necessary  for a parti cipant to perm anent ly discont inue (definit ive discontinuation) 
study  interventi on. 
Parti cipants may  be discont inued fro m study  intervent ion in the following si tuations:
Parti cipant decisi on. The parti cipant i s at any  time free to di scont inue treatment, without 
prejudice to further treatment
An AEthat, in the opinion o f the Invest igator or AstraZeneca, warrants discontinuation 
from further dosing
Severe non -compliance wi th the CSP
Safety reasons as judged by the invest igator and/or sponsor where continued treatment 
may put participant at undue risk
Parti cipants will be discont inued fro m study  intervent ionin the fo llowing si tuations:
If the participa nt beco mes pregnant during the course of the study
Protocol -defined hyperkalaemia: Study  treatm ents must be discont inued in case of 
confirmed (ie, 2 consecut ive samples) serum /plasma K+>6.0mmo l/L, or confirmed 
serum /plasma K+>5.5mmo l/L (at investigat or’s discreti on), or serum /plasma
K+>5.5mmo l/L with repeat value > 6mmo l/L (see Appendix F 1for details on the 
monitoring and m anagement of hyperkalaemia)
Protocol -defined deteriorating renal function: Study treatments must be discont inued in 
case of confirmed eGFR reduction fro m baseline > 50% and/or any  confirmed decrease 
below 15 mL/min /1.73 m2(see Appendix F 2for details on the monitoring and 
management of deteriorating rena l funct ion)
There have been reports of ketoacidosis, including DKA, in pat ients with T2DM taking 
dapagliflozin and other SGLT2 inhibitors in previo us studies. Patients with T2DM on 
investigat ional treatm ent who present with signs and symptoms consistent wi th 
ketoacidosis, including nausea, vo miting, abdo minal pain, malaise and shortness of breath 
shoul d be assessed for ketoacidosis, even if blood glucose levels are < 14 mmo l/L 
(250 mg/dL). If ketoacidosis is suspected, discont inuat ion or tem porary  interrupt ion of the 
investigat ional treatm ent shoul d be considered and the patient should be promptly 
evaluated.
Note that discontinuation fro m study  intervent ion is NOT the same thing as a withdrawal fro m 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 55of 138the study .
If study  intervent ions are permanent ly disconti nued, the participant will remain in the study  
for the ETvisit and the safet y follow-up visi t.The pa rticipant m ay cont inue on open -label 
dapagliflozin during the safet y follow-up peri od as j udged by the Invest igator taking in 
consideration the reason for the permanent discontinuat ion of the study  interventi on.
See the SoA  for data to be collected at the time o f intervent ion discontinuation and fo llow-up 
and for any  further evaluat ions that need to be completed.
7.1.1 Temporary Discontinuation and Rechallenge
Temporary  discontinuati on of  study  treatm ents may  be considered if hyperkalaemia is 
observed and repeat tests are required to confirm protocol -defined discont inuat ion criteria (see 
Appendix F 1).
Temporary  discontinuati on of  dapagli flozin shoul d be considered if DKA issuspec ted and the
patientshould be promp tlyevaluated:
If DKA is confirmed ,study  treatm ents shoul d be disco ntinued permane ntly.
If DKA is not confirmed, dapagliflozin may be restarted.
7.2 Participant Withdrawal from the Study
A participant may withdraw fro m the study  at any  time at hi s/her own request or may be 
withdrawn at any  time at the di screti on of  the investi gator for safet y, behavioural, 
compliance, or administrative reasons. This is expected to be unco mmo n.
A participant who considers wit hdrawing fro m the study  must be informed by  the 
investigator about modified fo llow-up opti ons (eg, telephone contact, a contact with a 
relative or treating physician, or information fro m medical records).
At the time of withdrawal fro m the study , if possible, an ETvisit should be conducted, as 
shown in the SoA. See SoA for data to be collected at the ET visit .
The parti cipant will discon tinue the study  interventio n and be wit hdrawn from the 
study  at that time. The4-week safet y follow-up after last dose will not be performed.
If the participant withdraws consent for disclosure of future informat ion, the sponsor may  
retain and cont inue to use any data collected before such a withdrawal o f consent.
If a participant withdraws fro m the study , it shoul d be confirmed if he/she st ill agrees for 
exist ing samples to be used in line with the original consent. If he/she requests withdrawal 
of consent for use of samples, destruction of any samples taken and not tested should be 
carried out in line with what was stated in the informed consent and local regulat ion. The 
Clinical Study Protoco l -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 56of 138investigator must document the decisio n on use of exist ing samples in the site study  
records and inform the Global Study  Team .
7.3 Lost to Follow -up
A participant will be considered lost to fo llow-up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by  the study  site.
The fo llowing acti ons m ust be taken if a parti cipant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact the participant and reschedule the missed visit as soon as 
possible and counsel the participant on the importance o f maintaining the assigned visit
schedule and ascertain whether or not the participant wishes to and/or should continue in 
the study .
Before a participant is deemed lost to fo llow-up, the invest igator or designee must make 
every effort to regain contact with the participant (where possib le, 3 telephone calls and, 
if necessary , a certified l etter to the parti cipant’s last known mailing address or local 
equivalent m ethods). These contact attempts should be documented in the participant’s 
medical record.
Shoul d the participant continue to be unreachable, he/she will be considered to have 
withdrawn from  the study . 
Discontinuati on of  specific sites or of the study  as a who le are handled as part of  Appendix A.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 57of 1388 STUDY ASSESSMENTS AN D PROCEDURES
Study  procedures and their timing are summarised in the SoA. Protocol waivers or 
exempt ions are not allowed.
Immediate safet y concerns should be discussed wit h the sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
study  interventi on.
Adherence to the study  design requi rements, including those specified in the SoA, is 
essent ial and required for study  conduc t.
All screening evaluat ions must be com pleted and reviewed to confirm that potential 
participants m eet all eligibilit y criteria. The invest igator will maint ain a screening log to 
record details o f all participants screened and to confirm eligibilit y or re cord reasons for 
screening failure, as applicable.
Procedures conducted as part of the participant’s routine clinical management (eg, 
echocardiography )and obtained before signing of the ICF may be utilised for screening 
or baseline purposes provided the p rocedures m et the protocol -specified criteria and were 
perform ed wi thin the time frame defined in the SoA.
The m aximum  amount of  blood collected from  each parti cipant over the duration of the 
study , including any  extra assessments that may be required, wil l not exceed 400mL. 
Repeat or unscheduled samples may be taken for safet y reasons or for technical issues 
with the sam ples.
8.1 Efficacy Assessments
8.1.1 Prim ary/Secondary Variable: 
Urinary Albumin to Creatinine Ratio (UACR)
The UACR is calculated as fo llows:
UACR (m g/mm ol) = 10 × urine albumin (mg/dL) / urine creat inine (mmo l/L)
Urine samples for the determinat ion of albumin and creatinine and calculat ion of UACR will 
be co llected at the timepoints described in the SoA:
After consent at screening (Visi t1a), a container to collect the spot urine sample will be 
dispensed to the participants. The spot uri ne sample will be co llected at this visit. 
Collect ion of tri plicate u rine sampling will start at Visit 2. At Visit 1band at subsequent 
visits, containers to c ollect the urine samples will be dispensed to the participants prior to 
the visits described in the SoA. Invest igators will perform a phone call prior to the vi sit to 
remind the participants to collect the first morning vo id samples .Parti cipants will co llect 
first morning vo id urine samples at home on 3 consecut ive days (ideally day o f visit and 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 58of 138preceding 2 days [refrigerated overnight] which will be returned on the day  of visit). 
Samples will  be analysed centrally. At each visit, the geometric m ean of the tri plicate 
measurements will be computed centrally and used for all analyses of UACR. 
Note: The samples collected on visit days will also be used for the determination of 
exploratory  urinary  parameters (see Secti on8.5.2.1 and 8.6.2 ).
8.1.2 Exploratory Variables –Not Applicable
8.2 Safety Assessments
Planned timepo ints for all  safety  assessments are provided in the SoA.
8.2.1 Physical Exa minations
Physical examinat ion, and measurement of weight and height will be conducted as outlined in 
the SoA.
For wei ght and height m easurements, the pa rticipant will be allowed to wear indoor, 
daytime clothing wit h no shoes and no coats/jackets and removal o f heavy objects from 
pockets.
A co mplete physical examinat ion will be performed and include assessments of general 
appearance, respiratory , cardi ovascular, abdo minal, and neurological systems, the skin, 
lymph nodes, and an assessment of the presence and extent of peripheral (ankle/leg) 
oedem a.
For informat ion on how AEs based on physical examinat ion findings should be recorded and 
reported, see Sectio n8.3.5 .
8.2.2 Vital Signs
Blood pressure and pulse rate will be assessed at the study  site, as outlined in the SoA, prior to 
blood collection for laborator y tests wi th the pati ent resti ng in a supine posit ion using a 
completely autom ated device. Manual techniques will be used only  if an autom ated device is 
not available.
Blood pressure and pulse measurements should be preceded by  at least 5 minutes of rest f or 
the pati ent in a quiet setting wi thout di stracti ons (eg, tel evision, cell  phones) and will consist 
of 1 pul se and 3 BP measurements (3 consecut ive BP readings will be recorded at intervals o f 
at least 1 minute). The average o f the 3BP readings will be recorded on the eCRF .
For informat ion on how AEs based on vital sign results should be recorded and reported, see 
Secti on8.3.5 .
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 59of 1388.2.3 Electrocardiograms
Single 12 -lead ECG will be obtained after the patient has been rest ing in a supine position for 
at least 10 minutes, at the visits outlined in the SoA. A  dECG m achine that automat ically 
calculates the heart rate and measures PR, QRS, QT , and QT c intervals will be used. 
Interpretation of the clinical safet y dECG findings will be reviewed and confirmed by the 
investigator and recorded in the eCRF . Digital ECGs will  be collected, cleaned, and stored by  
ERT.
Invest igators will assess pat ients’ eligibilit y accor ding to the ECG report of V isit1a. Any 
abnorm al finding in the ECG tracing will be evaluated by  the invest igator and will be 
specifically documented and registered in the CRF . Throughout the study , clinically  relevant 
new findings or worsening of a pre -existing finding in the ECGs (parameters or abnormal 
findings in the tracing) must be considered an AE and must be recorded in the AE CRF form.
For informat ion on how AEs based on ECG results should be recorded and reported, see 
Secti on8.3.5 .
8.2.4 Clinical Safety Laboratory Assessments
Blood and urine samples for determinat ion of clinical chemistry , haematol ogy, and urinalysis 
will be tak en at the visits indicated in the SoA.
Addit ional safet y samples may  be collected if clinically indicated at the discret ion of the 
investigator . The date, time of collection ,and results (values, units ,and reference ranges) will 
be recorded on the appropriate eCRF .
The clinical chemistry , haematol ogy, and urinalysis will be performed at a local laboratory  for 
screening, and at a central laboratory  at baseline and subsequent visit s, as indicated in the 
SoA.
Measurement of electroly tes (Na+and K+) and creatinine at l ocal laboratori es may be done on
either plasma orserum samples ,depending on their capabilit ies,while these measurements at 
the central  laboratory  will be done on serum  samples. In addit ion,K+levels will be measured 
in plasma samples at the central laboratories for expl oratory  analysis .
The parti cipant ’s eGFR (mL/min/1.73 m2) will  be calculated based on the standard 
BSA -adjusted CKD -EPI f ormula using serum/plasma creat inine concentration alo ne (Levey  et 
al 2009 ) as measured at a l ocal laboratory  and using both serum  creat inine and s erum  
cystati nC concentrati ons (Inker et al  2012 )at a central  laboratory .Note that for eGFR 
calculat ion based on creatinine levels, the calibrated metho ds provide equivalent results for 
plasma and serum sample ty pes.
eGFR calculat ion using standard BSA -adjusted CKD -EPI f ormula using serum/plasma 
Clinical S tudy Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 60of 138creatinine concentration ( Levey  et al  2009 ):
eGFR (mL/min/1.73m2) = 141 ×min (SCr/ κ,1)α×max (SCr/ κ,1)-1.209×0.993Age×[1.018 if 
female] ×[1.159 if black]
κis 0.7 for females and 0.9 for males, αis -0.329 for females and -0.411 for m ales, min 
indicates the minimum of SCr/κ or 1, and m ax indicates the maximum o f SCr/κor 1.
eGFR calculat ion using standard BSA -adjusted CKD -EPI f ormula using both serum creat inine 
and serum cystatin C concentrations (Inker et al 2012):
eGFR (mL/min/1.73m2) = 135 × min(SCr/ κ, 1)α× max(SCr/ κ, 1)-0.601× min(Scys/0.8, 1)-0.375
× max(Scys/0.8, 1)0.711× 0.995Age× 0.969 [if female] × 1.08 [if black]
SCr (serum creat inine) = mg/dL, Scys (standardi sed serum  cystatin C) = mg/L, κ = 0.7 
(females) or 0 .9 (males), α = -0.248 (females) or -0.207 (males), min(SCr/ κ or 1) = indicates 
the minimum o f SCr/κ or 1, m ax(SCr/ κ or 1) = indicates the maximum o f SCr/κ or 1, 
min(Scys/0.8, 1) = indicates the minimum of Scys/0.8 or 1, max(Scys/0.8, 1) = indicates the 
maximum o f Scys/0.8 or1, age = years
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 61of 138The fo llowing laboratory  variables will be measured:
Table 6 Laboratory Safety V ariables
Haematology/Haemostasis (whole blood) aClinical Chemistry (serum or plasma) a
White blood cell (WBC) count Na+b
Red blood cell (RBC) count K+ b, c
Haemoglobin (Hb) Blood urea nitrogen (BUN)
Haematocrit (HCT) Serum creatinineb d
Neutrophils absolute countfUric acidf
Lymphocy tes absolute countfAlbumin
Monocytes absolute countfCalcium
Eosinophils absolute countfPhosphate
Basophils absolute countfAlka line phosphatase (ALP)
Platelets Alanine aminotransferase (ALT)
International normalised ratio (INR)eAspartate aminotransferase (AST)
MCVfTotal bilirubin (TBL)
MCHCfGlutamate dehydrogenase (GLDH) f
RBC distribution width fCreatine kinase (CK)f
HbA1c Bicarbonate (HCO 3-) f
Urinalysis (urine)aChloride (Cl-)f
Protein Magnesium (Mg+)f
Glucose Glucose
Blood Total cholesterol, direct HDL -C, trigly cerides, 
LDL -Cg, VLDL-C g(fasting, see Section 5.3.1 )f
Leukocyte esterase Other assessments
Specific gravityfCystatin Cd, h
pHfRT-PCR test for SARS -CoV -2 (optional, at 
pre-randomisation visit )
Microscopic examination of the sediment if blood or 
leukocyte esterase are positive on dipstickfFollicle stimulating hormone (FSH) (for confirmation 
of postmenopausal status of women < 50years old 
only [women who are permanently sterilised are
exempted], at screening)
Note: In case a participant shows an AST orALT ≥ 3 × ULN together with TBL ≥ 2 × ULN please refer to 
Appendix E. Actions required in cases of increases in liver biochemistry and evaluation of Hy’s law cases , for 
further instructions.
BSA=body surface area; CKD -EPI= chronic kidney disease epidemiology collaboration ; eGFR=estimated 
glomerular filtration rate; HbA1c=glycated haemoglobin; HDL -C=high density lipoprotein cholester ol; 
K+=potassium; LDL -C=low density lipoprotein cholester ol; MCHC=mean corpuscular haemoglobin 
concentration; MCV=mean corpuscula r volume; Na+=sodium; RT -PCR=reverse transcriptase polymerase chain 
reaction; SARS -CoV -2=severe acute respiratory syndrome coronavirus 2; SoA=schedule of activit ies; 
ULN=upper limit of normal; VLDL -C=very low density lipoprotein cholester ol
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 62of 138aLocal laborato ry at screening and pre-randomi sation(if applicable per SoA) and central laboratory at 
subsequent visits, unless specified otherwise.
bAt the local labor atories, e lectrolytes (Na+and K+) and creatinine ma ybe measured in plasma samples 
instead of serum samples depending on their capability.
cCentral laboratory measurement sfor K+levels will be with serum and plasma samples.
deGFR (mL/min/1.73 m2) will be calculated using the BSA -adjusted CKD -EPI formula andincluding both 
serum creatinine and serum cysta tin C for central laboratory assessments ;and with serum /plasma creatinine 
alone for local laboratory assessments .
eThe post -randomisation INR measurements may be done at a local laboratory if the necessary material 
provided by the central laboratory is not available; and the measurements may be omitted if the local 
laborato ry is not capable of doing the measurements. Refer to Laboratory Manual for details.
fThese tests are not required at screening or pre-randomi sation .
gPer Friedewald equation .
hCentral labor atory for all cystatin C measurements.
Instructi ons for the collect ion and handling of the samples will be provided in the study  
specific Laboratory  Manual.
8.3 Adverse Events and Serious Adverse Events
The PI is responsible for ensuring that all staff involv ed in the study  are f amiliar with the 
content of this sect ion.
The definit ions of an AE or SAE can be found in  Appendix B.
Adverse events will be reported by  the parti cipant (or, when appropriate, by  a caregiver, 
surrogate, or the participant ’s legally authorised representative). 
The invest igator and any designees are responsible for detecting, document ing, and recording 
events that meet t he definit ion of an AE.
8.3.1 Time Period and Frequency for Collecting AE and SAE Information
Adverse events will be collected from rando misat ion (V isit3) throughout the treatment period 
and including the fo llow-up peri od.
Serious AEs will be recorded from the time of signing of the fullICFfor the study (Visit1a).
No AE or SAE informat ion will be co llected after just signing of the opti onal pre -screening 
ICF.
If the invest igator becomes aware of a SAE, with a suspected causal relationship to at least 
1of the IMP, that occurs after the end of the clinical study  in a parti cipant treated by  him or 
her, the invest igator shall, without undue delay , report the SAE to the sponsor .
8.3.2 Follow- up of AEs and SAEs
Any AEs that are unreso lved at the participant ’s last AE assessment or other assessment/visit 
in the study  are f ollowed up by  the investi gator f or as l ong as m edically indicated, but without 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 63of 138further recording in the eCRF . AstraZeneca retains the right to request addit ional inform ation 
for any  parti cipant wi th ongoing AE(s)/SAE(s) at the end of the study , if judged necessary .
Adverse Event Variables
The fo llowing variables will be collected for each AE:
AE (verbat im)
Date and time when the AE started and stopped
Maximum intensit y
Whether the AE is serious or not
Invest igator causalit y rating against the invest igational products (y es or no)
Action taken with regard to invest igational products
AE caused participant’s wit hdrawal fro m study  (yes or no)
Outcom e
In addit ion, the fo llowing vari ables will be collected for SAEs:
Date AE m et cri teria for seri ous AE
Date invest igator became aware of serious AE
AE is seri ous due to
Date of hospitalisat ion
Date of discharge
Probabl e cause of death
Date of death
Autopsy  performed
Causalit y assessment in relat ion to study  procedure(s) and/or other medicat ion
Descript ion of AE
8.3.3 Causality Collection
The invest igator should assess causal relationship between each of the invest igational products 
and each AE, and answer ‘yes’ or ‘no’ to the question ‘Do y ou consider that there is a 
reasonable possibilit y that the event m ay have been caused by  the investi gational product? ’
For SAEs, causal relat ionship should also be assessed for other medi cation and study  
procedures. Note that for SAEs that could be associated with any study  procedure the causal 
relationship is implied as ‘yes’.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 64of 138A guide to the interpretation of the causalit y question is found in Appe ndix B .
8.3.4 Adverse Events Based on Signs and Symptoms
All AEs spontaneously reported by the participant or reported in response to the open question 
from the study  site staff: ‘Have y ou had a ny healt h probl ems since the previous visit ?’ or 
revealed by  observati on will be collected and recorded in the eCRF . When collecting AEs, the 
recording of diagnoses is preferred (when possible) to recording a list of signs and symptoms. 
However, if a diagn osis is known and there are other signs or symptoms that are not generally 
part of the diagnosis, the diagnosis and each sign or symptom will be recorded separately .
8.3.5 Adverse Events Based on Examinations and Tests
The results from the protocol -mandated laboratory tests and vital signs will be summarised in 
the CSR. 
Deteri oration as com pared to baseline in protocol -mandated l aboratory  values, vital signs, 
ECG parameters and echocardiography findings shoul d therefore only be reported as AEs if 
they fulfil any of the SAE cri teria, are the reason for discontinuation of treatment with the 
investigat ional product or are considered to be clinically relevant as judged by  the invest igator 
(which may include but not limited t o consi derati on as to whether treatment or non -planned 
visits were required or other action was taken wit h the study  treatm ent, eg, dose adj ustment or 
drug interruption).
If deteri oration in a laboratory  value/vi tal sign i s associ ated wi th clinical signs and symptoms, 
the sign or symptom  will be reported as an AE and the associated laboratory  resul t/vital sign 
will be considered as addit ional informat ion. Wherever possible the reporting invest igator 
uses the clinical, rather than the laboratory  term  (eg, a naemia versus low haemoglo bin value). 
In the absence of clinical signs or symptoms, clinically relevant deteriorations in non -
mandated parameters should be reported as AE(s).
Any new or aggravated clinically relevant abnormal medical finding at a physical examinat ion 
as com pared wi th the baseline assessment will be reported as an AE.
8.3.6 Hy’s Law
Cases where a participant shows elevations in liver biochemistry  may requi re further 
evaluat ion and occurrences of AST or ALT ≥ 3 × ULN together with TBL  ≥ 2 × ULN may
need to be reported as SAEs. Please refer to Appendix Efor further instructi on on cases of 
increases in liver biochemistry  and evaluat ion of Hy ’s law.
8.3.7 Reporting of Serious Adverse Events
All SAEs have to be reported, whether or not considered causally related to the invest igational 
product, or to the study  procedure(s). All SAEs will be recorded in the eCRF .
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 65of 138If any SAE occurs during the course of the study , then invest igators or other site personnel 
inform  the appropri ate AstraZeneca representatives within one day ie, immediately but no 
later  than 24 hours of when he or she becom es aware of i t.
The designated AstraZeneca representative works with the invest igator to ensure that all the 
necessary  informat ion is provided to the AstraZeneca Patient Safet y data entry  site within 
1calendar  day of initial receipt for fatal and life -threatening events and within 5 calendar
days of initial receipt for all other SAEs.
For fatal  or life -threatening AEs where important or relevant informat ion is missing, active 
follow-up is undertaken immediately . Invest igators or other site personnel inform AstraZeneca 
representatives of any  follow-up inform ation on a previou sly reported SAE within one 
calendar day  ie, immediately but no later  than 24 hours of when he or she becom es aware of 
it.
Once the invest igators or other site personnel indicate an AE is seri ous in the EDC system , an 
autom ated em ail alert is sent to the d esignated AstraZeneca representative.
If the EDC system is not available, then the investigator or other study  site staf f reports a SAE 
to the appropriate AstraZeneca representative by telephone.
The AstraZeneca representative will advise the investigator/ study site staff how to proceed.
For further guidance on the definit ion of a SAE, see  Appendix B.
The reference document for definit ion of expectedness/listedness is the Investigator ’s 
Brochure for both study  treatm ents. 
8.3.8 Pregnancy
All pregnancies and outcomes of pregnancy should be reported to AstraZeneca except when 
the pregnancy  is discovered before the study  participant has received any  study  drug.
8.3.8.1 Maternal Exposure
There i s no information about effects that AZD9977 could have on the development of the 
foetus in humans. Pre -clinical studies have shown that AZD9977 is not genotoxic, however 
formal pre -clinical reproductive toxico logy studi es hav e not y et been com pleted. 
Dapagliflozin must not be used in the second and third trimesters of pregnancy . In the time 
period corresponding to second and third trimester of pregnancy wit h respect to human renal 
maturati on, maternal exposure to dapagliflozi n in rat studi es was associated with increased 
incidence and/or severit y of renal pelvic and tubular dilatations in progeny . There are no 
adequate and well- controlled studies of dapagliflozin in pregnant women.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 66of 138Women of childbearing potential are not allow ed to be included in this study . Shoul d a 
pregnancy st ill occur, the invest igational products should be discont inued immediately , and 
the pregnancy  reported to AstraZeneca.
Pregnancy itself is not regarded as an AEunless there is a suspicio n that the inve stigational 
product under study  may have interfered with the effect iveness of a contraceptive medicat ion. 
Congenital anomaly/birth defects and spontaneous miscarriages should be reported and 
handled as SAEs. Elective abortions without complicat ions should not be handled as AEs. The 
outcom e of all pregnancies (spontaneous miscarriage, elective terminat ion, ectopic pregnancy , 
norm al birth, or congenital anomaly ) shoul d be f ollowed up and docum ented even if the 
participant was discont inued fro m the study .
If any pregnancy  occurs during the course of the study , then the invest igator or other site 
personnel informs the appropriate AstraZeneca representatives within 1 day, ie, immediately
but no later  than 24 hours of when he or she becomes aware of it .
The design ated AstraZeneca representative works with the invest igator to ensure that all 
relevant informat ion is provided to the AstraZeneca Pati ent Safet y data entry  site wi thin1 or 
5calendar days for SAEs (see Section  8.3.8) and within 30 days for all other pregnancies.
The same timelines apply when outcome informat ion is available.
The PREGREP module in the eCRF is used to report the pregnancy and the PREGOUT i s 
used to report the outcome of the pregnancy .
8.3.8.2 Paternal Exposure 
It is important that women of childbearing potential, who are the partners of male participants, 
do not become pregnant during the study  and f or a total  period of  3months after the male 
study  participant has received his last dose of IMP .
All male part icipants should avo id fathering a child by  either true abstinence or use together 
with their female partner/spouse a highly effect ive method of contraception (see definit ion 
below), st arting from the time o f IMP administration until 3 months after the last dose of IMP . 
For m ale parti cipants whose partner is already  pregnant, the m an shoul d use a condom for the 
durati on of  the study  and f or 1 week afterwards.
Male parti cipants shoul d not donate sperm for the duration of the study  and f or at l east 
3months after the study  follow-up visi t.
Methods that can achieve a failure rate of less than 1% per y ear when used consistent ly and 
correctly  are considered highly effect ive birth control meth ods such as:
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 67of 138Combined (oestrogen and progesterone containing) hormonal contraception associated 
with inhibit ion of ovulation:
Oral
Intravaginal
Transdermal
Progesterone -only hormonal contracepti on associ ated wi th inhibit ion of ovulation:
Oral
Injectable
Implantable
Intrauterine device
Intrauterine hormone -releasing system
Bilateral tubal occlusio n of female partner
Male vasectomy
True sexual abstinence: True abst inence refers to: When this is in line with the preferred 
and usual lifest yle of the patient. Pe riodic abst inence (eg, calendar, ovulat ion, 
symptom -thermal , post -ovulation methods), declaration of abst inence for the duration of a 
trial, and wi thdrawal are not acceptable methods of contraception.
If the partner of a male part icipant becomes pregnant during the study , this shoul d be reported 
to the invest igator . The invest igator should also be notified o f pregnancy occurring during the 
study  but confirmed after complet ion of the study . In the event that a participant ’s partner i s 
subsequent ly found to be pregnant after the study participant is included in the study , then 
consent will be sought from the partner and if granted any  pregnancy will be fo llowed and the 
status of mother and/or child will be reported to the sponsor after delivery .
8.3.9 Medication Erro r
If a medicat ion error occurs during the course of the study , then the invest igator or other site 
personnel informs the appropriate AstraZeneca representatives within 1day,ie, immediately 
but no l ater than 24 hours of when he or she becomes aware of i t.
The designated AstraZeneca representative works with the invest igator to ensure that all 
relevant informat ion is completed wi thin1 (Ini tial fatal /Life -Threatening or follow -up 
fatal/Life -Threatening) or 5 (other serious init ial and fo llow-up) cal endar days if there is an 
SAE associated with the medicat ion error (see Sectio n 8.3.9 )  and within 30 days for all other 
medicat ion errors.
The definit ion of a medicat ion error can be found in Appendix B.  
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 68of 1388.3.10 Medical Device Deficiencies
In thi s study  any deficiency  observed wi th a thi rdparty medical  device will  be collected and 
reported to the manufacturer.
A medical device deficiency is an inadequacy of a medical device wit h respect to its ident ity, 
qualit y, durabilit y, reliabilit y, safet y, or perform ance. Medi cal device deficiencies incl ude 
malfunct ions, use errors, and information supplied by the manufacturer .
The AstraZeneca (Appendix I), or m anufacturer ’s where available, medical device co mplaint 
report will be used to collect the deficiency.
8.4 Overdose
Dapagliflozin has been well tolerated at doses up to 500 mg/day in single dose testing in 
healt hy vo lunteers and up to 100 mg/day in repeat dose testing for 14 days in healt hy 
volunteers and patients with t ype 2 diabetes. Only  suspected single intake of more than 
500mg dapagliflozin or repeated intake of more than 100 mg dapagliflozin should be reported 
on the eCRF overdose module. 
Present ly there is no information regarding overdose of AZD9977 in man. For this study , any 
dose of AZD9977 greater than 150 mg within 24 hours will be considered an overdose.
If an overdose is suspected, monitoring of vital functions as well as treatment should be 
perform ed as appropri ate.
An overdose with associ ated AEs is recorded as the AE diagnosis/symptoms on the 
relevant AE m odules in the eCRF and on the Overdose eCRF module.
An overdose without associated symptoms is only  reported on the Overdose eCRF 
module.
If an overdose on an AstraZeneca study d rug occurs during the course of the study , the 
investigator or other site personnel inform appropriate AstraZeneca representatives 
immediately , but no later  than 24 hours of when he or she beco mes aware of it.
The designated AstraZeneca representative works wi th the invest igator to ensure that all 
relevant informat ion is provided to the AstraZeneca Pati ent Safet y data entry  site wi thin1 or 
5calendar days for overdoses associated with an SAE (see sect ion 8.3.7 )  and within 30 days 
for all other overdoses.
8.5 Human  Biological Samples
Instructi ons for the collect ion and handling of bio logical samples will be provided in the 
study -specific Laboratory  Manual. Sam ples shoul d be stored in a secure storage space with 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 69of 138adequate measures to protect confident iality. For further details on Handling of Human 
Biological Sample see  Appendix C.
Samples will  be stored for a m aximum  of 15years fro m the date of the i ssue of the CSR in 
line with consent and local requirements, after which they will be destroyed/repatriated. 
Pharmacokinet ic (PK) samples will be dispo sed of after the Bioanalyt ical Report 
finalisat ion or 6 months after issuance of the draft Bioanalyt ical Report (whi chever i s 
earlier), unless consented for future analyses. 
Pharmacokinet ic samples may be disposed of or anonymised by pooling. Addit ional 
analyses may  be conducted on the anonymised, pooled pharmacokinet ic samples to 
further evaluate and validate the analyt ical method. Any results fro m such analyses 
may be reported separately fro m the CSR.
8.5.1 Pharmacokinetics
Bloodsamples will be collected for measurement of plasma concentrations of AZD9977 
and dapagliflo zin, including predose samples from all part icipants and optional postdose 
samples fro m participants who consent, at the visit s and timepo ints specified in the SoA .
Samples may  be collected at addi tional timepo ints during the study  if warranted and 
agreed upon between the invest igator and the sponsor, eg, for safety reasons. The timing 
of sampling may be altered during the course of the study  based on newly  available data 
(eg, to obtain data closer to the time of peak or trough matrix concentrations) to ensure 
appropriate monitoring. 
Samples co llected for analyses of AZD9977 and dapagliflozin plasma concentrati ons m ay 
also be used to evaluate safet y or efficacy aspect s related to concerns arising during the 
study .
Samples will  be collected, l abelled, stored, and shipped as detailed in the Laboratory  
Manual.
8.5.1.1 Determination of Drug Concentration
Samples for determination of drug concentration in plasma will be assayed by Labcorp Drug 
Development onbehalf of AstraZeneca, using appropriately validated bioanalyt ical methods. 
Full details o f the analy tical methods used will be described in a separate Bioanaly tical 
Report.
Drug concentration informat ion that wouldunblind the study  will not be reported to 
investigat ive sites or blinded personnel until the study has been unblinded.
Incurred sample reproducibilit y analysis or addit ional assay  devel opment work, if any , will  be 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 70of 138perform ed al ongside the bioanalysis of the test sampl es. The results fro m the evaluat ion, if 
perform ed, will  be reported in a separate Bioanaly tical Report.
8.5.2 Pharmacodynamics
Urinary  and serum/plasma parameters will be measured during the study  for the evaluat ion of 
the exploratory  endpoints:
NT-proBNP , aldos terone, renin, ACTH, cortiso l, copeptin, and FPG (per the SoA)
The fo llowing param eters will  be measured from  the bl ood sam ples co llected for safet y and 
analysed centrally (see Sect ion8.2.4 ): 
Bicarbonate (HCO 3-), Na+, K+, creatinine, uric acid, BUN (at Visits 3 to11) as part of 
clinical chemistry
Haematocrit (at Visits 3 to11) and MCV, MCHC, RBC distribut ion width, ery throcyte 
count (at Visits 3, 8, and 10), as part of haematology
8.5.2.1 Collection of Samples
Urine Samples
Urine samples will be co llected and analysed at a central laboratory  for the determinat ion of 
the exploratory  urinary  param eters at the timepoints specified in the SoA. 
The urine samp les co llected on visit days for the analysis o f UACR (see Sect ion8.1.1 ) will be 
split, so that it can also be used for the determinat ion of Na+, K+, uric acid, urea, osmo lality, 
glucose and corti sol levels.
Blood Samples
Blood sam ples will be collected at the timepoints specified in the SoA  and analysed at a 
central  laboratory  for the determination of the fo llowing parameters:
NT-proBNP, aldosterone , active renin, ACTH, cortiso l, and copeptin
FPG (for fast ing condit ions, see Sect ion5.3.1 )
In addit ion, blood samples will be co llected at screening and analysed locally  for the 
determinat ion of NT -proBNP to confirm eligibilit y criteria.
Samples will  be collected, l abelled stored and shipped as detailed in the Laboratory  Manual.
For storage, re -use and destruction of pharmacodynamic samples see Section 8.5and 
Appendix C. 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dap agliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 71of 1388.6 Human  Biological Sample Biomarkers
8.6.1 Collection of Mandatory Samples for Biomarker Analysis
By consenting to parti cipate in the study  the parti cipant consents to the mandatory  research 
components of the study . Mandatory  collect ion of samples for bio marker research is part of 
this study .
Serum /plasma samples for cardiovascular biomarker research will be collected from all 
participants in thi s study  as specified in the SoA .These samples w illbeused for the 
determinat ion of cardi ovascular bio markers (including but not limited to hsTnT, PIIIP3, 
GDF -15, ST2, ADMA, SDMA, L -Arg, ICAM, NGAL) by  a central  laboratory .
8.6.2 Collection of Optional Biomarker Samples
Collect ion of opti onal samples for bi omarker research is also part of this study  as specified in 
the SoA  and is subject to participant ’s optional consent:
Serum , plasma, and urine samples will be co llected for future use aimed at exploring 
biomarkers invo lved in PK, pharmacodynamics, safet y and tol erabilit y related to 
AZD9977 and dapagliflozin or related to cardiorenal diseases.
For storage, re -use and destruction of bio marker samples see Section 8.5. 
8.7 Optional Genomics Initiative Sample
Collect ion of opti onal samples for Genomics Init iative research is also part of this study  as 
specified in the SoA  and is subject to participant ’s opti onal consent in the ICF addendum. 
Blood sam ple for DNA  isolation will be collected from participants who have consented to 
participate in the genet ic analysis co mponent of the study . Parti cipat ion is optional. 
Parti cipants who do not wi sh to parti cipate in the genet ic res earch may  still parti cipate in the 
study .
See
 Appendix Dfor informat ion regarding the Genomics Init iative genet ic sample. Details on 
processes for c ollect ion and shipment and destruction of these samples can be found either in 
the appendices or in the Laboratory  Manual . 
For storage and destruction of genetic samples see Appendix D.
8.8 Medical Resource Utilisation and Health Economics
Not Applicable.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 72of 1389 STATISTICAL CONSIDER ATIONS
9.1 Statistical Hypotheses
The primary  hypothesis for thi s study  is that AZD9977 in co mbinat ion with dapagliflo zin will 
induce a greater reducti on of  albuminuria than wit h dapagliflozin alo ne, as assessed by the 
percent change fro m baseline in UACR at 12 weeks.
9.2 Sample Size Determination
A total of 119evaluable part icipants per arm will provide 80% power t o detect a 30% 
difference in a AZD9977 dose group combined with dapagliflozin 10 mg co mpared to 
dapagliflozin 10 mg alone inpercent change fro m baseline in UACR at 12 weeks, assuming a 
SDof 1.0 on the natural log -scale and alpha =0.05. T o account for approximately 5% 
drop-outfrom the study , approximately  500participants will be rando mly assigned to study 
intervent ion (125participants per group) such that approximately 476evaluable participants 
(119per group) complete the study .
Patients randomi sed according to CSP  versions 1. 0to 5.0 (before dropping placebo and 
AZD9977 150 mg monotherapy  arms) will be considered as part of Cohort 1, while pat ients 
rando mised subsequent ly will be included in Cohort 2. The primary analysis for the remaining 
4treatm ent groups will combine data from both cohorts, while the accrued data from 
discontinued treatm ent groups will be analysed descript ively .
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 73of 1389.3 Populations for Analyses
The fo llowing popul ations are defined:
Table 7 Populations for  Analysis
Population/Analysis set Description
Enrolled All participants who sign the main ICF.
Full Analy sis Set (FAS) All participants who are randomised and either receive or do not receive any 
study intervention. Participants are evaluated according to the treatment 
assigned at randomisation.
The FAS will be used for all analyses of demographic baseline 
characteristics and efficacy data.
Per Protocol Set (PPS) A subset of the FAS consisting of all participants who do not violate the 
terms of the protocol in a way that may affect the primary efficacy endpoint 
significantly. All decisions to exclude participants from the per protocol 
analy sis set will be made and documented prior to the unblinding of the 
study.
Safety Set ( SS) All participants who are randomised and receive any study intervention. 
Participants are evaluated according to the actual treatment they received.
If a participant received a different treatment dose than randomised 
throughout the study, they will be analysed according tothe treated dose, 
not the randomisation dose. If a participant received study drug from the 
wrong kit for only part of the treatment duration, they will be analysed 
according to their randomisation dose.
The S Swill be used for all safety ana lyses.
Addit ional analysis sets , such as PK population may be defined the SAP for exploratory 
analyses.
9.4 Statistical Analyses
The SAP will be finalised prior to database lock for the interim analysis and will include a 
more technical and detailed descript ion of  the statistical analyses described in this sect ion. 
This sect ion is a summary of the planned statist ical analyses of the most important endpoints 
including primary  and key  secondary endpoints.
9.4.1 General Considerations
All results will be presented by  treatm ent group and overall, with descript ive statist ics 
appropriate to the nature of the variables. 
Dem ographic and baseline characterist ics as well as prior and conco mitant m edicat ion will be 
presented. For continuous va riables, the number of non -missing observations, mean, SD, 
median, first and third quartiles, minimum, and maximum will be presented. For categorical 
variables: counts (n) and percentages (%) (where specified) will be presented. These 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 74of 138summaries will be pro vided by t imepoint of assessment as appropriate.
When change fro m baseline will be described, the baseline value will be, in general, the last 
non-missing value prior to administration of the first dose of each treatment period. Further 
details will be described in the SAP .
The SAS® versio n 9.4 or later will be used for the data analysis.
In general, there will be no imputation of missing data for the safety analyses. Addit ional 
details will be provided in the SAP .
Deviat ions from  the protocol  will be as sessed as “important ” or “not-important ”. Important 
deviat ions from the protocol  may lead to the exclusion of part icipants fro m any of the study  
analysis sets. Deviat ions will be defined before database hard lock. Important deviat ions will 
include the fo llowing:
Violation of inclusio n and/or exclusio n criteria
Administrati on of  prohibi ted concomi tant m edicat ions that are expected to influence the 
measurement of the primary endpo int.
All protocol deviat ions will be discussed at the data review meet ing prior to database hard 
lock in order to define the analysis sets for the study . All the important protocol deviat ions will 
be listed by part icipants. Further details will be described in the SAP .
9.4.2 Efficacy
The analysis of all efficacy variables will be performed on the F AS. In addit ion, the primary  
efficacy endpo int will also be analysed using the PPS, as a sensit ivity analysis.
9.4.2.1 Primary Endpoint
The primary  efficacy endpo int for thi s study  is the percent change fro m baseline in UACR at 
12weeks.
Baseline for UACR will be defined as the geom etric mean of 3 UACR values derived fro m 
samples co llected at consecut ive days prior to the first dose of study  treatm ent.
As UACR is assumed to fo llow a l og-norm al distribut ion, it will  be log transform ed for 
statist ical analys is purposes. The mean log percent changes in UACR at 12 weeks for each of 
the 3doses of AZD9977 combined wit h dapagliflo zin 10 mg and dapagliflozin 10mgalone 
will be estimated in a mixed model for repeated measures (V isits7, 8, 9, and 10). The values 
will be back-transformed onto the original scale to give the geometric mean relat ive percent 
change from baseline at 12 weeks.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 75of 138Patients randomi sed according to CSP  versions 1. 0to 5.0 (before dropping placebo and 
AZD9977 150 mg monotherapy  arms) will be considered as part of Cohort 1, while pat ients 
rando mised subsequent ly will be included in Cohort 2. The primary analysis for the remaining 
4treatm ent groups will combine data from both cohorts, while the accrued data from 
discontinued treatm ent groups wi ll be analysed descript ively .
The analysis model will include UACR baseline value, treatment ,and visit as fixed effect , and 
the stratifying factors (T2DM [y es/no] and eGFR [ ≥20to<30mL/min/1.73 m2;or ≥30 to 
<45mL/min /1.73 m2; or≥45mL/min/1.73 m2])as well as the Cohort variable (1 or 2) as 
covari ates. Moreover, treatment -by-visit interaction will also be included in the model. The 
final analyt ical approach will be described in detail in the SAP . For the primary  analysis, the 
main treatment compa risons to be evaluated are (in a fixed -sequence testing) :
1Overall comparison of the percentage changes from baseline in UACR at week 12 across 
all 4 treatm ent groups
2Each of the 3 doses of AZD9977 in co mbinat ion wit h dapagliflozin 10 mg versus 
dapagliflozin 10 mg in the fo llowing order :
1.AZD9977 150 mg + dapagliflo zin 10 mg versus dapagliflo zin 10 mg
2.AZD9977 50 mg + dapagliflo zin 10 mg versus dapagliflozin 10 mg
3.AZD9977 15 mg + dapagliflo zin 10 mg versus dapagliflozin 10 mg
9.4.2.2 Secondary En dpoint
The dose -response relat ionship of percent change from baseline in UACR at 12 weeks will be 
assessed using data fro m dapagliflozin (10 mg) alo ne and 3 doses of AZD9977 (15, 50, or 
150mg) co mbined with dapagliflozin (10 mg).
More details of all these models will be provided in the SAP .
9.4.3 Pharmacokinetics
Plasma concentrations o f AZD9977 and dapagliflo zin will be listed and summarised by 
treatm ent groups, based on the PK Analysis Set.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 76of 1389.4.4 Pharmacodynamics and Biomarkers
The fo llowing exploratory  pharmacodyna mic and bio marker endpo ints will be summarised by 
treatm ent group based on the F AS:
Change from baseline in serum NT-proBNP over time
Change from baseline in blood uric acid, BUN, FPG, haematocri t, renin, ACTH, corti sol 
and copeptin levels over time
Change from baseline in blood MCV, MCHC, RBC distribution width, ery throcyte count 
over time
Change from baseline in urine Na+, K+, uric acid, urea, osmo lality, glucose, creatinine, 
and cortiso l levels over time
Change from baseline in blood and urine bio markers over time
The fo llowing analyses will not be part of the CSR:
Dose/exposure of AZD9977 and dapagliflo zin relative to safet y and pharm acodynamic 
variables (eg, serum /plasma K+, eGFR, al dosterone)
Exploratory  research into genes/genetic variat ion that may influence response to 
treatm ent
Analysis for these exploratory  objectives will be described in a separate analysis plan and 
resul ts will  be presented separately  from the m ain CSR.
9.4.5 Safety
Safety analyses will be performed using the SS. Safet y data will be presented using 
descript ive statistics unless otherwise specified.
In general, the baseline value for statist ical analysis i s the l ast non -missing value prior to 
administration of the first dose of IMP . Details are described in the SAP .
9.4.5.1 Adverse Events
Adverse events will be coded using the most recent versio n of the MedDRA  that will  have 
been released for execution at AstraZeneca or designee. 
AEs will be presented for each treatment group by  SOC and/or PT covering number and 
percentage of patients reportin g at least 1 event and number of events where appropriate. 
Only AEs occurring with an onset date, or worsening, on or after first dose of IMP and within 
28days after l ast dose of IMP will be presented in summary tables. Serious AEs occurring 
prior to sta rt of IMP will be included in data list ings.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 77of 138An overview of AEs will present for each treatment group the number and percentage of 
patients wi th any AE, AEs wit h outcome of death, SAEs, and AEs leading to discont inuat ion 
of IMP , as well as AEs leading to I MP dose interruptions, and AEs leading to withdrawal fro m 
study  as well as the number of individual occurrences in those categories.
Separate AE tables will be provided taken into consideration relationship as assessed by the 
investigator, maximum intensit y, seriousness, death, and AEs leading to discont inuat ion of 
IMP as well as other action taken related to IMP , other significant AEs,and t iming of events.
An addit ional table will present number and percentage of patients with most commo n AEs. 
Most commo n (eg, frequency o f >5%) will be defined in the SAP .
In accordance with the requirements of the FDA, a separate table will present no n-serious AEs 
occurring in more than 5% of patients in any treatment group. 
Key pat ient information will be presented for patients with AEs with outcome of death, SAEs, 
and AEs leading to discont inuat ion of IMP .
An AE listing for the SSwill cover details for each individual AE; an AE list ing for patients 
who were not exposed to IMP is presented separately .
Full details o f AE analyses will be provided in the SAP .
9.4.5.2 Vital Signs
Vital sign param eters will  be presented for each treatment group. Summary  statist ics for 
continuous variables cover n, mean, SD, minimum, Q1, median, Q3, and maximum. 
For each scheduled post- baseline visit, descript ive statist ics for all vital sign param eters will  
be presented for observed values and change fro m baseline.
Key pat ient information will be presented for patients with treatment -emergent changes in 
vital sign param eters outsi de of  predefined criteria (see Section 9.4.5.6 ). 
Supportive vital sign list ings cover observed values and changes from baseline as well as 
abnorm alities. 
Details o f vital sign analyses including definit ion of abnormal ity criteria (eg, defini tion of  low, 
norm al, high; clinically  significant) and proj ect-specific predefined criteria for treatment -
emergent changes in relevant vital sign parameters (eg, sy stolic and di astolic BP) will be 
provi ded in the SAP . 
9.4.5.3 Laboratory
Laboratory  parameters will be presented for each treatment group. Summary  statistics for 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 78of 138continuous variables cover n, mean, SD, minimum, Q1, median, Q3, and maximum. 
Frequency tables cover number and percentage of patients in the respective category .
For ea ch scheduled post -baseline visit, descript ive statist ics for all clinical chemistry  and 
haematology  parameters will be presented for observed values and change from baseline. 
A frequency  table will  present number of patients reporting at least one treatme nt-emergent 
change in laboratory  param eters outsi de predefined cri teria (see Section 9.4.5.6 ).
Elevat ion in liver parameters for assessment of Hy ’s law will be done and reported 
appropriately  if potenti al cases have been i dentified during the course of the study . 
Key pat ient information will be presented for patients with treatment -emergent changes in 
laboratory  parameters outsi de of predefined criter ia. 
For uri nalysis, a frequency  table will  present number of patients reporting at least 
1treatm ent-emergent increase in baseline category and/or a shift table will present the 
baseline assessment against the maximum on- treatment category . 
Supportive la boratory  listings cover observed values and changes fro m baseline for each 
individual pat ient as well as abnormalit ies. 
Details o f laboratory  analyses including definit ion of abnormalit y criteria (eg, defini tion of  
low, norm al, high; clinically  significan t) and proj ect-specific predefined criteria for 
treatm ent-emergent changes in relevant laboratory parameters will be provided in the SAP .
9.4.5.4 Electrocardiograms
Descript ive statistics will be produced at each schedule assessment timepo int for all 
quant itative ECG param eters (heart rate, PR, RR, QRS, QT , and QT cF intervals) for both 
observed absolute values and changes fro m baseline.
Electrocardiogram findings will also be listed. 
An analysis o f potenti ally clinically  significant ECG values on QT , QTcF, QRS and PR 
interval , and heart rate will be performed. The number and percentage of patients with 
potenti ally clinically significant ECG values will be tabulated across time and treatment 
group. The criteria based on severit y will be defined in the SAP .
Outliers with respect to QT cF will also be tabulated for the following categories:
Absolute value > 450 m s
Absolute value > 480 m s
Absolute value > 500 m s
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 79of 138Increase from baseline > 30 m s
Increase from baseline > 60 m s
9.4.5.5 Physical Examination
The list ings of the physical examinat ion will include date of examinat ion and confirmat ion of 
assessment performed (Y es/No).
9.4.5.6 Safety Topics of Interest
Hyperkalaemia
Hyperkalaemia will be evaluated by  the analysis of serum /plasma K+levels (eg, abso lute 
values and change fro m baseline, values outside predefined ranges, values meeting 
protocol -defined discont inuat ion criteria for hy perkal aemia). Further details will be provided 
in the SAP .
Hypotension
Symptom atic hypotensio n/decreased blood pressure will be evaluated by the anal ysis o f BP 
measurements (eg, values outside predefined ranges) and the analysis o f pre-defined AE PTs 
related to hy potensi on, as well as di scontinuati ons due to hy potensi on. Further details will be 
provi ded in the SAP .
Deteriorating Renal Function
Deteri orating renal funct ion will be evaluated by  analysis o f serum  creat inine and eGFR 
values (eg, percent change fro m baseline in eGFR, abso lute values and change fro m baseline, 
values meet ing protocol -defined discont inuat ion criteria for deteriorating renal fun ction) and 
analysis of pre -defined AE PTs related to deteriorating renal function. Further details will be 
provi ded in the SAP .
9.5 Interim Analyses
An interim analysis willbe perform ed when 300 patients have been treated for 12 weeks, 
unless the planned date of the interim analysis is tooclose to the expected data base lock date, 
for the com plete study . The purpose of the interim analysis is to have the possibilit y to tri gger 
Phase 3 activit ies; therefore, there will be no alpha spent. The co nduct of the study will not be 
impacted by  the resul ts of the interim  analysis. The deci sion to conduct an interim analysis 
will be documented.
The SAP will describe the planned interim analyses in greater details.
9.6 Data Monitoring Committee
A Safet y Unblin ded Data Review Co mmittee will be set up for this study  for ongoing safet y 
monitoring. In addit ion to general safet y/tolerabilit y, the committee will focus on potential 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 80of 138risks related to hy potensi on, deteri orating renal function and hyperkalaemia. An Interi m 
Unblinded Data Review Co mmittee will be set up to review data fro m the pre -planned interim 
analysis and make recommendat ions on future clinical development.
For details on the review co mmit tee, refer to Appendix  A 5.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 81of 13810 SUPPORTING DOCUMENTA TION AND OPERATIONAL
CONSIDERATIONS
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 82of 138Appendix ARegulatory, Ethical, and Study Oversight Considerations
A1 Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and CIOMS Internat ional Ethical Guidelines
Applicable ICH GCP Guidelines
Applicable laws and regul ations
The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant 
docum ents (eg, adverti sements) m ust be submitted to an IRB/IEC by  the invest igator and 
reviewed and approved by the IRB/IEC before the study  is init iated.
Any amendments to the protocol will require IRB/IEC and applicable Regulatory  
Authori ty approval  before implementati on of  changes m ade to the study  design, except 
for changes necessary  to eliminate an immediate hazard to study  parti cipants.
AstraZeneca will be responsible for obtaining the required authorisations to conduct the 
study  from the concerned Regulatory  Authori ty. This responsibilit y may be delegated to a 
CRO ,but the accountabilit y remains wi th AstraZeneca.
Regulatory Reporting Requirements for SAEs
Prom pt notificat ion by the invest igator to the sponsor of a SAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies towards the safet y of parti cipants and the safet y of 
a study  intervent ion under clinical invest igation are m et.
The sponsor has a legal responsibilit y to notify both the l ocal regulatory  authori ty and 
other regulatory  agencies about the safet y of a study  intervent ion under clinical 
investigat ion. The sponsor will co mply with country -specific regulatory  requi rements 
relating to safet y reporting to the regulatory  authorit y, IRB/IEC, and invest igators.
For all studies except those utilising medical devices investigator safet y reports m ust be 
prepared for SUSAR s according to local regulatory requirements and sponsor policy and 
forwarded to invest igators as necessary.
An invest igator who receives an invest igator safety report describing a SAE or other 
specific safet y informat ion (eg, summary or list ing of SAEs) fro m the sponsor will review 
and then file it along with the [Invest igato r’s Brochure or state other documents] and will 
notify the IRB/IEC, if appropriate according to local requirements.
A2 Financial Disclosure
Invest igators and sub -invest igators will provide the sponsor with sufficient, accurate financial 
inform ation as reques ted to allow the sponsor to submit complete and accurate financial 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 83of 138certification or disclosure statements to the appropriate regulatory  authori ties. Investi gators 
are responsible for providing information on financial interests during the course of the stu dy 
and for 1 year after completion o f the study .
A3 Informed Consent Process
The invest igator or his/her representative will explain the nature of the study to the 
participant or his/her legally  authorised representative and answer all quest ions regarding 
thestudy .
A pre -screening ICF and /ora full ICF have to be signed before any study intervent ion 
will take place. 
Parti cipants m ust be inform ed that thei r parti cipat ion is vo luntary,and they  are f ree to 
refuse to participate and may wit hdraw their consent a t any  time and for any  reason 
during the study . Partici pants will be requi red to sign a statement of informed consent that 
meets the requirements of 21 CFR 50, local regul ations, ICH gui delines, HIPAA 
requi rements, where applicable, and the IRB/IEC or stud y centre.
The m edical  record m ust include a statem ent that wri tten inform ed consent was obtained 
before the participant was enrolled in the study  and the date the written consent was 
obtained. The authorised person obtaining the informed consent must also sign the ICF.
Parti cipants m ust be re -consented to the most current versio n of the ICF(s) during their 
participat ion in the study.
A copy  of the ICF(s) m ust be provi ded to the participant or the participant’s legally  
authori sed representative.
Parti cipants who are rescreened are required to sign a new ICF .
The ICF will contain a separate section that addresses and documents the collect ion and use of 
any mandatory  and/or opti onal human bio logical  sam ples. The invest igator or authorised 
designee will explain to each partici pant the objectives of the analysis to be done on the 
samples and any potential future use. Participants will be told that they  are free to refuse to 
participate in any optional samples or the future use and may wit hdraw their consent at an y 
time and for any  reason during the retention period. 
A4 Data Protection
Parti cipants will be assigned a unique ident ifier by the sponsor. Any part icipant records or 
datasets that are transferred to the sponsor and its research collaborators will contain the 
ident ifier only; part icipant names or any  information which would make the participant 
ident ifiable will not be transferred.
The parti cipant m ust be inform ed that hi s/her personal  study -related data will  be used by  
the sponsor and its research collabor ators in accordance with local data protection law. 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 84of 138The l evel of  disclosure and use of their data must also be explained to the participant in 
the informed consent. 
The parti cipant m ust be inform ed that hi s/her m edical  records m ay be examined by 
Clinical Quali ty Assurance auditors or other authorised personnel appointed by  the 
sponsor, by  appropriate IRB/IEC members, and by inspectors from regulatory  authori ties.
A5 Committees Structure
A Safet y Unblinded Data Review Co mmittee will be set up for this study  tomonitor general  
safet y/tolerabili ty, with a focus on hypotensi on, deteri orating renal funct ion and 
hyperkalaemia.
An Interim Unblinded Data Review Co mmittee will be set up to review data from the 
pre-planned interim analysis and make recommendations regarding future clinical 
development.
The safet y of all AstraZeneca clinical studies is clo sely monitored on an ongoing basis by 
AstraZeneca representatives in consultat ion with Patient Safet y. Issues ident ified will be 
addressed; for instance, this could involve amendments to the CSP and letters to investigators.
A6 Dissemination of Clinical Study Data
A descri ption of this clinical study  will be available on http://astrazenecaclinicaltrials.com and 
http://www .clinicaltrials.gov as will the summary of the ma in study  resul ts when they  are 
available. The clinical study  and/or summary  of main study  resul ts may also be available on 
other websites according to the regulat ions of the countries in which the main study  is 
conducted.
A7 Data Quality Assurance
All partici pant data rel ating to the study  will be recorded on eCRF unless transmitted to 
the sponsor or designee , and i ts research collaborators, electronically (eg, laboratory  
data). The investigator is responsible for verifying that data entries are accurate and 
correct by  physically or el ectroni cally  signing the eCRF.
The invest igator must maintain accurate documentation (source data) that supports the 
inform ation entered in the eCRF.
The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review, a nd 
regul atory  agency inspecti ons and provi de di rect access to source data documents.
Moni toring details describing strategy  (eg, risk -based init iatives in operations and qualit y 
such as Risk Management and Mit igation Strategies and Analyt ical Risk-Based 
Monitoring), methods, responsibilit ies and requirements, including handling of 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 85of 138non-compliance issues and monitoring techniques (central, remote, or on -site monitoring) 
are provided in the Moni toring Plan.
The sponsor or designee , and i ts research collaborators areresponsible for the data 
management of this study  including qualit y checking of the data.
The sponsor assumes accountabilit y for acti ons delegated to other individuals (eg, CRO s).
Study  monitors will perform  ongoing source data verificati on to confirm  that data entered 
into the eCRF by authorised site personnel are accurate, complete, and verifiable fro m 
source documents; that the safet y and ri ghts of  participants are being protected; and that 
the study  is being conducted in accordance wit h the currently approved protocol and any 
other study  agreem ents, ICH GCP, and all applicable regulatory  requi rements.
Records and documents, including signed ICFs, pertaining to the conduct of this study  
must be retained by the invest igator for 15 years a fter study  com pletion unless local 
regul ations or inst itutional policies requi re a l onger retenti on peri od. No records m ay be 
destroy ed during the retention period without the written approval of the sponsor. No 
records m ay be transferred to another locati on or party  without wri tten notificat ion to the 
sponsor.
A8 Source Documents
Source documents provide evidence for the existence of the participant and substantiate 
the integrit y of the data collected. Source documents are filed at the invest igator’s site.
Data reported on the eCRF or entered in the eCRF that are transcribed fro m source 
docum ents m ust be consistent with the source documents or the discrepancies must be 
explained. The invest igator may need to request previous medical records or transfer 
record s, depending on the study. Also, current medical records must be available.
Definit ion of what constitutes source data can be found in the source data agreement and 
computeri sed data checklist for electronic source data.
A9 Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruit ment of 
participants.
The first act of recruitment is the first patient enrolled (ie, who signed consent) and will be the 
study  start date.
The sponsor designee reserves th e right to cl ose the study  site or terminate the study  at any  
time for any  reason at the sole discret ion of the sponsor . Study  sites will  be closed upon study  
completion. A study  site is considered cl osed when all  requi red docum ents and study  supplies 
have been co llected and a study site closure visit has been performed.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C 00001
CONFIDENTIAL AND PROPRIETARY 86of 138The invest igator may init iate study  site closure at any  time, provi ded there i s reasonable cause 
and sufficient notice is given in advance of the intended terminat ion.
Reasons for the early closure of a study  site by the sponsor or investigator may  include but are 
not limited to:
Failure of the invest igator to comply wit h the protocol, the requirements of the IRB/IEC 
or local health authori ties, the sponsor’s procedures, or GCP guidelines
Inadequate recruit ment of parti cipants by  the investi gator
Discontinuati on of  further study  intervent ion developm ent
If the study  is prem aturely  terminated or suspended, the sponsor shall prompt ly inform  the 
investigators, the IECs/IRBs, the regulatory  authorities, and any CRO (s) used in the study  of 
the reason for terminat ion or suspensio n, as specified by the applicable regulatory  
requi rements. The invest igator shall prompt ly inform the parti cipant and shoul d assure 
appropriate participant therapy  and/or follow-up.
Parti cipants from  terminated si tes will  have the opportuni ty to be transferred to another site to 
continue the study .
A10 Publication Policy
The results of this study  may be published or presented at scient ific meet ings. If this is 
foreseen, the invest igator agrees to submit all manuscripts or abstracts to the sponsor 
before submissio n. This allows the sponsor to protect proprietary  information and to 
provi de comments.
The sponsor will co mply wit h the requirements for publication o f study  resul ts.In 
accordance with standard editorial and ethical practice, the sponsor will generally support 
publicat ion of mult i-centre studi es only  in thei r entirety  and not as individual site data. In 
this case, a co -ordinat ing invest igator will be designated by mut ual agreement.
Authorship will be determined by  mutual  agreement and in line wit h Internat ional 
Committee of Medical Journal Editors authorship requirements.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 87of 138Appendix BAdverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
B1 Definition of Adverse Events
An AEis the development of any untoward medical occurrence in a participant or clinical 
study  participant administered a medicinal product and which does not necessarily have a 
causal relat ionship with this treatm ent. An AE can therefore be any unfavourable and 
unintended sign (eg, an abnormal laboratory  finding), symptom (for example nausea, chest 
pain), or disease temporally associated with the use of a medicinal product, whether or not 
considered related to the medicinal produc t. 
The term  AE is used to include both serious and non -serious AEs and can include a 
deteri oration of  a pre -exist ing medical occurrence. An AE may occur at any  time, including 
run-in or washout periods, even if no study  treatm ent has been administered.
B2 Definitions of Serious Adverse Event
A SAEis an AE occurring during any study period (ie, run -in, treatment, washout, follow -up), 
that fulfils one or more of the fo llowing cri teria:
Results in death
Is immediately life -threatening
Requi res in -partici pant ho spitalisat ion or prolongatio n of exist ing hospitalisat ion 
Results in persistent or significant disabilit y or incapaci ty 
Is a congenital ano maly or bi rth defect
Is an important medical event that may jeopardise the participant or may require medical 
treatment to prevent one of the outcomes listed above
Adverse events for malignant tumours reported during a study  shoul d generally be assessed 
as serious AEs. If no other seriousness criteria apply , the ‘Important Medi cal Event ’ criterion 
shoul d be used. In c ertain situat ions, however, medical judgement on an individual event basis 
shoul d be applied to cl arify that the malignant tumour event should be assessed and reported 
as a non-serious AE. For example, if the tumour is included as medical history and 
progr ession occurs during the study , but the progressio n does not change treatment and/or 
prognosi s of the m alignant tum our, the AE m ay not fulfil the attributes for being assessed as 
serious, al though reporti ng of the progression of the malignant tumour as an AE is valid and 
shoul d occur .Also, some t ypes of malignant tumours, which do not spread remotely after a 
routi ne treatm ent that does not require hospitalisat ion, may be assessed as non -serious; 
examples in adults include Stage 1 basal cell carcino ma and S tage 1A1 cervical cancer 
removed via cone biopsy .
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 88of 138Life-threatening
‘Life-threatening ’ means that the participant was at immediate risk of death fro m the AE as i t 
occurred ,or it is suspected that use or continued use of the product would result in the 
participant ’s death. ‘Life-threatening ’ does not m ean that had an AE occurred in a more severe 
form it might have caused death (eg, hepatit is that resolved wit hout hepatic failure).
Hospitalisation
Outpati ent treatm ent in an emergency room is not in itself a s erious AE, although the reasons 
for it may be (eg, bronchospasm, laryngeal oedema). Hospital admissions and/or surgical 
operati ons planned before or during a study  are not consi dered AEs if the illness or disease 
existed before the participant was enrolled in the study , provi ded that i t did not deteriorate in 
an unexpected way  during the study .
Important Medical Event or Medical Treatment
Medical and scientific judgement should be exercised in deciding whether a case is serious in 
situations where important medical events may  not be immediately life -threatening or resul t in 
death, hospi talisat ion, disabili ty or incapaci ty but may jeopardise the participant or may  
requi re medical treatm ent to prevent one or more outcomes listed in the definit ion of seri ous. 
These should usually be considered as serious.
Simply stopping the suspect drug does not mean that it is an important medical event; medical 
judgement must be used. Below are some examples of events that may be considered 
medically important based on the in vestigator ’s judgement:
Angioedema not severe enough to require intubation but requiring iv hydrocortisone 
treatm ent
Hepatotoxicit y caused by paracetamo l (acetaminophen) overdose requiring treatment with 
N-acetylcysteine
Intensive treatment in an emergency room  or at home for allergic bronchospasm
Blood dy scrasias (eg, neutropenia or anaemia requiring blood transfusion, etc.) or 
convulsio ns that do not result in hospitalisat ion
Development of drug dependency or drug abuse
Intensity Rating Scale
mild (aware ness of sign or symptom, but easily tolerated)
moderate (di scomf ort sufficient to cause interference with normal act ivities)
severe (incapacitat ing, with inabilit y to perform norm al activities)
It is important to dist inguish between serious and severe AEs . Severi ty is a measure of 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 89of 138intensity whereas seri ousness is defined by the criteria in Appendix B 2. An AE of severe 
intensity need not necessarily be considered serious. For example, nausea that persists for 
several hours may  be consi dered severe nausea, but not a SAE unless it meets the criteria 
shown in Appendix B 2. On the other hand, a stroke that results in only a limited degree of 
disabili ty may be considered a mild stroke but would be a SAE when it satisfies the criteria 
shown in Appendix B 2.
B 3 A Guide to Interpreting the Causality Question
When making an assessment of causalit y consi der the foll owing f actors when deciding if there 
isa ‘reasonable possibilit y’that an AE m ay have been caused by the drug.
Time Course. Exposure to suspect drug. Has the participant actually received the suspect 
drug? Did the AE occur in a reasonable temporal relat ionship to the administration of the 
suspect drug?
Consistency wit h known drug profile. Was the AE consistent with the previous 
knowl edge of the suspect drug (pharmaco logy and toxi cology) or drugs of the same 
pharmaco logical class? Or could the AE be ant icipated from its pharmaco logical 
propertie s?
De-challenge experience. Did the AE resolve or improve on stopping or reducing the dose 
of the suspect drug?
No al ternative cause. The AE cannot be reasonably explained by another aetio logy such 
as the underlying disease, other drugs, other host, or env ironmental  factors.
Rechallenge experience. Did the AE reoccur if the suspected drug was reintroduced after 
having been stopped? AstraZeneca would not normally reco mmend or support a 
rechallenge .
Laboratory  tests. A specific laboratory  invest igation (if pe rformed) has confirmed the 
relationship .
In difficult cases, other factors could be considered such as:
Is this a recogni sedfeature of overdose of the drug?
Is there a known mechanism?
Causalit y of ‘related ’ is made if fo llowing a review of the relevant data, there is evidence for a 
‘reasonable possibilit y’of a causal relationship for the individual case. The expression 
‘reasonable possibilit y’ of acausal  relati onship is meant to convey , in general, that there are 
facts (evidence) or arguments to sugge st a causal relat ionship.
The causalit y assessment i s perform ed based on the available data including enough 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagli flozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 90of 138inform ation to m ake an informed judgement. W ith no available facts or arguments to suggest a 
causal relat ionship, the event(s) will be assessed as ‘not rel ated’.
Causal relat ionship in cases where the disease under study  has deteri orated due to l ack of 
effect shoul d be classified as no reasonable possibilit y.
B4 Medication Error
For the purposes of this clinical study  a medicat ion error is an unintended failure or mistake in 
the treatment process for an AstraZeneca study  drug that ei ther causes harm to the participant 
or has the potential to cause harm to the participant. 
A medicat ion error is not lack of efficacy of the drug, but rather a human or proc ess related 
failure while the drug is in control of the study  site staf f or parti cipant.
Medicat ion error includes situat ions where an error .
occurred
was i dentified and intercepted before the participant received the drug
did not occur, but circumstances were recognised that could have led to an error
Examples of events to be reported in clinical studies as medication errors:
Drug name confusio n
Dispensing error eg, medication prepared incorrectly , even if i t was not actually  given to 
the participant
Drug not administered as indicated, for example, wrong route or wrong site of 
administration
Drug not taken as indicated eg, tablet disso lved in water when it should be taken as a 
solid tablet
Drug not stored as instructed eg, kept in the fridge when it should be at room  temperature
Wrong participant received the medicat ion (excluding IRT/RTSM errors)
Wrong drug administered to participant (excluding IRT/RTSM errors)
Examples of events that do not require reporting as medicat ion errors in clinical studies:
Errors related to or resulting fro m IRT/RTSM –including those which lead to one of the 
above listed events that would otherwise have been a medication error
Parti cipant acci dentally  missed drug dose(s) eg, forgot to take medication
Accidental  overdose (will be captured as an overdose)
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 91of 138Parti cipant f ailed to return unused medicat ion or empt y packaging
Errors related to background and rescue medicat ion, or standard of care medicat ion in 
open l abel studi es, even if an AstraZeneca product
Medicat ion errors are not regarded as AEs, but AEs may occur as a consequence of the 
medicat ion error .
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 92of 138Appendix CHandling of Human Biological Samples
C1 Chain of Custody
A full chain of custody  is maintained for all samples throughout their lifecycle.
The invest igator at each centre keeps full traceability  of collected bi ological sam ples f rom the 
participants while in storage at the centre until shipment or disposal (where appropriate) and 
records relevant processing information related to the samples while at site.
The sample receiver keep s full traceabili ty of the sam ples while in storage and during use unt il 
used or disposed of or until further shipment and keeps record of receipt of arrival and onward 
shipment or disposal.
AstraZeneca or delegated representatives will keep oversight of t he ent ire life cycle through 
internal  procedures, m onitoring of study  sites, auditing or process checks, and contractual 
requi rements of external laboratory  provi ders
Samples retained for further use will be stored in the AstraZeneca -assigned bi obanks or o ther 
sample archive facilit ies and will be tracked by  the appropri ate AstraZeneca T eam during for 
the rem ainder of the sam ple life cycle.
C2 Withdrawal of Informed Consent for Donated Biological Samples 
If a participant withdraws consent to the use of donate d biological  samples, the sam ples will 
be disposed of/destroy ed/repatriated, and the action documented. If samples are already  
analysed ,AstraZeneca is not obliged to destroy  the resul ts of this research.
Following wi thdrawal  of consent for bio logical samp les, further study  partici pation shoul d be 
considered in relat ion to the wi thdrawal  processes outlined in the informed consent.
The invest igator:
Ensures participant’s withdrawal of informed consent to the use of donated samples is 
highlighted immediately to AstraZeneca or delegate.
Ensures that relevant human bio logical samples from  that parti cipant, if stored at the 
study  site, are immediately  identified, disposed of as appropriate, and the action 
docum ented.
Ensures that the participant and AstraZeneca a re inform ed about the sample disposal.
AstraZeneca ensures the organisation(s) holding the samples is/are informed about the 
withdrawn consent immediately and that samples are disposed of or repatriated as appropriate, 
and the action documented ,and study site notified.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 93of 138C3 International Airline Transportation Association (IATA) 6.2 
Guidance Document
LABELLING AND SHIPMENT OF BIOHAZARD SAMPLES
International Airline Transportation Associat ion (IA TA) 
(https://www .iata.org/whatwedo/cargo/dgr/Pages/download.aspx ) classifies infect ious 
substances into 3 categories: Category  A, Category B or Exempt
Category A Infectious Substances are infect ious substances in a form that, when exposure to 
it occurs, i s capable of causing permanent disabilit y, life-threatening or fatal disease in 
otherwi se healt hy humans or animals. 
Category A Pathogens are eg, Ebol a, Lassa fever virus. Infectious substances meet ing these 
criteria which cause disease in humans or both in humans and animals must be assigned to 
UN2814. Infect ious substances which cause disease only in animals must be assigned to 
UN2900.
Category B Infectious Substances are infect ious substances that do not meet the criteria for 
inclusio n in Category  A. Category  B pathogens are eg, hepatit is A, C, D, and E viruses. They 
are assigned the fo llowing UN number and proper shipping name
UN3373 –Biological Substance, Category  B
are to be packed in accordance with UN 3373 and IATA 650
Exempt –Substances which do not contain infect ious substances or substan ces which are 
unlikely  to cause disease in humans or animals are not subject to these regulat ions unless they  
meet the criteria for inclusio n in another class.
Clinical study  samples will fall into Category B or exempt under IATA regulat ions
Clinical study samples will routinely  be packed and transported at ambient temperature in 
IATA 650 com pliant packaging 
(https://www.iata.org/whatwedo/cargo/dgr/Documents/DGR -60-EN-PI650.pdf )
Biological samples transported in dry  ice requi re addi tional dangerous goods specificat ion 
for the dry  ice content
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 94of 138Appendix DOptional Genomics Initiative Sample
D1 Use/analysis of DNA
AstraZeneca intends to collect and store DNA for genet ic research to explore how genetic 
variat ions may affect clinical parameters, risk and prognosis o f diseases, and the response 
to medicat ions. This genetic research may lead to better understanding of diseases, better 
diagnosis of diseases or other improvements in healt h care and to the discovery o f new 
diagnosti cs, treatm ents, or medicati ons. Therefore, where local regulations and IRB/IEC 
allow, a blood sample will be collected for DNA analysis fro m consent ing participants.
This optional genet ic research may consist of the analysis o f the structure of the 
participant´s DNA, i e, the enti re genom e. 
The re sults of genet ic analyses may be reported in a separate study summary.
The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confident iality.
The samples will be retained while research on AZD9977 and dapagliflo zin or other 
AstraZeneca study  treatm ents of the same classes or for these indicat ions continues but no 
longer than 15 years or other period as per local requirements.
D2 Genetic research plan and procedures
Selection of Genetic Resear ch Population
All parti cipants will be asked to participate in this genet ic research. Participat ion is 
voluntary and if a participant declines to participate there will be no penalt y or loss of 
benefit. The participant will not be excluded fro m any aspect of the main study .
Inclusion Criteria
For inclusio n in this genet ic research, participants must fulfil all of the inclusio n criteria 
described in the main body  of the CSP and: Provi de inform ed consent for the Geno mics 
Initiative sampling and analyses.
Exclusion Criteria
Exclusi on from this genet ic research may be for any o f the excl usion criteria specified in the 
main study  or any  of the fo llowing:
Previous allogeneic bone marrow transplant
Non-leukocyte depleted whole blood transfusio n in 120 days of genetic sample collection
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 95of 138Withdrawal of Consent for Genetic Research: 
Parti cipants may  withdraw from  this genet ic research at any t ime, independent of any 
decisio n concerning participation in other aspects of the main study . Vol untary  
withdrawal  will not prej udice further treatmen t. Procedures for withdrawal are outlined in 
Secti on7.2of the CSP.
Collection of Samples for Genetic Research
The blood sample for this genetic re search will be obtained fro m the parti cipants at 
Visit 3, at or after randomisat ion. Although DNA is stable, early sample co llection is 
preferred to avoid introducing bias through excluding participants who may wit hdraw due 
to an AE. If for any  reason the sample is not drawn at Visit 3, it may be taken at any  visit 
until the last study visit. Only one sample should be collected per participant for genetics 
during the study .
Coding and Storage of DNA Samples
The processes adopted for the coding and storage of samples for genet ic analysis are 
important to maintain participant confident iality. Sam ples will  be stored for a m aximum  
of 15years, from the date of last participant last visit, after which they will be destroyed. 
DNA is a finite resource that is used up during analyses. Samples will be stored and used 
until no further analyses are possible or the maximum storage time has been reached.
An addit ional second code will be assigned to the sample eit her before or at the time of 
DNA extraction replacing the informat ion on the sample tube. Thereafter, the sample will 
be ident ifiable only by the second, unique number. This number is used to identify the 
sample and corresponding data at the AstraZeneca genet ics laboratori es, or at the 
designated organisation. No personal details ident ifying the individual will be available to 
any person (AstraZeneca emplo yee or desi gnated organi sations working with the DNA).
The link between the participant enrolment/randomisat ion code and the second number 
will be maintained and stored in a secure environment, with restricted access at 
AstraZeneca or designated organisat ions. The link will be used to identify the relevant 
DNA samples for analysis, facilitate correlat ion of genoty pic resul ts wi th clinical data, 
allow regulatory  audit, and permi t tracing of samples for destruction in the case of 
withdrawal  of consent.
Ethical and Regulatory Requirements
The principles for ethical and regulatory  requi rements for the study , incl uding this 
genet ics research component, are outlined in Appendix A .
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 96of 138Informed Consent
The genetic component of this study  is opti onal,and the participant may part icipate in 
other components of the main st udy without parti cipating in this genet ic component. To 
participate in the genet ic component of the study the participant must sign and date both 
the consent form for the main study  and the addendum  for the Genomics Init iative 
component of the study . Copi es of both signed and dated consent forms must be given to 
the participant and the original filed at the study  centre. The PIis responsible for ensuring 
that consent is given freely ,and that the participant understands that they  may freely  
withdrawal  from the genet ic aspect of the study at any time.
Participant Data Protection
AstraZeneca will not provide individual genoty pe resul ts to parti cipants, any  insurance 
company, any emplo yer, thei r family members, general physician unless required to do so 
by law.
Extra precautions are taken to preserve confident iality and prevent genetic data being 
linked to the ident ity of the parti cipant. In except ional circumstances, however, certain 
individuals might see both the genet ic data and the personal ident ifiers of a parti cipant. 
For example, in the case of a medical emergency , an AstraZeneca Physician or an 
investigator might know a participant’s ident ity and al so have access to his or her genetic 
data. Regul atory  authori ties may requi re access to the rel evant files , though the 
participant’s m edical  information and the genet ic files would remain physically separate.
Data Management
Data will be reported will be reported separately  from the CSR.
Any genet ic data generated in this study will be stored at a secure syst em at AstraZeneca 
and/or designated organisat ions to analyse the samples.
AstraZeneca and its designated organisat ions may share summary results (such as genet ic 
differences fro m groups of individuals with a disease) fro m this genetic research with 
other r esearchers, such as hospitals, academic organisations, or health insurance 
companies. This can be done by placing the results in scientific databases, where they  can 
be co mbined with the results of similar studies to learn even more about health and 
disease. The researchers can only  use thi s inform ation for heal th-related research 
purposes. Researchers may  see summary  resul ts,but they  will not be able to see 
individual part icipant data or any  personal  identifiers. 
Some or all  of the clinical datasets from the main study  may be merged wi th the genet ic 
data in a suitable secure environment separate from the clinical database.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 97of 138Appendix EActions Required in Cases of Increases in Liver Biochemistry 
and Evaluation of Hy’s Law
E1 Introduction
This Appendix describes the proc ess to be fo llowed in order to i dentify and appropriately 
report potential Hy ’s law (PHL) cases and Hy ’s law (HL) cases. It i s not intended to be a 
comprehensive gui de to the m anagement of el evated liver biochemistries. 
During the course of the study  the invest igator will remain vigilant for increases in liver 
biochemistry . The investigator is responsible for determining whether a participant meets 
potenti al PHL  criteria at any  point during the study .
All sources of l aboratory  data are appropri ate for the determinat ion of PHL  and HL  events; 
this includes samples taken at scheduled study  visits and other vi sits including central  and all 
local laboratory  evaluat ions even if co llected outside of the study  visit s; for exam ple, PHL  
criteria coul d be m et by  an el evated ALT from a central  laboratory  and/or elevated TBL  from 
a local laboratory . 
The invest igator will also review AEdata (for example, for AEs that may indicate elevat ions 
in liver bio chemistry ) for possible PHL  events.
The invest igator participates, t ogether with AstraZeneca clinical project representatives, in 
review and assessment of cases meet ing PHL  criteria to agree whether HL  criteria are m et. HL  
criteria are met if there is no alternat ive explanation for the elevat ions in liver biochemistry  
other than DILI caused by  the IMP . 
The invest igator is responsible for recording data pertaining to PHL/HL  cases and for 
reporting SAEs and AEs according to the outcome of the review and assessment in line with 
standard safet y reporting processes.
E2 Definitions
Potential Hy’s Law (PHL)
Aspartate Aminotransferase (AST) or ALT ≥3xULN together  with TBL ≥2xULN at any 
point during the study  following the start of study  medicat ionirrespect ive of an increase in 
alkaline phosphatase (ALP).
Hy’s Law (HL)
AST or ALT ≥3xULN together  with TBL ≥2xULN, where no other reason, other than the 
IMP, can be found to explain the co mbinat ion of increases, eg, elevated ALP indicat ing 
cholestasis, viral hepat itis, another drug. 
For PHL  and HL  the el evation in transaminases must precede or be coincident with (ie, on the 
Clinical Study Protoc ol-7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 98of 138same day ) the el evati on in TBL, but there is no specified time frame wit hin which the 
elevations in transaminases and TBL  must occur .
E 3 Identification of Potential Hy’s Law Cases
In order to i denti fy cases of PHL  it is important to perform a comprehensive review of 
laboratory  data for any  parti cipant who m eets any of the fo llowing identificat ion criteria in 
isolation or in combinat ion:
ALT ≥ 3 x ULN
AST ≥ 3 x ULN
TBL ≥ 2 x ULN
Central Laboratories Being Used:
When a participant meets any of the PHL  identification criteria, in iso lation or in co mbinat ion, 
the central  laboratory  will immediately send an alert to the investigator (also sent to 
AstraZeneca representative). 
The invest igator will also re main vigilant for any  local  laboratory  reports where the PHL  
ident ificat ion criteria are met, where this is the case the invest igator will:
Notify  the AstraZeneca representative
Request a repeat of the test (new blood draw) by  the central  laboratory without 
delay
Com plete the appropri ate unscheduled laboratory  eCRF m odule(s) wi th the 
original  local laboratory  test resul t
When the identificat ion criteria are m et from central  or local laboratory  resul ts the invest igator 
will wit hout del ay:
Determine whether the participant meets PHL criteria (see Section  E 2for 
definit ion) by  reviewing l aboratory  reports from  all previ ous visi ts (including both 
central  and l ocal laboratory  resul ts)
E 4 Follow -up
E4.1 Potential Hy’s Law Criteria not met
If the participant does not meet PHL  criteria the investigator will:
Inform  the AstraZeneca representative that the participant has not met PHL criteria.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 99of 138Perform  follow-up on subsequent laboratory  resul ts according to the guidance provided in 
the CSP.
E4.2 Potential Hy’s Law Criteria met
If the participant does meet PHL  criteria the inves tigator will:
Notify  the AstraZeneca representative who will then inform the central Study  Team  
Within 1 day of PHL criteria being met, the invest igator will report the case as an SAE of 
Potenti al Hy’s Law; seri ous cri teria ‘Im portant Medi cal Event’ and c ausalit y assessment 
‘yes/related’ according to CSP process for SAE reporting
For parti cipants that met PHL criteria prior to starting IMP, the invest igator is not 
requi red to submit a PHL SAE unless there is a significant change #in the participant’s 
condi tion
The Study  Physician contacts the investigator, to provide guidance, discuss and agree an 
approach for the study  parti cipants’ fo llow-up (including any further laboratory  testing) 
and the continuous review of data
Subsequent to this contact the invest igator will:
Moni tor the parti cipant until liver bio chemistry  param eters and appropri ate clinical 
symptoms and signs return to normal or baseline levels, or as long as medically 
indicated. Completes fo llow-up SAE Form as required.
Invest igate the aetiology of the event and perform diagnostic investigat ions as 
discussed wi th the Study  Physician. This includes deciding which tests available in 
the Hy ’s law lab ki t shoul d be used.
Com plete the 3 Liver eCRF Modules as informat ion beco mes available. 
#A ‘signifi cant’ change in the participant ’s condi tion refers to a clinically  relevant 
change in any  of the individual liver biochemistry  param eters (AL T, AST or TBL) in iso lation 
or in co mbination, or a clinically relevant change in associated symptoms. The determin ation 
of whether there has been a significant change will be at the discretion o f the invest igator , this 
may be in consultat ion with the Study  Physician if there is any uncertaint y.
E5 Review and Assessment of Potential Hy’s Law Cases
The instructions in this section shoul d be fo llowed for all  cases where PHL  criteria are met.
As soon as possible after the biochemistry  abnormalit y was ini tially detected, the Study  
Physician contacts the invest igator in order to review available data and agree on whether 
there is an alternat ive explanat ion for meeting PHL  criteria other than DILI caused by  the 
IMP, to ensure timely analysis and reporting to healt h authorit ies wit hin 15 calendar days fro m 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 100of 138date PHL  criteria was m et. The AstraZeneca Glo bal Clinical Lead or equivale nt and Gl obal 
Safety Physician will also be invo lved in this review together with other subject matter experts 
as appropri ate. According to the outcome of the review and assessment, the investigator will 
follow the instructi ons bel ow.
Wher e ther e isan agr eed alternative explanation for the ALT or AST and TBL elevat ions, a 
determinat ion of whether the alternat ive explanat ion is an AE will be made and subsequent ly 
whether the AE meets the criteria for a SAE:
If the alternat ive explanat ion is notan AE, record the alternative explanation on the 
appropriate eCRF.
If the alternat ive explanat ion is an AE/SAE: update the previously submitted Potential 
Hy’s Law SAE and AE eCRFs accordingly wit h the new informat ion (reassessing event 
term; causalit y andseriousness cri teria) fo llowing the AstraZeneca standard processes.
If it is agreed that there is no explanat ion that would explain the AL T or AST and TBL 
elevations other than the IMP:
Send updated SAE (report term ‘Hy’s law’) according to AstraZeneca s tandard processes. 
 The ‘Medically  Important’ seri ous cri terion shoul d be used if no other serious 
criteria apply.
 As there is no alternat ive explanation for the HL case, a causalit y assessment of 
‘related’ should be assigned.
If, there i s an unavo idable delay , of over 15 calendar days in obtaining the informat ion 
necessary  to assess whether or not the case meets the criteria for HL, then it is assumed that 
there is no alternat ive explanation unt il such time as an informed decisio n can be made:
Provi des an y further update to the previously submitted SAE of Potential Hy’s Law, 
(report term now ‘Hy’s law case’) ensuring causality  assessment i s related to IMP and 
seriousness cri teria is m edically important, according to CSP process for SAE reporting.
Continue follow-up and review according to agreed plan. Once the necessary  
supplementary  informat ion is obtained, repeat the review and assessment to determine 
whether HL criteria are still met. Update the previously submitted PHL SAE report 
following CSP process f or SAE reporting, according to the outcome of the review and 
amending the reported term if an alternat ive explanat ion for the liver biochemistry  
elevations is determined.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 101of 138E6 Laboratory Tests
Hy’s Law Lab Kit for Central Laboratories 
Additional standard chem istry and coagulation 
testsGGT
LDH
Prothrombin time
INR
Viral hepatitis IgM anti -HAV
HBsAg
IgM and IgG anti -HBc
HBV DNAa
IgG anti -HCV
HCV RNA b
IgM anti -HEV
HEV RNA
Other viral infections IgM & IgG anti -CMV
IgM & IgG anti -HSV
IgM & IgG anti -EBV
Alcoholic hepatitis Carbohydrate deficient transferrin 
(CD-transferrin) c
Autoimmune hepatitis Antinuclear antibody (ANA)
Anti-Liver/Kidney Microsomal Ab (Anti -LKM)
Anti-Smooth Muscle Ab (ASMA)
Metabolic diseases alpha -1-antitrypsin
Ceruloplasmin
Iron
Ferritin
Transferrinc
Transferrin saturation
CMV=cytomegalovirus; DNA=deoxyribonucleic acid; EBV=Epstein -Barr virus; GGT=gamma glutamyl 
transferase; HBc=hepatitis B core; HBsAg=hepatitis B surface antigen; HBV=hepatitis B virus; HCV=hepatitis 
C virus; HEV=hepatitis E virus; HSV=herpes simplex virus; IgG=immunoglobulin G; IgM=immunoglobulin M; 
INR=international normalised ratio; LDH=lactate dehydrogenase; RNA=ribonucleic acid.aHBV DNA is only recommended when IgG anti -HBc is positivebHCV RNA is only recommended when IgG anti -HCV is positive or inconclusive cCD-transferrin and Transferrin are not available in China. Study teams should amend this list accordingly
E7 References
Aithal et al, 2011
Aithal et al 2011, Clinical Pharmaco logy and Therapeutics 89(6):806 -815.
FDA Guidance for Industry, July 2009
FDA  Guidance for Industry  (issued July 2009) ‘Drug -induced liver injury: Premarket ing 
clinical evaluat ion’. Available fro m; https://www .fda.gov/regulatory -informat ion/search -fda-
Clinica l Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 102of 138guidance -docum ents/drug -induced -liver-injury -premarket ing-clinical -evaluati on
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 103of 138Appendix FManagement of Hyperkalaemia and Deteriorating Renal 
Function
F1 Hyperkalaemia
At all baseline and on -treatm ent visi ts (according to the SoA) K+will be measured in either 
serum  or pl asma sam ples at a l ocal laboratory depending on the laboratory ’s capabilit y and in 
serum  samples at a central laboratory . Repeat sampl es shoul d be sent for both central and local 
laboratory  assessment.
Inappropriate s ample handling/storage or lengthy  transport time to the central laboratory  may 
resul t in falsely elevated serum K+levels in the centrally analysed blood samples. It is 
expected that local laboratory  resul ts (from either serum /plasma samples) will be avail able 
prior to central laboratory  resul ts and expected to take priorit y for 
decisio n-making/mo nitoring:
Serum /plasma K+>5.5 to ≤6mmo l/L (based on l ocal laboratory  samples) shoul d be 
reassessed wit hin 72 hours.
If the repeat local laboratory  sample has se rum/plasma K+>6.0 mmo l/L, study  
treatm ents m ust be di scontinued perm anent ly.
If the repeat local laboratory  sample has serum /plasma K+>5.5 to ≤6.0mmo l/L, 
consider corrective actions, including dietary  changes and/or 
adjustm ent/discont inuat ion of non -essent ial medicati ons that might have caused or 
contributed to hy perkalaemia and reassess within 72 hours:
oIf local serum /plasma K+remains > 5.5mmo l/L to ≤6mmo l/L, consider 
perm anent discont inuat ion or con tinue m onitoring at the di screti on of  the 
investigator. Permanent ly discontinue if repeat local and/or central samples have 
serum /plasma K+>6.0mmo l/L.
Serum /plasma K+>6mmo l/L (based on local laboratory  samples) shoul d be reassessed 
immediately  and study  treatm ents shoul d be di scont inued temp orarily  while wai ting for 
resul ts:
If the repeat local laboratory  sample has serum /plasma K+>6.0mmo l/L, study  
treatm ents m ust be di scontinued perm anent ly. 
If the repeat local laboratory  sample has serum /plasma K+>5.5 to ≤6.0mmo l/L and 
the central  laboratory  sample has serum K+is >6.0mmo l/L, study  treatm ents m ust 
be discont inued permanent ly.
If the repeat local laboratory  sample has serum /plasma K+>5.5 to ≤6.0mmo l/L and 
the central  laboratory  sample has serum K+≤6.0mmo l/L, based on the disc retion of 
the Invest igator, consider corrective act ions, including dietary  changes and/or 
adjustm ent/discont inuat ion of non -essent ial medicati ons that might have caused or 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 104of 138contributed to hy perkalaemia; and/or con tinuati on wi th reassessment; or permanent 
discontinuat ion.
If the repeat local laboratory  sample has serum /plasma K+≤5.5 mmo l/L, then study  
treatm ents can be resumed, even if the central laboratory  sample has serum  
K+>6.0mmo l/L.
If the invest igator is aware of any change in the participant ’s clinical status that may  influence 
serum  electroly te levels or fluid balance (eg, vomit ing and/or diarrhoea > 1day), it is 
recommended to reassess serum /plasma K+levels as soon as possible a fter the acute event. In 
case of permanent discontinuation, serum /plasma K+levels shoul d be m onitored until  
resol ution or stabilisat ion.
F2 Deterioration of Renal Function
Serum  creatinine will be measured both at a local laboratory  and a central laboratory  at all 
baseline and on -treatm ent visi ts according to the SoA. Repeat samples should be sent for both 
central  and l ocal laboratory  assessment. It i s expected that local laboratory  resul ts will be 
available prior to central laboratory  resul ts. As local and c entral  laboratori es will  calculate 
eGFR using different formulas, central eGFR values should always be co mpared to central 
eGFR values and local eGFR values should always be compared to local eGFR values. For 
local laboratori es, the eGFR assessment at V isit3 (prior to the start of study  treatm ent)will be 
taken as the baseline eGFR value.
If eGFR shows a 30 -50% decline fro m baseline and an abso lute value 
≥15mL/min /1.73 m2(based on l ocal and/or central laboratory  samples), eGFR should be 
reassessed wit hin 1 week.
If persistent 30 -50% decline stabilises upon weekly fo llow-ups, eGFR m onitoring 
may return to the standard SoA, at invest igator’s discretion.
If eGFR shows a >50% decline from baseline and/or decreases to an abso lute value 
<15ml/min /1.73 m2(based on l ocal and/or central laboratory  samples), eGFR should be 
reassessed wit hin 48 hours.
If eGFR shows a 30% to 50% decline fro m baseline and an abso lute value 
≥15mL/m in/1.73 m2, eGFR shoul d be reassessed wi thin 1 week.
If eGFR again shows a >50% reduction from baseline and/or absolute value 
<15mL/min /1.73 m2, study  treatm ents m ust be discontinued immediately  and eGFR 
shoul d be f ollowed up wi thin a week and weekly unt il signs of improvement and 
stabilisat ion.
If an unexpected, acute decline in kidney function is observed, the patient should be prompt ly 
evaluated. V olume deplet ion, hypotension, inter -current m edical probl ems, metabolic 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00 001
CONFIDENTIAL AND PROPRIETARY 105of 138derangements, and conco mitant dru gs may cause increases in blood creatinine. Urinary tract 
infect ion and urinary  obstructi on shoul d be considered. Several drugs may cause a decline in 
kidney funct ion, especially NSAID and certain antibiot ics such as trimethoprim. If any drug is 
suspected of causing or con tribut ing to worsening kidney funct ion, thei r use shoul d be 
reconsidered.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 106of 138Appendix GCOVID -19 Specifics
G1 Background to COVID -19
There i s currently an outbreak of respiratory  disease (COVID -19) caused by a novel 
SARS -CoV-2 that was first detected in W uhan Cit y, Hubei  Province, China in 2019. This new 
virus has rapidly spread across the globe causing the WHO to declare a pandemic situat ion on 
12March 2020. The countermeasures init iated by  national and local governments worldwide 
and the recommendat ions issued by  the heal th authori ties have impacted current and new 
clinical studies. As the threat of pandemic burden including new outbreaks, locally or globally , 
will impact the further conduct of clinical studies, appropriate risk assessments and mit igation
measures will need to be taken into considerat ion in all clinical studies to protect subjects, site 
staff, and societ y as a whol e.
Both EMA  and FDA  as well as nat ional health authori ties in Europe have issued new 
guidelines that aim to provide recommendat ions for actions for conduct of clinical studies o f 
medical products during COVID -19 pandemic. Since the pandemic situation is evo lving, 
guidelines, recommendations, nat ional laws, and local restrictions may change at high pace. 
Given the circumstances o f potenti ally relapsing pandemic or epidemic situat ion with regard 
to the spread of COVID -19 in future, special attentio n will be paid to protect subjects 
participat ing in the study and site staff invo lved in the invest igations against infect ion with 
SARS -CoV-2 as requested by  the newly issued EMA  guideline.
G2 Risk Assessment for COVID -19 Pandemic
Risk of infection with SARS -CoV-2
The 2 study  drugs wi th different mechanisms of action are unlikely to impact on the course of 
infect ion with SARS -CoV-2. Dapagliflozin is an ant i-glycaemic agent and AZD9977 is a 
select ive mineralocortico id receptor modulator; neit her is expected to cause immune 
suppressio n. Therefore, risk of the participants exposure to SARS -CoV-2 or to suffer fro m 
COVID -19 is expected to be similar to the background population wit h the same 
co-morbidities, in part icular HF and CKD. The risk of exposure to infected people cannot be 
completely excluded as the participants may need to be in public areas (eg, commute to the 
site) and have addi tional human contact (eg, with site staff and other participants of the 
clinical study ).
Measures to mit igate the addit ional risks caused by COVID -19 are:
This study  is going to start enrolling only when the Sponsor and CRO in collaboration 
deem  it is safe to start the study . In addi tion, the study  will not start until the local 
confinement measures or other safet y restri ctions linked to the COVID -19 pandemic 
imposed by  the l ocal authori ties are com patible with safe conduct of the study.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 107of 138Current national la ws and l ocal recommendat ions for prevent ion of pandemic will be 
strictly adhered to.
Parti cipants will be cl osely m onitored f or any  signs and symptom s of COVID -19, 
including fever, dry  cough, dyspnoea, sore throat, and fatigue throughout the study  during 
the pandemic. Once clinical signs of infect ion are reported by part icipants, the 
Invest igator needs to determine whether samples can be collected, and safet y data can be 
recorded on site. If not, AEs and concomitant medications will be obtained via phone 
calls. The decisio n to continue wit h dosing the participant with the study  drugs in the 
event of him/her showing symptoms o f COVID -19 infect ion will be per Invest igator’s 
discreti on.
The probabilit y of virus transmission will be controlled as much as possibl e by:
Advice for participant to adhere to local requirements for reduction of the public 
exposure while ambulatory .
Confirmation o f COVID -19 infect ion by optional laboratory  assessment will be 
conducted based on availabilit y (test capaci ty and turnaround t ime) of approved tests 
and on Invest igator’s discret ion.
Request ing all part icipants are contacted by  phone 1 day prior to every  visit for 
assessing COVID -19 symptoms and signs and are asked not to attend the site in case 
of suspected reports. In addit ion,participants are asked for any  contact wi th a person 
who has tested posit ive for SARS -CoV -2. If applicable, participants will be referred 
to the l ocal health care system  for further fo llow-up and treatm ent.
Physical distancing and person -to-person contact restrict ions will be applied during 
site visi ts. 
Where physical distancing is not possible, personal protective equipment will be used 
by study  parti cipants (surgi cal face m ask, gl oves) and staff (for example but not 
limited to m asks, gl oves, protectors, medical suits) if deemed appropriate by  the 
Invest igators and site staff and guided by local requirements.
Logist ical improvements of the site and structural measures of the study  site building 
will be implemented to further improve physical distancing.
If site visi ts are not possible due to local restrictions, home nursing visits may  be 
considered after discussion wit h and approval by the Sponsor.
Risk Related to COVID -19 vaccination
The 2 study  drugs are predicted to have a low risk of influencing COVID -19 vaccine 
effectiveness and no addit ional safety  concerns are anticipated. Clinical trial participant who 
have already taken the COVID -19 vaccine of any type are permitted to enrol in the study . 
Clinical trial participant who are not y et vaccinated should consider current/local guidelines, 
vaccine availabilit y, and benefit -risk assessment of the COVID -19 vaccine. Ult imately , the 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 108of 138decisio n to vaccinate will be based on the judgment of the treating physician taking into 
account the participant's best interest .
G3 Restrictions Related to COVID -19
During the COVID -19 pandemic, participants are advised to adhere to local requirements for 
reducti on of  the public SARS -CoV-2 exposure while ambulatory . If applicable, pri or to 
screening (V isit1a), potenti al parti cipants shoul d be called to confirm they  are not 
experiencing any  COVID -19 symptom s and signs and are asked not to attend the site in case 
of suspected infect ion. If appropriate, participants will be referred to the local health care 
system . Physical distancing a nd person -to-person contact restrictions will be applied and 
explained to participants while staying at the study site. Where physical distancing is not 
possible, study  parti cipants will be asked to use surgical face masks and/or gloves if deemed 
appropria te by  the Invest igator and site staff and guided by local requirements.
G4 Data Quality Assurance Related to COVID -19
Moni toring visit s at si te will  be limi ted to a minimum  requi red as deemed appropriate during 
COVID -19 pandemic, per local regulations.
In add ition, where possible, other measures for carrying out protocol related activit ies, such as 
but not limited to home nursing, may be emplo yed as required.
G5 References
Guidance on the Management of Clinical Trials during the COVID19 (Coronavirus) 
pandemic, EM A, Version 3 (28/04/2020). 
https://ec.europa.eu/healt h/sites/health/files/files/eudralex/vo l-
10/gui danceclinicaltri als_covi d19_en.pdf
FDA  Guidance on Conduct of Clinical Trials of Medical Products during COVID -19 Public 
Health Emergency , March 2020, Update d on June 03, 2020 https://www .fda.gov/regul atory -
inform ation/search -fda-guidance -docum ents/fda -guidance -conduct -clinical -trials-medical -
products -during -covid -19-public -healt h-emergency
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapag liflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 109of 138Appendix HStrong and Moderate Cytochrome P450 3A4 (CYP3A4) 
Inhibitors and Induce rs
Strong or moderate CYP3A4 inhibitors or inducers are prohibited at least 3 weeks prior to 
rando misat ion (ie, start of run -in period) and for the duration of the study .
The fo llowing list (Table8) is not i ntended to be exhaustive and a similar restriction will 
apply to other agents that are known to modulate CYP3A4 act ivity. Appropriate medical 
judgement is required. Please contact AstraZeneca with any queries y ou have on thi s issue.
Table8 CYP3A4 -Interacting Medication that are Prohibited During the Study
Medication Rationale
Boceprevir, cobicistat, danoprevir and ritonavir, elvitegravir and 
ritonavir, grapefruit juice, indinavir and ritonavir, itraconazole, 
ketoconazole, lopinavir and ritonavir, paritaprevir and ritonavir 
and (ombitasvir and/or dasabuvir), posaconazole, ritonavir, 
saquinavir and ritonavir, telaprevir, tipranavir and ritonavir, 
telithromycin, troleandomyc in, voriconazoleStrong CYP3A4 inhibitors which may 
increase AZD9977 concentrations.
Apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, 
rifampin, St. John’s wortStrong CYP3A4 inducers which may 
decrease AZD9977 concentrations.
Aprepitant, ci profloxacin, conivaptan, crizotinib, cyclosporine, 
diltiazem, dronedarone, erythromycin, fluconazole, fluvoxamine, 
imatinib, tofisopam, verapamilModerate CYP3A4 inhibitors which may 
increase AZD9977 concentrations.
Bosentan, efavirenz, etravirine, phenob arbital, primidone Moderate CYP3A4 inducers which may 
decrease AZD9977 concentrations.
H 1 Reference
FDA  guidance – Drug Development and Drug Interactions: T able of Substrates, Inhibitors and 
Inducers (content current as of 10 March 2020). Available at https: //www .fda.gov/drugs/drug -
interact ions-labeling/drug -development -and-drug-interacti ons-table -substrates -inhibitors -and-
inducers. Accessed on 9 June 2020.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 110of 138Appendix IClinical Study Medical Device / Device Cons tituent Report 
Form

Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 111of 138Appendix JAbbreviations
Abbreviation or special 
termExplanation
2D 2-dimensional
3D 3-dimensional
ABPM ambulatory blood pressure monitoring
ACCF American College of Cardiology Foundation
ACEI angiotensin -converting enzyme inhibitor
ACTH adrenocorticotropic hormone
ADMA asymmetric dimethylarginine
AE adverse event
AHA American Heart Association
ALP alkaline phosphatase
ALT alanine transaminase
ANA antinuclear antibody
ANCA anti-neutrophil cytoplasm antibody
ARB angiotensin II receptor blocker
ARNI angiotensin receptor -neprily sin inhibito r
AST aspartate transaminase
BP blood pressure
bpm beats per minute
BSA body surface area
BUN blood urea nitrogen
CFR Code of Federal Regulations
CIOMS Council for International Organizations of Medical Sciences
CKD chronic kidney disease
CKD -EPI chronic kidney disease epidemiology collaboration
CMV cytomegalovirus
CONSORT Consolidated Standards of Reporting Trials
COVID -19 coronavirus disease 2019
CRF Case Report Form
CRO Contract Research Organisation
CSP Clinical Study Protocol
CSR Clinical Study Report
CYP cytochrome P450
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 112of 138Abbreviation or special 
termExplanation
dECG digital electrocardiogram
DILI Drug -Induced Liver Injury
DKA diabetic ketoacidosis
DNA deoxyribonucleic acid 
EBV Epstein -Barr virus
EC Ethics Committee, synonymous to Institutional Review Board (IRB) and 
Independent Ethics Committee (IEC)
ECG electrocardiogram
eCRF electronic Case Report Form
EDC electronic data capture
EDV end diastolic volume
E/e’ ratio between early mitral inflow velocity and mitral annular early  diastolic 
velocity
eGFR estimated glomerular filtration rate
EMA European Medicines Agency
EOT end of treatment
ET early  termination
ERT eResearch Technology
ESRD end-stage renal disease
ESV end sy stolic volume
FAS Full Analy sis Set
FDA US Food and Drug Administration
FPG fasting plasma glucose
FSH follicle stimulating hormone
GCP Good Clinical Practice
GDF -15 growth differentiation factor -15
GFR glomerular filtration rate
GGT gamma glutamyl transferase
GLDH gamma -lacto ne dehydrogenase
GLP Good Laboratory Practice
GMP Good Manufacturing Practice
HbA1c glycated haemoglobin
HBc hepatitis B core
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 113of 138Abbreviation or special 
termExplanation
HCV hepatitis C virus
HEV hepatitis E virus
HSV herpes simplex virus
HCO 3-bicarbonate
HDL -C high density lipoprotein cholester ol
HDPE high-density polyethylene
HF heart failure
HFmrEF heart failure mid -range ejection fraction
HFpEF heart failure preserved ejection fraction
HFrEF heart failure reduced ejection fraction
HIPAA Health Insurance Portability and Accountability Act
HL Hy’s law
HR heart rate
HRQOL health -related quality of life
hsTnT high sensitivity troponin T
IATA International Airline Transportation Association
IC50 concentration required to inhibit 50% of the activity
ICAM intercellular adhesion molecule
ICF informed consent form
ICH International Council for Harmonisation
IEC Independent Ethics Committee
IgG immunoglobulin G
IgM immunoglobulin M
IMP Investigational Medicinal Product
INR internatio nal no rmalised ratio
IRB Institutio nal Review Board
IRT Interactive Response Technology
K+potassium
L-Arg l-arginine
LAVI left atrial volume index
LDH lactate dehydrogenase
LDL -C low density lipoprotein cholester ol
LV left ventricular
LVEF left ventricular ejection fraction
LV-GLS left ventricular global longitudinal strain
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 114of 138Abbreviation or special 
termExplanation
LVM left ventricle mass
MAD multiple ascending dose
Max maximum
MCHC mean corpuscular haemoglobin concentration
MCV mean corpuscular volume
MedDRA Medical Dictionary for Regulatory Activities
Min minimum
MIRACLE MIneRAlocorticoid reCeptor moduLator and sodium -glucosE cotransporter -2-
inhibito r in HF and CKD trial
MR mineralocorticoid receptor
MRA mineralocorticoid receptor antagonist
Na+sodium
NGAL neutrophil gelatinase -associated lipocalin
NIMP Non-Investigational Medicinal Product
NSAID non-steroidal anti -inflammatory drug
NT-proBNP N-terminal -pro-brain natriuretic peptide
NYHA New York Heart Association
OGTT oral glucose tolerance test
PAP pulmo nary artery  pressure
PHL potential Hy’s law
PI Principal Investigator 
PIIIP3 procollagen type III N -terminal propeptide
PK pharmacokinetic(s)
PPS Per Protocol Set
PRO patient -reported outcome
PT Preferred Term
Q1 first quartile
Q3 third quartile
QTcF QT interval corrected using Fridericia’s formula
RAAS renin-angiotensin -aldosterone system
RBC red blood cell
RNA ribonucleic acid
RT-PCR reverse transcriptase polymerase chain reaction
RTSM Randomisation and Trial Supply Management
SAE serious adverse event 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 115of 138Abbreviation or special 
termExplanation
SAP Statistical Analysis Plan
SARS -CoV -2 severe acute respiratory syndrome coronavirus 2
SCr serum creatinine
Scys standardi sed serum cystatin C
SD standard deviation
SDMA symmetric dimethylarginine
SGLT2 sodium -glucose co -transporter -2
SGLT2i sodium -glucose co -transporter -2 inhibitor
SoA Schedule of Activities
SOC System Organ Class
ST2 suppression of tumourigenicity 2 (biomarker)
SS Safety Set
SU sulfon ylurea
SUSAR suspected unexpected serious adverse reactions
T1DM type 1 diabetes mellitus
T2DM type 2 diabetes mellitus
TAPSE tricuspid annular plane systolic excursion
TBL total bilirubin
TR Vmax tricuspid regurgitation maximal velocity
UACR urinary  albumin to creatinine ratio
UGT uridine diphosphate glycosyltransferase
ULN upper limit of normal
VLDL -C very low density  lipoprotein cholester ol
WBC white blood cell
WHO World Health Organisation
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 116of 138Appendix KProtocol Amendment History
The Protocol Amendment Summary  of Changes T able for the current amendment , 
Amendment 6,is located di rectly before the T able of Contents.
Amendment 5 (20December 2021)
This amendment was considered to be substant ial based on the criteria set forth in 
Article10(a) of Direct ive2001/20/EC of the European Parlia ment and the Council o f the 
European Unio n.
Overall Rationale for  the Amendment
The previous Clinical Study  Protocol  (CSP) versi on, versi on5.0, dated 15 July 2021 has been 
updated to adjust the design to heart failure treatment guidelines ( ESC Gui delines 2021 ), by 
dropping the placebo and AZD9977 mo notherapy  arms to ensure all patients receive SGL T2i 
(dapagliflo zin) during the study , as we ll as to reduce the burden of study assessments on study  
patients. The updates are summarised below .
Section Number and 
NameDescription of Change Brief Rationale
Cover page
Section 1.1 Synopsis
Section 4 Study DesignRem oval of the LVEF criterion 
below 55%CSP title updated to not include any 
numbers for HF definition.
Cover page
Section 1.1 Synopsis
Section 1.2 Schema
Section 3 Objectives and 
Endpoints
Section 4.1 Overall 
Design
Section 4.2 Scientific 
Rationale for Study 
Design
Section 6.1.1 
Investigational ProductsChange of study design details
1) Treatment arms for AZD9977 
150mg and for placebo were 
removed.
2) Update of study duration 
3) Inclusio n of patients with or 
without SGLT2i treatmentTo reflect recent changes in heart failure 
guidelines (European Society of 
Cardiology, 2021) and rapid evolving 
uptake and change in clinical practice to 
treat patients with SGLT2i in the 
populatio n, adjustments have been made to 
the design by removal of the placebo 
treatment, thereby changing to acti ve-
controlled treatment. 
Section 1.1 Synopsis
Section 4.1 Overall 
DesignChange of targeted enrolment 
percentages of patients for the 
following cohorts
1. with eGFR ≥20 to 
< 30 mL/min/1.73 m2 and
2.eGFR ≥ 45 mL/min/1.73 m21. To avoid recruitment hurdles that are not 
of clinical relevance.
2. A mo re appropriate cap based on 
patients randomised so far.
Clinical St udy Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 117of 138Section Number and 
NameDescription of Change Brief Rationale
Section 1.1 Synopsis
Section 9.1 Statistical 
HypothesesUpdate of the primary hypothesis The primary hypothesis was adjusted
according to the new study design.
Section 1.1 Synopsis
Section 9.2 Sample Size 
DeterminationUpdate for sample size and 
drop-out rate, also for an interim 
analy sisThe sample size and the drop -out rate have 
been updated according to the new study 
design .
The expected effect size was reduced due 
to the fact that the new comparator is an 
active drug (dapagliflozin 10 mg).
Section 1.2 Schema Update of the figure concerning 
the study  designThe figure was updated according to the 
new study design.
Section 1.3 Schedule of 
ActivitiesTime windows for Visits 2 and 5 
to 10 were amended:
Visit 2: -10 to -3 days
Visit 5: ±2days
Visits 6, 7, 8, 9 and 10: ±3days
Visit 11: ±4daysTo allow for flexibility in scheduling for 
sites and subjects and adjustment to fit with 
number of tablets in one dapagliflozin 
bottle for the safety follow -up.
Section 1.3 Schedule of 
ActivitiesInclusion of central laboratory 
serum/plasma samples for K+, 
creatinine including eGFR 
calculation at Visit 2To have values from central l aboratory 
closer to randomisation Visit 3.
Section 1.3 Schedule of 
ActivitiesRem oval of PK sampling on 
Day 64Reduction of sampling procedures and 
blood volume to lessen burden on sites and 
subjects.
Section 1.3 Schedule of 
ActivitiesReduction of number of PD 
sampling visits (NT -proBNP, 
aldosterone, renin, ACTH, 
cortisol, copeptin, and FPG) from 
9 to 5 visits (visits 3, 5, 7, 10, 11)Reduction of sampling procedures and 
blood volume to lessen burden on sites and 
subjects.
Section 1.3 Schedule of 
ActivitiesInclusion of dapagliflozin 10 mg 
treatment after the EOT visitTo do safety follow -up under the same 
standard of care (dapagliflozin) as during 
run-in.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 118of 138Section Number and 
NameDescription of Change Brief Rationale
Section 1.3 Schedule of 
Activities
Section 3 Objectives and 
Endpoints
Section 4.2 Scientific 
Rationale for Study 
Design
Section 8.1.2.1 
Transthoracic 
Echocardiography -derived 
ParametersRem oval of transthoracic 
echocardiography; removal of the 
applicable exploratory objectiveLessen the operational study complexity in 
order to reduce burden on sit es and 
subjects. Extensive central echo protocol 
and needed to transfer data for central 
reading. In addition, local 
echocardiography is already being 
conducted at screening to confirm HF 
diagnosis.
Section 1.3 Schedule of 
Activities
Section 3 Objectives and 
Endpoints
Section4.2  Scientific 
Rationale for Study 
Design
Section 8.1.2.2 Patient 
Reported Outcomes
Appendix I Kansas City 
Cardiomyopathy 
Questionnaire
Appendix J Kidney 
Disease and Quality of 
Life
Appendix K Patient 
Global Impression of 
Severity  – Heart FailureRem oval of patient -reported 
outcomes questionnaires KCCQ, 
KDQOL -36, and PGIS -HFLessen the operational study complexity in 
order to reduce burden on sites and 
participants .
Section 1.3 Schedule of 
Activities
Section 3 Objectives and 
Endpoints
Section 8.1.2.3 
Bioimpedance 
SpectroscopyRem oval of bioimpedance 
spectroscopy; removal of weight 
measurements for bioimpedance at 
Visits 5 and 8, removal of 
applicable footnotes in Section 1.3
Schedule of ActivitiesLessen the operational study complexity in 
order to reduce burden on sites and 
subjects.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 119of 138Section Number and 
NameDescription of Change Brief Rationale
Section 1.3 Schedule of 
Activities
Section 3 Objectives and 
Endpoints
Section 8.1.2.4 Home 
based Monitoring of 
Activity
Section 9.3 Populations 
for AnalysesRem oval of home -based 
monitoring of activityLessen the operational study complexity in 
order to reduce burden on sites and 
subjects.
Section 1.3 Schedule of 
Activities
Section 3 Objectives and 
Endpoints
Section 8.1.2.5 
Ambulatory Blood 
Pressure MonitoringRem oval of ambulatory blood 
pressure monitoring in selected 
countriesLessen the opera tional study complexity in 
order to reduce burden on sites and 
subjects.
Section 1.3 Schedule of 
Activities
Section 3 Objectives and 
Endpoints
Section 8.6.1 Collection 
of Mandatory Samples for 
Biomarker AnalysisRem oval of collection of serum, 
plasma, and urine samples for 
exploratory biomarkers related to 
AZD9977 and dapagliflozin or 
related cardiorenal diseasesCorrection of an error.
Section 1.3 Schedule of 
Activities
Section 5.1 Inclusion 
CriteriaInclusion of an informed consent 
for optio nal pre -screeningAn optional pre -screening visit is 
introduced to reduce screen failures related 
to UACR and all patients who undergo the 
additional visit needs to sign a separate 
informed consent.
Section 1.3 Schedule of 
Activities
Section 8.6.1 Collection 
of Mandatory Samples for 
Biomarker AnalysisAlignment with number of visits 
for PD markers (Visit 3 [Day 1], 
Visit 7 [Day 22], Visit 10 [Day 
85], Visit 11 [Day 113])Reduction of sampling procedures and 
blood volume to lessen burden on sites and 
subjects.
Section 1.3 Schedule of 
Activities
Section 8.6.2 Collection 
of Optional Biomarker 
SamplesRem oval of blood samples for 
RNA expression analysis and 
information regarding unused 
samples of serum, plasma, and 
urine.
Addition of information regarding 
collection of serum, plasma, and 
urine samples for future useReduction of sampling procedures and 
blood volume to lessen burden on sites and 
subjects.
Descriptio n of exploratory biomarker 
research moved to the correct section.  
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 120of 138Section Number and 
NameDescription of Change Brief Rationale
Section 2.2.1.4 Sodium -
glucose Co-transporter 2 
Inhibitors in Heart Failure 
and Chronic Kidney 
DiseaseInclusion of an additional 
literature referenceTo provide the correct literature reference 
to a statement in this section.
Section 2.2 Background Inclusion of additional literature 
referencesTo add mo re background to the study.
Section 2.3.1 Risk 
AssessmentInclusion of data from completed 
combinatio n toxicology studyTo reflect new data in the drug 
development program.
Section 4.1 Overall 
DesignAddition of an optional 
pre-screeni ng including timelinesIn some clinics UACR is not part of 
clinical practice, introducing an optional 
pre-screening visit for UACR within the 
protocol will facilitate identifying eligible 
patients. 
Section 4.1 Overall 
Design
Section 9.2 Sample Size 
DeterminationUpdate of numbers of participants Based on new statistical calculations for 
the 4 -arm study .
Section 4.3 Justification 
for DoseInclusion of further information 
from studies with dapagliflozinUpdated to reflect recent regulatory 
approvals of dapagliflozin 10 mg for the 
treatment of CKD, which is of relevance to 
the patient population being studied.
Section 5.1 Inclusion 
CriteriaChange of the LVEF criterion 
below 55% to below 60%To broaden patient population by allowing 
additional patient s who fall into the HFpEF 
category to enrol into the study in order to 
increase recruitment.
Section 5.1 Inclusion 
CriteriaReduction of NT -proBNP 
threshold from 600pg/mL to 
300pg/mL for sinus rhythm 
patients and from 900 pg/mL to 
600pg/mL for atrial 
fibrillatio n/flutter patients To broaden the eligible HF population, 
taking into account this is an exploratory 
phase study.
Section 5.1 Inc lusion 
CriteriaRem oval of UACR values from 
the criterion for eGFRTo have UACR and eGFR as separate 
inclusion criteria.
Section 5.1 Inclusion 
CriteriaUpdate of the criterion for UACR 
at Visit 2To have UACR from Visit 2 performed at 
the central laborato ry to confirm eligibility 
for randomisation.
Section 5.1 Inclusion 
CriteriaInclusion of a separate paragraph 
regarding randomisation with all 
applicable criteria for Visit 3To explain what is required to be eligible 
for randomisation.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 121of 138Section Number and 
NameDescription of Change Brief Rationale
Section 5.1 Inclu sion 
Criteria
Section 6.5.2 Background 
MedicationsInclusion of a separate paragraph 
regarding the run -in period with 
all applicable criteria for Visit 2To explain the addition of open label 
dapagliflozin to all patients during run -in.
Section 5.1 Inclusion 
Criteria
Section 8.2.4 Clinical 
Safety Laboratory 
AssessmentsAddition of UACR measurement 
at screening including value 
ranges for participants who are 
either on SGLT2i or not on 
SGLT2iThe lower UACR limit at screening will be 
higher for patient s naïve to SGLT2i
treatment since UACR is expected to 
decrease during run -in in these patients and 
the UACR limits for eligibility to be 
randomised are the same for all patients. 
Section 5.2 Exclusion 
Criteria
Section 6.5.1 Prohibited 
MedicationsRem oval of SGLT2i from 
prohibited prior/ concomitant 
therapyIncreasingly  difficult to recruit SGLT2i 
naïve patients due to change in HF 
guidelines and rapid inclusion of SGLT2i’s 
in SoC for HF treatment.
Section 6.1.2 Medical 
DevicesRem oval of ABPM device, 
bioimpedance spectroscopy 
device, activity tracker, and sleep 
analy serSimplification for sites and participants.
Section 6.3 Measures to 
Minimise Bias: 
Randomisation and 
Blinding
Section 8.5.1.1 
Determination of Drug 
ConcentrationReplacement of Covance with 
Labcorp Drug Development for 
PK samplesLegal entity change.
Section 6.5.2 Background 
MedicationsAdditional information regarding 
the start for treatment with 
dapagliflozin 10 mg for 
participants being on treatment 
with SGLT2i or notAccording to new study design.
Section 6.7 Intervention 
After the End of the StudyClarification on the use of 
dapagliflozin during the safety 
follow -up period after the blinded 
randomised treatment period in 
the studyAll patients will be on open label 
dapagliflozin during run -in up to 
randomisation and after the blinded study 
treatment period during the safety 
follow -up.
Section 7.1 
Discontinuation of Study 
InterventionUpdated text on DKA events To be aligned with other AstraZeneca 
study protocols involving dapagliflozin.
Section 8 Study 
Assessments and 
ProceduresThe maximum amount of blood 
collected from each participant 
over the duration of the study, was 
re-calculated and updated from 
500mL to 400 mL.To reflect simplification of blood sampling 
and redu ced burden to patients. 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 122of 138Section Number and 
NameDescription of Change Brief Rationale
Section 8.1.1 
Primary /Secondary  
Variable: 
Urinary  Albumin to 
Creatinine Ratio (UACR)Inclusion of details regarding 
procedures For clarification on procedures. 
Section 8.2.4 Clinical 
Safety Laboratory 
AssessmentsAddition of f ormulas for the 
calculation of eGFRTo provide clarification on the calculation.
Section 9.3 Populations 
for Analyses
Section 9.4.5.1 Adverse 
EventsReplacement of Safety Analysis 
Set (SA F) by Safety  Set (SS)SS is the new AZ standard.
Section  9.4.2.1 Primary 
EndpointRem oval of AZD9977 alone and 
introduction of dapagliflozin 
10mg as active comparatorThe primary endpoint was updated 
according to the comparison with the active 
comparator.
Section 9.4.2.2 Secondary 
EndpointRem oval of AZD9977 150 mg 
aloneThe dose response relationship was 
modified due to the drop of the placebo and 
AZD9977 alone arm.
Section 9.4.2.3 
Explo ratory  EndpointsRem oval of exploratory endpoints The exploratory endpoints have been 
updated according to the removed related 
exploratory variables.
Section 9.4.4 
Pharmacodynamics and 
BiomarkersRem oval of MR -related gene 
transcriptionReduction of sampling procedures and 
blood volume to lessen burden on sites and 
subjects.
Section 9.5 Interim 
Analy ses
Section 9.6 Data 
Monitori ng CommitteeChange in size of interim analysis 
study populationChange in size of interim analysis 
populatio n due to the updated sample size 
of the new study design.
Section 11 
REFERENCESAddition of literature references To support the updated study des ign.
Amendment 4 (15 July 2021)
This amendment is considered to be substant ial based on the cri teria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n.
Overall Rationale for the Amendment
The previous CSP versio n, versio n 4.0, dated 19 March 2021 was updated to implement 
patient-centric measures and improve recruit ment. The updates are summari sed below .
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 123of 138Section Number and Name Description of Change Brief Rationale
Cover page Provided the f ull form of the study 
acrony m, MIRACLE.For clarity.
Section 1.1Synopsis
Section 4.1Overall DesignThe study  will now be conducted at 
approximately 210 sites in 
approximately 20 countries as a change 
from the previously planned 170 sites 
in approximately 18 countries.To increase potential 
participant pool.
Section 1.2Schema
Section 1.3Schedule of Activities
Section 5.1Inclusion Criteria
Section 5.2Exclusion CriteriaTime window between Visits 2 and 3 
was widened from −5 to −1 days to −7 
to −1 day s. Consequently, text in some 
of the inclusion and exclusion criteria 
was updated to align with this change 
in the time window.To relieve operational burden 
without compromising 
participant safety or study data 
quality .
Section 5.1Inclusion Criteria
Section 5.2Exclusion CriteriaMoved selection criteria regarding use 
of prior and conc omitant medications 
from the section on Inclusion criteria to 
the section on Exclusion criteria. Corrected because the content 
is appropriate under exclusion 
criteria rather than inclusion 
criteria.  
Section 5.1Inclusion Criteria Clarification that 50% of adjustment of 
loop diuretics is allowedToclarify and improve 
recruitment without 
compromising participant 
safety or study data quality.
Section 5.1Inclusion Criteria Change in inclusion criterion of lower 
limit of systolic BP from ≥100mmHg 
to ≥ 90 mmHg.To improve recruitment 
without compromising 
participant safety or study data 
quality .
Section 5.1Inclusion Criteria The cr iterio n NT-proBNP ≥ 900 pg/mL 
applies to patients with atrial 
fibrillatio n/flutter either at screening 
“or in medical history”.Clarification that medical 
history  is included in this 
criterion.
Section 5.1Inclusion Criteria
Section 6.5.1 Prohibited 
MedicationsThe time period during which prior 
treatment with an MRA or SGLT2i is 
not allowe d was updated from “for 
> 90 days to 12 months prior to 
screening” to be “within 90 days prio r 
to screening”.To improve recruitment 
without compromising 
participant safety or study data 
quality .
Section 5.2Exclusion Criteria The exclusion criterion of prolonged 
QT interval (QTcF > 470ms) o n ECG 
atscreening (Visit 1) was removed.To improve recruitment 
without compromising 
participant safety or study data 
quality .
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapaglif lozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 124of 138Section Number and Name Description of Change Brief Rationale
Section 5.4Screen Failures Clarification that individuals who do 
not meet the inclusion/exclusion 
criteria regarding eGFR and K+levels 
may have these blood tests redone once 
after Visit 1 and/or Visit 2 upon 
investigator's discretion.Clarification for transparency. 
Section 1.3Schedule of Activities
Section 6.1.2 Medical Devices
Section 8.1.2 Exploratory 
Variables
Section 9.4.2.3 Exploratory 
Endpoints
Appendix A 4Data ProtectionCancellation of plans to use Eko DUO 
device (stethoscope and integrated 
single -lead electrocardiogram [ECG]). 
Consequently, related text on these 
electrocardiograms and 
phonocardiograms in various sections 
was updated.Operational issues in
providing the device to all 
sites. 
Section 6.1.2 Medical Devices Clarification that wearable devices of 
activity  tracker and sleep analyser 
should be optional and based on the 
participants’ consent.Participant -centric approach.
Section 1.1Synopsis
Section 4.1Overall Design
Section 8.1.2.4 Home- based 
Monitoring of Activity
Section 9.3Populations for 
Analy sesThe requirement of selecting 
approximately 200 participants for 
home -based monitoring of activity was 
remo ved.As use of wearable devices is 
no lo nger mandato ry for the 
participants, the final sample 
size for this subgroup is 
uncertain.
Section 6.5Concomitant Therapy
Appendix G 2Risk Assessment 
for COVID -19 PandemicAdded that COVID -19 vaccination is 
not likely  to impact the study 
treatments and that the study treatments 
are not likely to impact COVID -19 
vaccination. Participants may be 
enrolled and or continue in the study 
regardless of their choice to be 
vaccinated or not.Participant -centric approach 
and transpare ncy.
Section 6.5.1 Prohibited 
MedicationsClarification that dietary K+
supplements or alternatives that are 
prohibited at screening/randomisation 
can be started during the study as a 
corrective action if hypokalaemia is 
confirmed.Participant -centric approach 
and transparency.
Section 1.3Schedule of Activities
Section 8.1.1 Primary /Secondary  
Variable: 
Urinary  Albumin to Creatinine 
Ratio (UACR)Clarification that the first morning void 
urine sample should be a full sample 
and not a spot sample.To ensure that adequate 
sample is available for the 
various analyses.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 125of 138Section Number and Name Description of Change Brief Rationale
Section 8.1.2.2 Patient -Reported 
OutcomesClarified that 2 questions from the 
Kansas City Cardiomyopathy 
Questionnaire will not be applicable in 
this study.For clarity.
Section 1.3Schedule of Activities
Section 8.1.2.3 Bioimpedance 
SpectroscopyAddition of body weight measurement 
at visits that include bioimpedance 
spectr oscopy. The bioimpedance 
spectroscopy device used in 
this study does not measure 
body weight (required for the 
analy sis).
Section 8.1.2.5 Ambulatory Blood 
Pressure MonitoringParticipants will be allowed to visit the 
study site in case required for adjusting 
or fitting the ABPM device. Participant -centric approach.
Section 1.3Schedule of Activities
Section 8.2.4 Clinical Safety 
Laborato ry Assessments
Appendix F 1Data on levels of electrolytes 
(potassium and sodium) and creatinine 
provided by local laboratories may be 
based on plasma or serum samples.To adapt the study design to 
local laboratory capabilities 
without compromising data 
quality . Data o n serum levels 
of electrolytes (potassium and 
sodium) and creatinine will be 
provided b y the central 
laborato ry.
Section 8.2.4 Clinical Safety 
Laborato ry AssessmentsThe post -randomisation INR 
measurements may be done at a local 
laborato ry if the necessary  mate rial 
provided by the central laboratory is 
not available; and the measurements 
may be omitted if the local laboratory 
is not ca pable of doing the 
measurements.To adapt the study design to 
the central and local 
laborato ry capabilities.
Section 8.2.4 Clinical Safety 
Laborato ry AssessmentsClarification that microscopic 
examination of urine sample sediments 
will be performed depending on the 
local laboratory’s capability.To ad apt the study design to 
local laboratory capabilities 
without compromising data 
quality .
Section 1.3Schedule of Activities
Section 8.2.4 Clinical Safety 
Labor atory AssessmentsCollection of a plasma sample for K+
measurement at the central laboratory.Clarification that a separate 
plasma sample should be 
collected for the purpose of 
exploratory p harmacodynamic 
analy sis.
Section 8.5.1 Pharmacokinetics Clarification that samples collected for 
PK assessments may be used, if 
necessary, for safety or efficacy 
assessments only during the study and 
not after the study.Correction of an error.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 126of 138Section Number and Name Description of Change Brief Rationale
Section 8.6.2 Collection of 
Optional Biomarker SamplesAdded text to clarify that unused 
samples of serum, plasma, and urine 
samples may be stored and used for 
future exploratory analyses if 
participant consents.To clarify exploratory 
biomarker sample collection 
and use.
Section 8Study Assessments and 
ProceduresThe maximum amount of blood 
collected from each participant over the 
duration of the study, was re -calculated 
and updated from 400 mL to 500 mL.For transparency.
Section 1.1Synopsis
Section 4.1Overall DesignAddition of a table to present the study 
treatment groups.To improve clarity and 
readability.
Section 1.2Schema
Section 1.3Schedule of Activities
Section 3Objectives and 
EndpointsAddition of a note that Visits at Week 7 
and Week 13 (Visits 8 and 10) 
correspond to visits after completion of 
6weeks and 12 weeks of study 
treatment, respectively.To provide a clarification and 
align with the explanation 
provided in the Statistical 
Analy sis Plan.
Section 1.2Schema
Section 3Objectives and 
EndpointsLanguage updated to clarify that at 
“12weeks” and other similar usage 
indicates “at the end of 12 weeks” ie, in 
Week 13. For clarity.
Section 1.1Synopsis
Section 4.1Overall DesignChange in stratification based on eGFR 
in (mL/min/1.73 m2) from: ≥30 to 
≤45; or >45 to: ≥ 30 to <45; or ≥45.Correction of an error.
Section 1.1Synopsis
Section 4.1Overall Design
Appendix F 2Updated language describing eGFR -
based participant stratificationFor clarity
Throughout the document, 
wherever app licable.Units of eGFR were corrected to 
mL/min/1.73 m2consistently 
throughout the document.Correction of an error.
Section 5.1Inclusion Criteria
Section 8.2.4 Clinical Safety 
Laborato ry AssessmentsPregnancy test and lactation status that 
were ment ioned for menopausal 
women were deleted. Correction of an error.
Section 8.2.4 Clinical Safety 
Laborato ry Asse ssmentsThe CKD -EPI formula was mentioned 
as “non -BSA adjusted”, w hich was 
corrected to “BSA -adjusted”. Correction to align with the 
standard CKD -EPI formula.
Throughout the document, 
wherever applicable.Minor language changes. To improve readability.
Amendment 3 (19 March 2021)
This amendment is considered to be non- substantial based on the criteria set forth in Article 
10(a) of Direct ive 2001/20/EC of the European Parliament and the C ouncil o f the European 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 127of 138Unio n because it neither significant ly impacts the safet y or phy sical/mental  integrity of 
participants nor the scient ific value o f the study .
Overall Rationale for the Amendment
Revised CSP , Final 3.0, dated 26 January 2021 was updated to 19 March 2021.
Section Number and Name Description of Change Brief Rationale
Protocol Amendment 
Summary of ChangesCorrection of rationale for 
change relating to Eko DUO 
deviceEko DUO device is site -based not 
home -based
Correction of typo in
description of change for 
exclusion criterion 6 for 
HBA1c (<10% corrected to 
>10%)Correction of typo
Section 2.3.1 Risk 
AssessmentMitigation strategy for 
patients with uncontrolled 
diabetes mellitus corrected in 
line with change to inclusion 
criterion 6 made at Protocol 
Amendment 2 (HbA1c 
changed from >12% to >10%)Alignment with change to definition of 
uncontrolled diabetes mellitus made in 
previous amendment
Section 6.3 Measures to 
Minimise Bias: 
Randomisation and BlindingClarified that unused retur ned 
study intervention must not be 
re-dispensed to the 
participantsIn response to Regulatory Authority in 
Slovakia request
Section 8.1.2.6 Digital 
Cardiac Auscultation and 
ElectrocardiogramClarified that the Eko DUO 
device will be used in clinic 
not at homeEko DUO device is site -based not 
home -based
Section 8.3.5 Going forward, any new or 
aggravated clinically relevant 
abnormal medical finding will 
be reported as an AE 
regardless of relationship to 
the disease under study.Condition that medical findin gs 
unequivocally related to disease under study 
did not need to be reported as an AE was 
removed in response to Regulatory Authority 
in Germany request|
Section 8.3.8.1 Maternal 
ExposureCorrection to align with 
mandated template textAligned with template
Section 9.4.2.3 Exploratory 
EndpointsRespiratory  rate was removed 
from the exploratory endpoint, 
Change f rom baseline in 
activity , heart rate, respiratory 
rate, body fluid retention, and 
sleep patterns over timeRespiratory  rate was included in error; it is 
not collected in the study as per Schedule of 
Activities.
Clinical Study Protocol -7.0 AstraZeneca
AZD9 977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 128of 138In addit ion, the fo llowing administrative changes were made:
Tables of Contents updated.
Minor edi torial changes.
Amendment 2 (26 January 2021)
This amendment is considered to be sub stant ial based on the cri teria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n.
Overall Rationale for the Amendment
Revised CSP , Final 2.0, dated 06 October 2020 was updated to 26January 2021.
Section Number and Name Description of Change Brief Rationale
Section 1.1 Synopsis
Section 4.1 Overall Design
Section 8.1.2.4 Home -based 
Monitoring of ActivityAdded text to describe 
secondary randomisation for 
Home -based Monitoring of 
Activity  subgroupTo clarify randomisation of subgroups
Section 1.1 Synopsis
Section 9.4.2.1 Primary 
EndpointAdded text to analysis model 
on stratifying factors as 
covariatesTo clarify the analysis model
Section 1.1 Synopsis
Section 4.1 Overall Design, 
Section 9.4.2.1 Primary 
EndpointLower limit of eGFR was 
changed from “<30 mL/min” 
to “≥20 to <30 mL/min”To clarify that the lower limit of eGFR is 
20mL/min in this study
Section 1.3 Schedule of 
Assessments
Section 5.1 Inclusion 
Criteria
Section 8.2.4 C linical Safety 
Laborato ry Assessments 
(including Table 5)Added text on FSH testing and 
adjusted table layout; text on 
LH was removedTo clarify tests regarding female 
reproductive status
Section 1.3 Schedule of 
Assessments; Section 8.1.2.3Added text to exclude 
participants with pacemakers 
or other implanted devices 
from the bioimpedance 
assessmentThe use of bioimpedance devices is 
contraindicated for patients with pacemakers 
or other electronic implanted devices
Section 1.3 Schedule of 
AssessmentsAdde d text on hypertension 
medication; cross -references 
addedTo clarify that hypertension treatment can be 
adjusted if needed at the screening visit
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 129of 138Section Number and Name Description of Change Brief Rationale
Section 1.3 Schedule of 
Assessments
Section 3 Objectives and 
Endpoints
Section 6.1.2 Medical 
Devices
Section 8.1.2.6 Digital 
Cardiac Auscultation and 
Electrocardiogram
Section 8.3.10 Medical 
Device Deficiencies
Section 9.4.2.3 Exploratory 
Endpoints
Appendix A4 Data 
Protection
Appendix A7 Data Quality 
AssuranceAdded text on the Eko DUO 
device and dECG device; new
sections added 
(Section 8.1.2.6 and 
Section 8.3.10), other 
applicable sections updated, 
SoA revised accordingly, 
cross -references added as 
appropriateTo describe addition of new device to the 
protocol for site -based ECG monitoring
Section 2.2 Background
Section 2.2.1.4 
Sodium -glucose Co -
transporter 2 Inhibitors in 
Heart Failure and Chronic 
Kidney  Disease
Section 2.3 Benefit/Risk 
Assessment (Table 2)
Section 2.3.2 Benefit 
Assessment
Section 11 ReferencesUpdated introductory text 
according to revised 
Investigator’s Brochure of 
dapagliflozin; redundant 
reference was deletedTo include findings from recent clinical trials 
with dapagliflozin that suggest it has an 
additive treatment effect when given 
concomitantly with MRAs (DAPA -HF trial) 
and to further desc ribe the dapagliflozin risk 
and benefit in patients with chronic kidney 
disease (DAPA -CKD trial)
Section 3 Objectives and 
Endpoints
Section 9.4.2.3 Exploratory 
EndpointsCorrected typo in alignment 
with Schedule of AssessmentsTo clarify that the KCCQ mus t be completed 
at 6 and 12 weeks, not at 8 and 12 weeks
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 130of 138Section Number and Name Description of Change Brief Rationale
Section 5.1 Inclusion 
CriteriaAdded “flutter” to criterion 5; 
added timepoints to 
criterion 6; revised the 
timepoint wording at 
criterion 11; corrected the 
cross -reference at criterion 12; 
added age -specific 
requirements to criterion 16 
and revised text according; 
systolic BP inclusion 
criterion 9 clarified and 
diastolic BP inclusion 
criterion 10 removedTo clarify eligibility criteria
Section 5.2 Exclusion 
CriteriaRevised the timepoint wording 
in criteria 11and18; 
definition of uncontrolled 
diabetes mellit us changed 
from HBA1c >12% to >10% 
in criterion 6; any  major 
cardiovascular surgery 
planned or within 3 months 
added as new criterion 12; 
COVID -19 criterion 25 (c) 
clarifiedTo clarify eligibili ty criteria
Section 6.5.1 Prohibited 
MedicationsRevised list and added text in 
alignment with Section 5.1 
Inclusion CriteriaTo clarify medication restrictions
Section 6.7 Intervention 
After the End of the StudyEdited text To clarify when patients shou ld return to 
their usual treatments
Section 7.2 Participant 
Withdrawal from the StudyAdded text on ET and safety 
follow -up visitsTo clarify procedures upon participant 
withdrawal
Section 8 Study 
Assessments and ProceduresAdded text on procedures 
performed at another facilityTo clarify time frames for procedures 
performed at another facility than the study 
site
Section 8.1.2.4 Home -based 
Monitoring of Activity
Section 8.1.2.5 Ambulatory 
Blood Pressure Monitoring
Section 8.1.2.6 Digital 
Cardiac Au scultation and 
ElectrocardiogramAdded text on outcomes of the 
monitoring proceduresTo clarify availability of results and handling 
of health -related issues
Section 8.4 Overdose Added text on dose limit in 
terms of number of capsulesTo clarify overdose definition whilst 
maintaining the study blinding
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 131of 138Section Number and Name Description of Change Brief Rationale
Section 8.3.10 Medical 
Device Deficiencies
Appendix LNew section added and 
Clinical Study Medical Device 
/ Device Constituent Report 
Form included as an appendixRequired for studies in which a medical 
device is provided for use in the study
Section 9.3 Populations for 
Analy ses
Section 9.4.2 EfficacyAdded text in alignment with 
the SAPTo further describe statistical considerations 
of the study
In addit ion, the fo llowing administrative changes were m ade:
A duplicate scanned page was remo ved fro m Appendix J (Kidney Disease and Qualit y of 
Life).
Protocol  amendment history  for previ ous amendment was m oved to a new Appendix 
(Appendix N).
Tables of Contents and the List of Abbreviat ions were updated.
Minor editorial changes were m ade throughout.
Amendment 1 (06 October 2020)
This amendment is considered to be substant ial based on the cri teria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n.
Overall rationale for the Amendment
The ori ginal  CSP , Final 1.0, dated 25 August 2020, was updated to include modificat ions to 
the number of sites and countries and updates to laboratory  parameters for clarit y. Minor 
editorial updates were m ade thro ughout.
Section Number and Name Description of Change Brief Rationale
Section 1.1 Synopsis
Section 4.1 Overall DesignUpdate of number of sites and 
countriesTo increase potential participant pool
Section 4.1 Overall Design Update of eGFR strata for 
randomisationTo fix inconsistencies between protocol 
summary and Section 4.1
Section 8.1.1 
Primary /Secondary  Variable 
Urinary  Albumin to 
Creatinine Ratio (UACR)Correction of typo in Urinary 
Albumin to Creatinine Ratio 
unitTo fix a typo
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 132of 138Section Number and Name Description of Change Brief Rationale
Section 8.2.4 C linical Safety 
Laborato ry AssessmentsUpdate of local laboratory 
requirements to make 
Glutamate dehydrogenase, 
RBC distribution width, and 
Bicarbonate at screening 
dependent on local capabilitiesTo account for the fact that some countries 
are not able to perform these tests locally
Section 9.2 Sample Size 
DeterminationAddition of alpha value To align with FDA comments
Section 9.3 Populations for 
Analy sesClarification of the Full 
Analy sis Set including 
participants who both receive 
and do not receive study 
interventio nTo align with FDA comments
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 133of 13811 REFERENCES
Abbas et al 2015
Abbas S, Ihl e P,Harder S, Schubert, I. Risk of hyperkalemia and combined use of 
spironol actone and l ong-term ACE inhibitor/angiotensin receptor blocker therapy  in heart 
failure u sing real -life data: a populat ion-and insurance -based cohort. Pharmacoepidemio l 
Drug Saf .2015;24:406 –13.
Ambrosy et al 2014
Ambrosy  AP, Gheorghiade M, Chio ncel O, Mentz R J, Butler J. Global perspect ives in 
hospi talized heart failure: regional and ethnic variati on in pat ient characteristics, management 
and outcom es. Curr Heart Fail Rep. 2014;11(4):416 -27.
Ather et al 2012
Ather S, Chan W , Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, et al. Impact of 
noncardiac co morbidities on m orbidity and mortality  in a predominant ly male populat ion with 
heart failure and preserved versus reduced eject ion fract ion. J Am Co ll Cardi ol. 2012 Mar 
13;59(11):998 -1005. 
Bakris et al 2015
Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort R T, Haller H, et al. Effect of 
Finerenone on Albuminuria in Patients W ith Diabeti c Nephropathy : A Rando mized Clinical 
Trial. JAMA. 2015;314(9):884 –894.
Bakris et al 2020
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P , et al . Effect of Finerenone 
on Chronic Kidney Disease Outcom es in Type 2 Diabetes. N Engl J Med. 2020 
Dec3;383(23):2219 -2229.
Bamberg et al 2018
Bamberg K, Johansson U, Edman K, W illiam -Olsson L, Myhre S, Gunnarsson A, et al. 
Preclinical pharmaco logy of AZD9977: A  novel mineralocorti coid receptor m odulator 
separating organ protection fro m effects on el ectroly te excreti on. PLoS One. 
2018;13(2):e0193380.
Braunwald 2015
Braunwald E. The war against heart failure: the Lancet lecture. Lancet .2015; 385:812 -24.
Capelli et al 2020
Capelli, I, Gasperoni, L, Ruggeri, M, Donati  G, Baral di O, Sorrenti  G, et al . New 
mineralocortico id receptor antagonists: update on their use in chronic kidney disease and heart 
failure. J Nephrol .2020;33:37 -48. 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 134of 138Cook et al 2014
Cook C, Col e G, Asaria P , Jabbour R, Francis DP . The annual global economic burden of heart 
failure. Int J Cardio l.2014; 171:368 -76.
Cooper et al 2017
Cooper LB, Lippmann SJ, Greiner MA, Sharma A, Kelly JP , Fonarow GC, et al. Use of 
Mineralocortico id Receptor Antagoni sts in Pati ents W ith Heart Failure and Co morbid
Diabetes Mellitus or Chronic Kidney Disease. J Am Heart Assoc. 2017;6(12):e006540.
ESC Guidelines 2021
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur 
Heart J .2021; 42(36) :3599 -3726 doi:10.1093/eurheartj/ehab36 8
Ferrannini et al 2016
Ferrannini E, Mark M, May oux E. CV Protection in the EMP A-REG OUTCOME Trial: A  
"Thrift y Substrate" Hy pothesis. Diabetes Care .2016; 39(7):1108 -14.
Fitchett et al 2016
Fitchett D, Zinman B, W anner C, Lachin JM, Hantel S, Salsali A, e t al. Heart failure outcom es 
with empaglifl ozin in pat ients with type 2 di abetes at hi gh cardi ovascular ri sk: results of the 
EMP A-REG OUTCOME® tri al. Eur Heart J .2016 14;37(19):1526 -34.
Green et al 2000
Green CP , Porter CB, Bresnahan DR, Spertus, JA. Deve lopment and Evaluat ion of the Kansas 
City Cardi omyopathy  Questi onnai re: A  New Heal th Status Measure for Heart Failure. JACC. 
2000;35(5):1245 -55.
Hays et al 1994
Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB. Development of the kidney disease 
qualit y of life (KDQOL)instrument. Qual Life Res .1994, Oct;3(5):329 -38.
Heerspink et al 2020
Heerspink HJL, Stefánsson BV , Correa -Rotter R, Chertow GM, Greene T , Hou FF , et al. 
Dapagliflozin in pat ients with chronic kidney  disease. N Engl  J Med .2020; 383: 1436 –46.
Inker et al 2012
Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T et al. Estimat ing 
glomerular filtrat ion rate from serum creat inine and cy statin C. N Engl J Med .2012; 367: 
20-9.
Jongs et al 2021
Jongs N, Greene T , Chertow GM, McMurray  JJV, Langkilde AM, Correa -Rotter R, et al. 
Effect of dapagliflozin on urinary  albumin excret ion in pat ients with chronic kidney  disease 
with and wi thout ty pe 2 di abetes: a prespecified analysis from the DAP A-CKD tri al. Lancet 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 135of 138diabetes Endocrinol .2021; 9(11):755 -66.
Kasichayanula et al 2012
Kasichayanula S, Chang M, Liu X, Shyu WC, Griffen SC, LaCreta FP , et al . Lack of 
pharmacokinet ic interacti ons between dapagliflozin and simvastatin, valsartan, warfarin, or 
digoxin. Adv Ther . 2012;29(2):163 -77.
Kato et al 2015
Kato S, Maruy ama S, Makino H, W ada J, Ogawa D, Uzu T , et al. Anti‐albuminuric effects of 
spironol actone in pati ents wi th type 2 di abetic nephropathy : a m ulticenter, randomized clinical 
trial. Clin Exp Nephrol . 2015;19:1098‐106.
Levey et al 2009
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI et al. et al. A  new 
equati on to estimate gl omerular filtrat ion rate. Ann Intern Med .2009;150(9):604 -12.
Matsumoto et al 2006
Matsum oto S, T akebayashi K, Aso Y . The effect of spirono lactone on circulat ing 
adipocy tokines in pat ients with type 2 di abetes m ellitus com plicated by  diabet ic nephropathy . 
Metabo lism. 2006;55(12):1645 -52.
McMurray et al 2019
McMurray  JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez F A, et al. 
Dapa gliflozin in Pat ients with Heart Failure and Reduced Eject ion Fract ion. N Engl J Med. 
2019;381(21):1995 -2008.
Nassif et al 2019
Nassif ME, W indsor SL, T ang F , Khari ton Y, Husain M, Inzucchi SE, et al. Dapagliflozin 
effects on bio markers, symptoms, and func tional status in patients with heart failure with 
reduced ej ection fraction. The DEFINE -HF Trial. Circulat ion.2019;140:1463 -76.
Neal et al 2017
Neal B, Perkovi c V, Matthews DR, Mahaffey KW , Fulcher G, Meininger G, et al. Rationale, 
design and baseline cha racteri stics of the CANagliflozin cardio Vascular Assessment Study -
Renal (CANV AS-R): A randomized, pl acebo -controlled trial. Diabetes Obes Metab. 
2017;19(3):387 –93.
Nielsen et al 2012
Nielsen SE, Persson F , Frandsen E, Sugay a T, Hess G, Zdunek D et al. Spironolactone 
diminishes urinary  albumin excreti on in pat ients wit h type 1 di abetes and microalbuminuria: a 
rando mized placebo -controlled crossover study . Diabet Med .2012;29(8):e184 -90.
Petrie et al 2020 
Petri e MC, V erma S, Docherty  KF, Inzucchi SE, Anand I , Bel ohlávek J, et al . Effect of 
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 136of 138Dapagliflozin on W orsening Heart Failure and Cardiovascular Death in Patients W ith Heart 
Failure W ith and W ithout Di abetes. JAMA. 2020;323(14):1353 -68.
Pitt et al 1999
Pitt B, Zannad F , Remme WJ, Cody  R, Castai gne A, Perez A, et al . The Effect of 
Spironol actone on Morbi dity and Mortali ty in Pat ients with Severe Heart Failure N Engl J 
Med.1999;341:709 -17.
Pitt et al 2015
Pitt B, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, et al. Rationale and Design of 
MinerAlocortico id Receptor antagonist T olerabili ty Study -Heart Failure (AR TS-HF): A 
Randomized Study  of Finerenone vs. Epl erenone in Patients Who Have W orsening Chronic 
Heart Failure W ith Diabetes and/or Chroni c Kidne y Disease. Eur J Heart Fail. 
2015;17(2):224 -32.
Pitt et al 2021
Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P , Joseph A. Cardi ovascular 
Events wi th Finerenone in Kidney  Disease and T ype 2 Diabetes . N Engl  J Med. 2021; 
385(24):2252 -63.
Pollock et al 2019
Pollock C, Stefánsson B, Reyner D, Rossing P , Sjöström  CD, Wheeler DC, et al. Albuminuria -
lowering effect of dapagliflo zin alo ne and in co mbinat ion with saxaglipt in and effect of 
dapagliflozin and saxagliptin on glycaemic control in pat ients wi th type 2 di abetes and chronic 
kidney disease (DELIGHT): a randomised, double -blind, placebo -controlled trial. Lancet 
Diabetes Endocrinol . 2019;7(6):429 -41.
Rådholm et al 2018
Rådholm K, Figtree G, Perkovic V , Solomon SD, Mahaffey KW , de Zeeuw D, et al. 
Canagliflozin and Heart Failure in T ype 2 Di abetes Mellitus -Results Fro m the CANV AS 
Program . Circulat ion. 2018;138:458 -68.
Rossignol et al 2014
Rossi gnol P, Dobre D, McMurray  JJ, Swedberg K, Krum H, van V eldhuisen DJ , et al .
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal 
funct ion in patients with heart failure receiving the mineralocortico id receptor antagonist 
eplerenone or pl acebo in addit ion to optimal medical therapy : resul ts from the Epl erenone in 
Mild P atients Hospi talizat ion and Survival Study  in Heart Failure (EMPHASIS -HF). Circ 
Heart Fail. 2014;7(1):51 -8.
Sarraf et al 2009
Sarraf M, Masoumi A, Schrier R W. Cardi orenal  syndrom e in acute decompensated heart 
failure. Clin J Am Soc Nephrol. 2009;4(12):2013 -26.
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 137of 138Savarese et al 2018 
Savarese G, Lund LH. Up -titrating angiotensin -convert ing enzyme inhibitors in heart failure: 
evidence and challenges. Eur J Heart Fail. 2018;20(2):370 -2.
Selvaraj et al 2018
Selvaraj S, Claggett B, Shah SJ, Anand I, Rouleau JL, O ’Meara E, et al . Prognosti c value of 
albuminuria and influence of spirono lactone in heart failure with preserved ejection fraction. 
Circ Heart Fail .2018;1 1(11):e005288.
Spertus et al 2005
Spertus J, Peterson E, Conard MW , Hei denreich P A, Krumho lz HM, Jones P , et al . Moni toring 
clinical changes in patients with heart failure: a comparison of methods. Am Heart J. 
2005;150(4):707 -15.
Vukadinovi ćet al 2017
Vukadinović D, Lavall D, V ukadinović AN, Pitt B , Wagenpfeil S, Böhm M. True rate of 
mineralocortico id receptor antagonists -related hy perkal emia in placebo -controlled trials: A  
meta -analysis. Am Heart J. 2017;188:99 -108.
Yancy et al 2017 
Yancy CW , Jessup M, Bozkurt B, Butl er J, Casey  DE Jr , Col vin MM, et al. 2017 
ACC/AHA/HFSA  Focused Update of the 2013 ACCF/AHA  Guideline for the Management of 
Heart Failure: A  Report of the American Co llege of Cardio logy/American Heart Association 
Task Force on Clinical Practice Guidelines and the Heart Failure Societ y of Amer ica. J Am 
Coll Cardio l. 2017;70(6):776 -803.
Zannad et al 2011
Zannad F , McMurray  JJ, Krum  H, van V eldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in 
patients wi th systolic heart failure and mild symptoms. N Engl J Med. 201 1;364(1):11 -21.
Zannad et al 2013
Zannad F , Garci a AA, Anker SD, Armstrong PW , Calvo G, Cl eland JG, et al . Clinical  outcom e 
endpo ints in heart failure trials: a European Society o f Cardi ology Heart Failure Associat ion 
consensus document. Eur J Heart Fail .2013;15(10): 1082 –94.
Zelniker et al 2019
Zelniker T A, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP , et al . SGLT2 inhibi tors f or 
primary  and secondary prevention of cardiovascular and renal outcomes in t ype 2 diabetes: a 
system atic review and meta -analysis o f cardi ovascul ar out come trials. Lancet. 
2019;393(10166):31 -9.
Zinman et al 2015
Zinman B, W anner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, 
cardi ovascular outcom es, and m ortali ty in type 2 diabetes. N Engl J Med .
Clinical Study Protocol -7.0 AstraZeneca
AZD9977 and dapagliflozin -D6402C00001
CONFIDENTIAL AND PROPRIETARY 138of 1382015;373(22):2117 -28.
SIGNATURE PAGE
This is a representation of an electronic record that was signed
electronically and this page is the manifestation of the electronic signature
Document Name: d6402c00001-csp-v7
Document Title: D6402C00001 Clinical Study Protocol version 7
Document ID: Doc ID-004268198
Version Label: 8.0 CURRENT LATEST APPROVED
Server Date
(dd-MMM-yyyy HH:mm ‘UTC’Z)Signed by Meaning of Signature
02-Feb-2022 18:29 UTC Content Approval
02-Feb-2022 20:29 UTC Content Approval
02-Feb-2022 18:52 UTC Content Approval
Notes: (1) Document details as stored in ANGEL, an AstraZeneca document management system.
PPD
PPD
PPD